

11.22.00

A

PATENT

CASE 3204/2

NEW APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Michael S. South 11671 Chieftain Drive, St. Louis, MO 63146
Darin E. Jones 408 Johanna Place, Ballwin, MO 63021
Melvin L. Rueppel 1904 Grassy Ridge Road, St. Louis, MO 63122

TITLE: SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL
FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

Commissioner of Patents and Trademarks
Washington, D. C. 20231

Sir:

Transmitted herewith for filing is the above-identified patent application which, in accordance with 37 CFR 1.51, comprises:

- ☒ Abstract and Specification including 172 Claims
- ☐ An Assignment of the application and a Declaration and Power of Attorney
- ☒ An Assignment of the application and a Declaration and Power of Attorney to follow under separate cover
- ☐ Sheets of formal/informal drawings
- ☒ Post Card
- ☐ Prior Art Statement (37 CFR 1.97)
- ☐ Preliminary Amendment
- ☒ A **triplicate** copy of this transmittal paper is enclosed.
- ☒ The present application claims priority under Title 35, United States Code §119 and §120 from United States Patent Application Serial No. 09/574,207, filed May 18, 2000, and United States Provisional Patent Application Serial No. 60/134,957, filed May 19, 1999.
- ☒ Amend the specification by inserting before the first line the sentence: -- This is a continuation-in-part of application Serial 09/574,207, filed May 18, 2000, which claims priority from United States Provisional Patent Application Serial No. 60/134,957, filed May 19, 1999.

The Commissioner is hereby authorized and requested to charge any fees* in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025.

NOTE: THIS AUTHORIZATION DOES NOT INCLUDE FEES REQUIRED UNDER 37 CFR 1.18

11/20/00

JC825 U.S. PTO
09/717051
11/20/00

09717051 11/20/00

Figure 1 consists of 11 bar charts, each representing a different variable. The x-axis for all charts is 'Year' with categories '2008' and '2012'. The y-axis is 'Percentage' ranging from 0 to 100. The data is as follows:

Variable	2008 (%)	2012 (%)
Age	18, 22, 28, 35, 42, 48, 55, 62, 68, 75, 82, 88, 95	15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95
Sex	Male: 55, Female: 45	Male: 52, Female: 48
Education	High School: 35, College: 45, Graduate: 20	High School: 30, College: 50, Graduate: 20
Income	\$10,000-\$20,000: 25, \$20,000-\$30,000: 35, \$30,000-\$40,000: 20, \$40,000-\$50,000: 15, \$50,000-\$60,000: 10, \$60,000-\$70,000: 5, \$70,000-\$80,000: 5, \$80,000-\$90,000: 5, \$90,000-\$100,000: 5	\$10,000-\$20,000: 20, \$20,000-\$30,000: 30, \$30,000-\$40,000: 25, \$40,000-\$50,000: 15, \$50,000-\$60,000: 10, \$60,000-\$70,000: 5, \$70,000-\$80,000: 5, \$80,000-\$90,000: 5, \$90,000-\$100,000: 5
Marital Status	Married: 65, Single: 25, Divorced: 5, Widowed: 5	Married: 60, Single: 30, Divorced: 5, Widowed: 5
Religion	Christian: 75, Muslim: 15, Jewish: 5, Hindu: 5, Other: 0	Christian: 70, Muslim: 20, Jewish: 5, Hindu: 5, Other: 0
Ethnicity	White: 60, Black: 25, Hispanic: 10, Asian: 5, Other: 0	White: 55, Black: 20, Hispanic: 15, Asian: 5, Other: 0
Political Affiliation	Democrat: 65, Republican: 30, Independent: 5	Democrat: 60, Republican: 35, Independent: 5
Party Affiliation	Democrat: 65, Republican: 30, Independent: 5	Democrat: 60, Republican: 35, Independent: 5
Attitude towards the environment	Very concerned: 45, Concerned: 35, Not concerned: 20	Very concerned: 50, Concerned: 30, Not concerned: 20
Attitude towards the government	Very satisfied: 35, Satisfied: 45, Dissatisfied: 20, Very dissatisfied: 0	Very satisfied: 30, Satisfied: 40, Dissatisfied: 25, Very dissatisfied: 5

* Calculated as follows:

\$ 690.00

\$ 2736.00

\$ 0.00

\$ 230.00

\$ 3656.00

\$
\$
\$
\$
\$

Kathleen M. Williams

Scott A. Williams

Attorney for Applicants

Registration No. 39,876

314-694-4474 (St. Louis)

Substituted Polycyclic Aryl and Heteroaryl Uracils Useful for Selective Inhibition of the Coagulation Cascade

Field of the Invention

5

This invention is in the field of anticoagulant therapy, and specifically relates to compounds, compositions and methods for preventing and treating thrombotic conditions such as coronary artery and cerebrovascular disease. More particularly, the invention relates to substituted polycyclic aryl and heteroaryl uracil compounds that inhibit serine proteases of the coagulation cascade.

Background of the Invention

15

Physiological systems control the fluidity of blood in mammals [Majerus, P. W. et al: Anticoagulant, Thrombolytic, and Antiplatelet Drugs. In Hardman, J. G. and Limbird, L. E., editors: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th edition. New York, McGraw-Hill Book Co., 1996, pp. 1341-1343]. Blood must remain fluid within the vascular systems and yet be able to undergo hemostasis, cessation of blood loss from a damaged vessel, quickly. Hemostasis or clotting begins when platelets first adhere to macromolecules in subendothelial regions of an injured and/or damaged vessels. These platelets aggregate to form the primary hemostatic plug and stimulate local activation of plasma coagulation factors leading to generation of a fibrin clot that reinforces the aggregated platelets.

25

Plasma coagulation factors include factors II, V, VII, VIII, IX, X, XI, and XII; these are also called protease zymogens. These coagulation factors or protease zymogens are activated by serine proteases leading to coagulation in a so called "coagulation cascade" or chain reaction [Handin, R. I.: Bleeding and Thrombosis. In Wilson, J., et al. editors: Harrison's Principles of Internal Medicine. 12th Edition, New York, McGraw-Hill Book Co., 1991, p.350]. Coagulation or clotting occurs in two ways through different pathways. An intrinsic or contact pathway leads from XII to XIIa to XIa to IXa and to the conversion of X to Xa. Xa with factor Va converts prothrombin (II) to thrombin (IIa) leading to conversion of fibrinogen to fibrin. Polymerization of

35

fibrin leads to a fibrin clot. An extrinsic pathway is initiated by the conversion of coagulation factor VII to VIIa by Xa. The presence of Tissue Factor and VIIa accelerates formation of Xa in the presence of calcium ion and phospholipids. Formation of Xa leads to thrombin, fibrin, and a fibrin clot as described above. The presence of one or more of these many different coagulation factors and two distinct pathways of clotting could enable the efficacious, selective control and better understanding of parts of the coagulation or clotting process.


While clotting as a result of an injury to a blood vessel is a critical physiological process for mammals such as man, clotting can also lead to disease states. A pathological process called thrombosis results when platelet aggregation and/or a fibrin clot blocks (i.e., occludes) a blood vessel. Arterial thrombosis may result in ischemic necrosis of the tissue supplied by the artery. When the thrombosis occurs in a coronary artery, a myocardial infarction or heart attack can result. A thrombosis occurring in a vein may cause tissues drained by the vein to become edematous and inflamed. Thrombosis of a deep vein may be complicated by a pulmonary embolism. Preventing or treating clots in a blood vessel may be therapeutically useful by inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, inhibiting embolus formation, and for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels.

There have been several reports of non-peptidic and peptidic uracil compounds that act as an inhibitor of a coagulation factor present in the coagulation cascade or clotting process. In US Patent 5,656,645, Tamura et al. describe 4,5,6-substituted-3-aminopyridonyl-acetamides, 1,6-substituted-5-aminouracinylacetamides, and 2,4-substituted-5-aminopyrimidinonyl-acetamides in which the amide substituents all have a formyl group and which reportedly have activity against thrombin. In US Patent 5,658,930, Tamura et al. again describe 4,5,6-substituted-3-aminopyridonyl-acetamides, 1,6-substituted-5-aminouracinylacetamides, and 2,4-substituted-5-amino-pyrimidinonylacetamides in which the amide substituents all have a formyl group and which reportedly have activity against thrombin. In PCT Patent

Applications 96/18644 and 97/46207, Tamura et al. further describe 4,5,6-substituted-3-aminopyridonylacetamides, 1,6-substituted-5-aminouraciny-lacetamides, and 2,4-substituted-5-amino-pyrimidinonylacetamides in which the amide substituents all have a formyl group and which reportedly have activity
5 against thrombin.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide compounds that are
10 beneficial in anticoagulant therapy and that have a general structure:



Formula (I).

It is another object of the present invention to provide methods for preventing and treating thrombotic conditions, such as coronary artery disease, cerebrovascular disease, and other coagulation related disorders. Such
15 thrombotic conditions are prevented and treated by administering to a patient in need thereof an effective amount of compounds of Formula (I).


Various other objects and advantages of the present invention will become apparent from the following description of the invention.

20

25

DESCRIPTION OF THE INVENTION

The present invention relates to a class of compounds comprising Substituted Polycyclic Aryl and Heteroaryl uracils, which are beneficial in
 5 anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular disease, as given in Formula (I):



or a pharmaceutically acceptable salt thereof, wherein;

10 J^a and J^b are independently selected from the group consisting of O and S;

J^a is optionally selected from the group consisting of $CH-R^6$ and $N-R^6$ wherein R^6 is a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of a substituent selected from the group
 15 consisting of R^{4a} , R^{4b} , R^{14} , R^{15} , R^{39} , R^{40} , and R^5 to form a heterocyclyl ring having 5 through 8 contiguous members;

J^b is optionally selected from the group consisting of $CH-R^6$ and $N-R^6$ wherein R^6 is a linear spacer moiety having from 1 through 4 contiguous atoms linked to the point of bonding of a substituent selected from the group
 20 consisting of R^1 , R^{4a} , R^{4b} , R^{14} and R^{15} to form a heterocyclyl ring having 5 through 8 contiguous members;


J^a and J^b are optionally independently selected from the group consisting of $CH-R^6$ and $N-R^6$ wherein R^6 is a linear spacer moiety having

from 1 through 4 contiguous atoms linked to the points of bonding of both R^{4a} and R^{4b} to form a heterocyclyl ring having 5 through 8 contiguous members:

J^a is optionally selected from the group consisting of $CH-R^6$ and $N-R^6$ wherein R^6 is a linear spacer moiety having from 1 through 4 contiguous atoms

5 linked to the points of bonding of both R^{39} and R^{40} to form a heterocyclyl ring having 5 through 8 contiguous members;

B is formula (V):



wherein D^1, D^2, J^1, J^2 and K^1 are independently selected from the group

10 consisting of C, N, O, S and a covalent bond with the provisos that no more than one can be a covalent bond, no more than one of D^1, D^2, J^1, J^2 and K^1 is O, no more than one of D^1, D^2, J^1, J^2 and K^1 is S, one of D^1, D^2, J^1, J^2 and K^1 must be a covalent bond when two of D^1, D^2, J^1, J^2 and K^1 are O and S, and no more than four of D^1, D^2, J^1, J^2 and K^1 are N, with the provisos that

15 D^1, D^2, J^1, J^2 and K^1 are selected to maintain an aromatic ring system and that $R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

R^{36} are independently selected from the group consisting of

6

R^{16} , R^{19} , R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently optionally

R^{32} and R^{33} , R^{33} and R^{34} , R^{34} and R^{35} , and R^{35} and R^{36} are

15 and R³⁶ are used at the same time;

25 and R¹³ are used at the same time;

7



consisting of C, N, O, and S, no more than one of D^3 , D^4 , J^3 , and J^4 is O, no

and J^2 are N , with the provisos that D^3 , D^4 , J^3 , and J^4 are selected to maintain

10 B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkylenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R₃₂, R₃₃,

B is optionally selected from the group consisting of C3-C15 cycloalkyl, C5-C10 cycloalkenyl, C4-C12 saturated heterocyclyl, and C4-C9 partially saturated heterocyclyl, wherein each ring carbon is optionally substituted with R³³, a ring carbon other than the ring carbon at the point of

8

position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen atom three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

10 A is selected from the group consisting of single covalent bond, $(W^7)_{rr}-(CH(R^{15}))_{pa}$ and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is an integer selected from 0 through 1, pa is an integer selected from 0 through 6, and W^7 is selected from the group consisting of O, S, C(O), C(S), C(O)S, C(S)O, C(O)N(R^7), C(S)N(R^7), (R^7)NC(O), (R^7)NC(S), S(O), S(O)₂, S(O)₂N(R^7),
 15 (R^7)NS(O)₂, Se(O), Se(O)₂, Se(O)₂N(R^7), (R^7)NSe(O)₂, P(O)(R^8), N(R^7)P(O)(R^8), P(O)(R^8)N(R^7), C(NR⁷)N(R^7), (R^7)NC(NR⁷), (R^7)NC(NR⁷)NR⁷, and N(R^7) with the proviso that no more than one of the group consisting of rr and pa is 0 at the same time;

R^7 and R^8 are independently selected from the group consisting of
 20 hydrido, hydroxy, alkyl, alkenyl, aryl, aralkyl, aryloxy, alkoxy, alkenyloxy, alkylthio, alkylamino, arylthio, arylamino, acyl, aroyl, heteroaroyl, aralkoxyalkyl, heteroaralkoxyalkyl, , aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
 25 heteroaralkyloxy, heteroaralkylamino, and heteroaryloxyalkyl;

R^{14} , R^{15} , R^{37} , R^{38} , R^{39} , R^{40} , R^{41} and R^{42} are independently

- selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, halo, cyano, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, aminoalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, sulfhydryl, acylamido, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkylalkoxy, alkylsulfinylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, monocarboalkoxyalkyl, dicarboalkoxyalkyl, monocyanoalkyl, dicyanoalkyl, carboalkoxycyanoalkyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfinyl, aralkylsulfonyl, cycloalkylsulfinyl, cycloalkylsulfonyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinyl, heteroarylsulfonyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, aralkylsulfonylalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, carboxamidoalkyl, carboaralkoxy, trialkylsilyl, dialkoxyphosphono, diaralkoxyphosphono, dialkoxyphosphonoalkyl, and diaralkoxyphosphonoalkyl with the proviso that R^{37} and R^{38} are independently selected from other than formyl and with the further proviso that R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;

- R^{14} and R^{14} , when bonded to different carbons, are optionally taken together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring selected from the group consisting of cycloalkyl ring having from 5 through 8 contiguous members, cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;

R^{14} and R^{15} , when bonded to different carbons, are optionally taken

together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring selected from the group consisting of a cycloalkyl ring having from 5 through 8
 5 contiguous members, a cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;

R^{15} and R^{15} , when bonded to different carbons, are optionally taken

together to form a group selected from the group consisting of covalent bond, alkylene, haloalkylene, and a linear moiety spacer selected to form a ring
 10 selected from the group consisting of cycloalkyl ring having from 5 through 8 contiguous members, cycloalkenyl ring having from 5 through 8 contiguous members, and a heterocyclyl having from 5 through 8 contiguous members;

Ψ is selected from the group consisting of NR^5 , O, C(O), C(S), S, S(O), S(O)₂, ON(R⁵), P(O)(R⁸), and CR³⁹R⁴⁰;

15 R^5 is selected from the group consisting of hydrido, hydroxy, amino, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, alkenyloxy, alkylthio, arylthio, aralkoxyalkyl, heteroaralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, aralkoxyalkyl, heteroaralkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl,
 20 cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, heteroaryl, heteroarylalkyl, monocarboalkoxyalkyl, monocarboalkoxy, dicarboalkoxyalkyl, monocarboxamido, monocyanoalkyl, dicyanoalkyl,
 25 carboalkoxycyanoalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, and dialkoxyphosphonoalkyl;

R^{39} and R^{40} , when bonded to the same carbon, are optionally taken

together to form a group selected from a group consisting of oxo, thiono, R^5-N , alkylene, haloalkylene, and a linear moiety spacer having from 2 through 7
 30 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl

M is selected from the group consisting of N and R¹-C:

5 Q, hydrido, alkyl, alkenyl, and halo;

R² is optionally selected from the group consisting of amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, heteroarylamino, amino, nitro, alkylamino, arylamino, aralkylamino, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, hydroxyhaloalkyl, cyano, and phosphono;

R² is optionally independently selected to form a linear moiety having
 25 from 2 through 5 contiguous atoms linked to the points of bonding of both R^{4a}
 and R^{4b} to form a heterocyclyl ring having from 5 through 8 contiguous
 members;

Z^0 is selected from the group consisting of covalent single bond,
 $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 6, $(CH(R^{41}))_g$ -
 30 $W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0


through 2 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$,
 $CR^{41}R^{42}=C$; vinylidene), ethynylidene ($C\equiv C$; 1,2-ethynyl), 1,2-cyclopropyl,
1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl,
2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-
morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl,
1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl,
3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-
pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-
tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the
provisos that R^{41} and R^{42} are selected from other than halo and cyano when
directly bonded to N, Z^0 is directly bonded to the pyrazinone ring, and W^{22} is
optionally substituted with one or more substituents selected from the group
consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} ;

13

alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl,
 cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl,
 halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, haloalkenyloxyalkyl,
 halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryl,
 5 perhaloaralkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl,
 heteroaralkylthioalkyl, cyanoalkyl, dicyanoalkyl, carboxamidoalkyl,
 dicarboxamidoalkyl, cyanocarboalkoxyalkyl, carboalkoxyalkyl, dicarboalkoxyalkyl,
 cyanocycloalkyl, dicyanocycloalkyl, carboxamidocycloalkyl,
 dicarboxamidocycloalkyl, carboalkoxycyanocycloalkyl, carboalkoxycycloalkyl,
 10 dicarboalkoxycycloalkyl, formylalkyl, acylalkyl, arylsulfinylalkyl, arylsulfonylalkyl,
 aralkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonylalkyl,
 heteroarylsulfonylalkyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl,
 aralkylsulfonylalkyl, carboxy, dialkoxyphosphono, diaralkoxyphosphono,
 dialkoxyphosphonoalkyl and diaralkoxyphosphonoalkyl;

15 R^{28} and R^{29} are optionally taken together to form a linear moiety spacer
 having from 2 through 7 contiguous atoms and forming a ring selected from the
 group consisting of a cycloalkyl ring having from 3 through 8 contiguous members,
 a cycloalkenyl ring having from 3 through 8 contiguous members, and a
 heterocyclyl ring having from 3 through 8 contiguous members;


20 Q is formula (II):



wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group
 consisting of C, N, O, S and a covalent bond with the provisos that no more
 than one can be a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1
 25 can be O, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 can be S, one of D^1 , D^2 ,

- J^1, J^2 and K^1 must be a covalent bond when two of D^1, D^2, J^1, J^2 and K^1 are O and S, and no more than four of D^1, D^2, J^1, J^2 and K^1 can be N, with the provisos that D^1, D^2, J^1, J^2 and K^1 are selected to maintain an aromatic ring system and that $R^9, R^{10}, R^{11}, R^{12}$, and R^{13} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

Q is optionally selected from formula (III):



- wherein D^3, D^4, J^3 , and J^4 are independently selected from the group consisting of C, N, O, and S, no more than one of D^3, D^4, J^3 , and J^4 is O, no more than one of D^3, D^4, J^3 , and J^4 is S, and no more than three of D^1, D^2, J^1 , and J^2 are N, with the provisos that D^3, D^4, J^3 , and J^4 are selected to maintain an aromatic ring system and that R^9, R^{10}, R^{11} , and R^{12} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

- Q is optionally selected from the group consisting of hydrido, alkyl, alkoxy, alkylamino, alkylthio, haloalkylthio, alkenyl, alkynyl, saturated heterocyclyl, partially saturated heterocyclyl, acyl, aroyl, heteroaroyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkylalkenyl, haloalkyl, haloalkoxy, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxyalkyl, and halocycloalkenyloxyalkyl with the proviso that Z^0 is selected from other than a single covalent bond when Q is hydrido;

K is $(CR^{4a}R^{4b})_n$ wherein n is an integer selected from 1 through 4;

R^{4a} and R^{4b} are independently selected from the group consisting of

- halo, hydrido, hydroxy, cyano, hydroxyalkyl, alkyl, alkenyl, aryl, aralkyl, aralkoxyalkyl, aryloxyalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, aralkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkenyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, cyanoalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylsulfinyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylsulfinylalkyl, aralkylsulfinylalkyl, and aralkylsulfonylalkyl with the provisos that halo, hydroxy, and cyano are bonded to different carbons when simultaneously present and that R^{4a} and R^{4b} are other than hydroxy or cyano when bonded to the carbon directly bonded to the uracil nitrogen;

- R^{4a} and R^{4b} , when bonded to the same carbon, are optionally taken together to form a group selected from the group consisting of oxo, thiono, and a linear spacer moiety having from 2 through 7 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkyl ring having 3 through 8 contiguous members, a cycloalkenyl ring having 5 through 8 contiguous members, and a heterocyclyl ring having 5 through 8 contiguous members with the proviso that R^{4a} and R^{4b} taken together is other than oxo or thiono when the common carbon is directly bonded to the uracil nitrogen;

- E^0 is E^1 , when K is $(CR^{4a}R^{4b})_n$, wherein E^1 is selected from the group consisting of a covalent single bond, O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R^7), (R^7)NC(O), C(S)N(R^7), (R^7)NC(S), OC(O)N(R^7), (R^7)NC(O)O, SC(S)N(R^7), (R^7)NC(S)S, SC(O)N(R^7), (R^7)NC(O)S, OC(S)N(R^7), (R^7)NC(S)O, N(R^8)C(O)N(R^7), (R^7)NC(O)N(R^8), N(R^8)C(S)N(R^7), (R^7)NC(S)N(R^8), S(O), S(O)₂, S(O)₂N(R^7), N(R^7)S(O)₂, S(O)₂N(R^7)C(O), C(O)N(R^7)S(O)₂, Se, Se(O), Se(O)₂, Se(O)₂N(R^7).

K is optionally selected to be $(\text{CH}(\text{R}^{14}))_j\text{-T}$ wherein j is selected from a integer from 0 through 3 and T is selected from the group consisting of single covalent bond, O, S, and $\text{N}(\text{R}^7)$ with the provisos that R^{14} is other than hydroxy, cyano, halo, amino, alkylamino, dialkylamino, and sulfhydryl when j is 1 and that $(\text{CH}(\text{R}^{14}))_j$ is bonded to the uracil ring;


K is optionally selected to be $G-(CH(R^{15}))_k$ wherein k is selected from an integer from 1 through 3 and G is selected from the group consisting of O, S, and $N(R^7)$ with the proviso that R^{15} is other than hydroxy, cyano, halo, amino, alkylamino, dialkylamino, and sulfhydryl when k is 1;

17

$(R^7)NC(O)S$, $OC(S)N(R^7)$, $(R^7)NC(S)O$, $N(R^8)C(O)N(R^7)$,
 $(R^7)NC(O)N(R^8)$, $N(R^8)C(S)N(R^7)$, $(R^7)NC(S)N(R^8)$, $S(O)$, $S(O)_2$,
 $S(O)_2N(R^7)$, $N(R^7)S(O)_2$, Se , $Se(O)$, $Se(O)_2$, $Se(O)_2N(R^7)$, $N(R^7)Se(O)_2$,
 $P(O)(R^8)$, $N(R^7)P(O)(R^8)$, $P(O)(R^8)N(R^7)$, $N(R^7)$, $ON(R^7)$, $SiR^{28}R^{29}$,

- 5 $CR^{4a}=CR^{4b}$, ethynylidene ($C\equiv C$; 1,2-ethynyl), and $C=CR^{4a}R^{4b}$;

Y^0 is formula (IV):



- wherein D^5 , D^6 , J^5 , and J^6 are independently selected from the group
 consisting of C, N, O, S and a covalent bond with the provisos that no more
 10 than one is a covalent bond, K^2 is independently selected from the group
 consisting of C and N^+ , no more than one of D^5 , D^6 , J^5 , and J^6 is O, no more
 than one of D^5 , D^6 , J^5 , and J^6 is S, one of D^5 , D^6 , J^5 , and J^6 must be a
 covalent bond when two of D^5 , D^6 , J^5 , and J^6 are O and S, no more than three
 of D^5 , D^6 , J^5 , and J^6 are N when K^2 is N^+ , and no more than four of D^5 , D^6 ,
 15 J^5 , and J^6 are N when K^2 is carbon, with the provisos that R^{16} , R^{17} , R^{18} , and
 R^{19} are each independently selected to maintain the tetravalent nature of carbon,
 trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature
 of oxygen and that D^5 , D^6 , J^5 , and J^6 are selected to maintain an aromatic ring
 system;

R^{16} and R^{17} are independently optionally taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl;

R^{18} and R^{19} are independently optionally taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, $+NR^{20}R^{21}R^{22}$, oxy, alkyl, aminoalkyl, alkylamino, dialkylamino, dialkylsulfoniumalkyl, acylamino and hydrido, wherein R^{20} , R^{21} , and R^{22} are independently selected from the group consisting of hydrido, amino, alkyl, hydroxy, alkoxy, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkyl with the provisos that no more than one of R^{20} , R^{21} , and R^{22} is hydroxy, alkoxy, alkylamino, amino, and dialkylamino at the same time and that R^{20} , R^{21} , and R^{22} must be other than be hydroxy, alkoxy, alkylamino, amino, and dialkylamino when K^2 is N^+ ;

R^{20} and R^{21} , R^{20} and R^{22} , and R^{21} and R^{22} are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 4 through 7 contiguous atoms connecting the points of bonding of said spacer pair members to form a heterocyclyl ring having 5 through 8 contiguous members with the proviso that no more than one of the group consisting of spacer pairs R^{20} and R^{21} , R^{20} and R^{22} , and R^{21} and R^{22} is used at the same time;

Q^b is optionally selected from the group consisting of $N(R^{26})SO_2N(R^{23})(R^{24})$, $N(R^{26})C(O)OR^5$, $N(R^{26})C(O)SR^5$, $N(R^{26})C(S)OR^5$ and $N(R^{26})C(S)SR^5$ with the proviso that no more than one of R^{23} , R^{24} , and R^{26} can be hydroxy, alkoxy, aminoalkyl, alkylamino, amino,

- 5 or dialkylamino when two of the group consisting of R^{23} , R^{24} , and R^{26} are bonded to the same atom;

Q^b is optionally selected from the group consisting of dialkylsulfonium, trialkylphosphonium, $C(NR^{25})NR^{23}R^{24}$,

- $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $N(R^{26})C(O)N(R^{23})(R^{24})$,
 10 $N(R^{26})C(S)N(R^{23})(R^{24})$, $C(NR^{25})OR^5$,
 $C(O)N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $C(S)N(R^{26})C(NR^{25})N(R^{23})(R^{24})$,
 $N(R^{26})N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $ON(R^{26})C(NR^{25})N(R^{23})(R^{24})$,
 $N(R^{26})N(R^{26})SO_2N(R^{23})(R^{24})$, $C(NR^{25})SR^5$, $C(O)NR^{23}R^{24}$, and
 $C(O)NR^{23}R^{24}$ with the provisos that no more than one of R^{23} , R^{24} , and R^{26}
 15 can be hydroxy, alkoxy, alkylamino, amino, or dialkylamino when any two of the group consisting of R^{23} , R^{24} , and R^{26} are bonded to the same atom and that said Q^b group is bonded directly to a carbon atom;

- R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, alkoxy, aminoalkyl, amino, alkylamino,
 20 dialkylamino, and hydroxyalkyl;

R^{23} and R^{24} are optionally taken together to form a linear spacer moiety having from 4 through 7 contiguous atoms connecting the points of bonding to form a heterocyclyl ring having 5 through 8 contiguous members;

R^{23} and R^{25} , R^{24} and R^{25} , R^{25} and R^{26} , R^{24} and R^{26} , and R^{23} and R^{26}

are independently optionally selected to form a spacer pair wherein a spacer pair is taken together from the points of bonding of selected spacer pair members to form the group L-U-V wherein L, U, and V are independently selected from the group

- 5 consisting of O, S, C(O), C(S), C(J_H)₂ S(O), SO₂, OP(OR³¹)R³⁰, P(O)R³⁰, P(S)R³⁰, C(R³⁰)R³¹, C=C(R³⁰)R³¹, (O)₂POP(O)₂, R³⁰(O)POP(O)R³⁰, Si(R²⁹)R²⁸, Si(R²⁹)R²⁸Si(R²⁹)R²⁸, Si(R²⁹)R²⁸OSi(R²⁹)R²⁸, (R²⁸)R²⁹COC(R²⁸)R²⁹, (R²⁸)R²⁹CSC(R²⁸)R²⁹, C(O)C(R³⁰)=C(R³¹), C(S)C(R³⁰)=C(R³¹), S(O)C(R³⁰)=C(R³¹), SO₂C(R³⁰)=C(R³¹),
- 10 PR³⁰C(R³⁰)=C(R³¹), P(O)R³⁰C(R³⁰)=C(R³¹), P(S)R³⁰C(R³⁰)=C(R³¹), DC(R³⁰)(R³¹)D, OP(OR³¹)R³⁰, P(O)R³⁰, P(S)R³⁰, Si(R²⁸)R²⁹ and N(R³⁰), and a covalent bond with the proviso that no more than any two of L, U and V are simultaneously covalent bonds and the heterocyclyl comprised of by L, U, and V has from 5 through 10 contiguous member;

- 15 D is selected from the group consisting of oxygen, C=O, C=S, S(O)_m wherein m is an integer selected from 0 through 2;

J_H is independently selected from the group consisting of OR²⁷, SR²⁷ and N(R²⁰)R²¹;

- R²⁷ is selected from the group consisting of hydrido, alkyl, alkenyl, alkynyl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfanylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkylthioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, haloalkenyloxyalkyl,
- 20 halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, perhaloaryloxyalkyl, heteroaryl, heteroarylalkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, arylsulfanylalkyl, arylsulfonylalkyl, cycloalkylsulfanylalkyl, cycloalkylsulfonylalkyl, heteroarylsulfonylalkyl, heteroarylthioalkyl, aralkylsulfanylalkyl and aralkylsulfonylalkyl;
- 25

hydrido, hydroxy, thiol, aryloxy, amino, alkylamino, dialkylamino, hydroxyalkyl, heteroaryloxyalkyl, alkoxy, alkylthio, arylthio, alkyl, alkenyl, alkynyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkyl, alkylsulfanylalkyl, alkylsulfonylalkyl, aralkylthioalkyl, heteroaralkoxythioalkyl, alkoxyalkyl, heteroaryloxyalkyl, alkenyloxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, haloaralkylsulfanylalkyl, aralkylsulfonylalkyl, cyanoalkyl, dicyanoalkyl, carboxamidoalkyl, dicarboxamidoalkyl, cyanocarboalkoxyalkyl, carboalkoxyalkyl, dicarboalkoxyalkyl, cyanocycloalkyl, dicyanocycloalkyl, carboxamidocycloalkyl, dicarboxamidocycloalkyl, carboalkoxycyanocycloalkyl, carboalkoxycycloalkyl, dicarboalkoxycycloalkyl, formylalkyl, acylalkyl, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, phosphonoalkyl, dialkoxyphosphonoalkoxy, diaralkoxyphosphonoalkoxy, phosphonoalkoxy, dialkoxyphosphonoalkylamino, diaralkoxyphosphonoalkylamino, phosphonoalkylamino, dialkoxyphosphonoalkyl, diaralkoxyphosphonoalkyl, sulfonylalkyl, alkoxysulfonylalkyl, aralkoxysulfonylalkyl, alkoxysulfonylalkoxy, aralkoxysulfonylalkoxy, sulfonylalkoxy, alkoxysulfonylalkylamino, aralkoxysulfonylalkylamino, and sulfonylalkylamino;

25 R^{23} and R^{25} , R^{24} and R^{25} , R^{25} and R^{26} , R^{24} and R^{26} , and R^{23} and R^{26}

22

substituents are independently selected from C=O, C=S, C(R²⁸)R³², S(O), S(O)₂, OP(OR³¹)R³⁰, P(O)R³⁰, P(S)R³⁰ and Si(R²⁸)R²⁹;

R²³ and R²⁵, R²⁴ and R²⁵, R²⁵ and R²⁶, R²⁴ and R²⁶, and R²³ and R²⁶

- are independently optionally selected to form a spacer pair wherein a spacer pair is taken together from the points of bonding of selected spacer pair members to form the group L-U-V wherein L, U, and V are independently selected from the group of radicals consisting of 1,2-disubstituted alkylene radicals and 1,2-disubstituted alkenylene radical wherein said 1,2-substituents are independently selected from C=O, C=S, C(R²⁸)R²⁹, S(O), S(O)₂, OP(OR³¹)R³⁰, P(O)R³⁰, P(S)R³⁰, and Si(R²⁸)R²⁹ and said alkylene and alkenylene radical are substituted with one or more R³⁰ or R³¹ substituents;

- Q^s is selected from the group consisting of a single covalent bond, (CR³⁷R³⁸)_b-(W⁰)_{az} wherein az is an integer selected from 0 through 1, b is an integer selected from 1 through 4, and W⁰ is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴), (R¹⁴)NC(O), C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), SC(S)N(R¹⁴), SC(O)N(R¹⁴), OC(S)N(R¹⁴), N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵), N(R¹⁵)C(S)N(R¹⁴), (R¹⁴)NC(S)N(R¹⁵), S(O), S(O)₂, S(O)₂N(R¹⁴), N(R¹⁴)S(O)₂, Se, Se(O), Se(O)₂, Se(O)₂N(R¹⁷), N(R¹⁴)Se(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R¹⁴), ON(R¹⁴), and SiR²⁸R²⁹, (CH(R¹⁴))_c-W¹-(CH(R¹⁵))_d wherein c and d are integers independently selected from 1 through 4, and W¹ is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴), (R¹⁴)NC(O), C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), (R¹⁴)NC(O)O, SC(S)N(R¹⁴),

- $(R^{14})NC(S)S$, $SC(O)N(R^{14})$, $(R^{14})NC(O)S$, $OC(S)N(R^{14})$, $(R^{14})NC(S)O$,
 $N(R^{15})C(O)N(R^{14})$, $(R^{14})NC(O)N(R^{15})$, $N(R^{15})C(S)N(R^{14})$,
 $(R^{14})NC(S)N(R^{15})$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, Se , $Se(O)$,
 $Se(O)_2$, $Se(O)_2N(R^{14})$, $N(R^{14})Se(O)_2$, $P(O)(R^8)$, $N(R^7)P(O)(R^8)$,
5 $P(O)(R^8)N(R^7)$, $N(R^{14})$, $ON(R^{14})$, $SiR^{28}R^{29}$, and $(CH(R^{14}))_e-W^{22}$.
 $(CH(R^{15}))_h$ wherein e and h are integers independently selected from 0
through 2 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$,
 $CR^{41}R^{42}=C$; vinylidene), ethynylidene ($C\equiv C$; 1,2-ethynyl), 1,2-cyclopropyl,
1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl,
10 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-
morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl,
1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl,
3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-
pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-
15 tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the
provisos that R^{14} and R^{15} are selected from other than halo and cyano when
directly bonded to N and that $(CR^{37}R^{38})_b$, $(CH(R^{14}))_c$, $(CH(R^{14}))_e$ and are
bonded to E^0 ;
 R^{37} and R^{38} , when bonded to different carbons, are optionally taken
20 together to form a linear moiety spacer having from 1 through 7 contiguous
atoms to form a ring selected from the group consisting of a cycloalkyl ring
having from 3 through 8 contiguous members, a cycloalkenyl ring having from
3 through 8 contiguous members, and a heterocyclyl ring having from 3
through 8 contiguous members;
25 R^{37} and R^{38} , when bonded to different carbons, are taken together to
form a linear moiety spacer having from 1 through 7 contiguous atoms to form
a ring selected from the group consisting of a cycloalkyl ring having from 3

through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;

R^{38} and R^{38} , when bonded to different carbons, are taken together to

- 5 form a linear moiety spacer having from 1 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;

- 10 R^{37} and R^{38} , when bonded to the same carbon, are taken together to form a group selected from a group consisting of oxo, thiono, alkylene, haloalkylene, and a linear moiety spacer having from 2 through 7 contiguous atoms to form a ring selected from the group consisting of a cycloalkyl ring having from 3 through 8 contiguous members, a cycloalkenyl ring having from 3 through 8 contiguous members, and a heterocyclyl ring having from 3 through 8 contiguous members;

Y^0 is optionally Y^{AT} wherein Q^b-Q^s ;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is selected from the group consisting of $(CR^{37}R^{38})_f$ wherein f is an integer selected from 1 through 6,

- 20 $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 4, and W^1 is selected from the group consisting of W^1 is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴), (R¹⁴)NC(O), C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), (R¹⁴)NC(O)O, SC(S)N(R¹⁴), (R¹⁴)NC(S)S, SC(O)N(R¹⁴), 25 (R¹⁴)NC(O)S, OC(S)N(R¹⁴), (R¹⁴)NC(S)O, N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵), N(R¹⁵)C(S)N(R¹⁴), (R¹⁴)NC(S)N(R¹⁵), S(O), S(O)₂, S(O)₂N(R¹⁴), N(R¹⁴)S(O)₂, Se, Se(O), Se(O)₂, Se(O)₂N(R¹⁴),

- $N(R^{14})Se(O)_2$, $P(O)(R^8)$, $N(R^7)P(O)(R^8)$, $P(O)(R^8)N(R^7)$, $N(R^{14})$,
 $ON(R^{14})$, $SiR^{28}R^{29}$, and $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$ wherein e and h are
 integers independently selected from 0 through 2 and W^2 is selected from the
 group consisting of $CR^{4a}=CR^{4b}$, ethynylidene ($C\equiv C$; 1,2-ethynyl), and
 5 $C=CR^{4a}R^{4b}$ with the provisos that R^{14} and R^{15} are selected from other than
 halo and cyano when directly bonded to N, that $(CR^{37}R^{38})_f$, $(CH(R^{15}))_c$, and
 $(CH(R^{15}))_e$ are bonded to E^0 , and Q^b is selected from other than
 $N(R^{26})N(R^{26})C(NR^{25})N(R^{23})(R^{24})$ or $ON(R^{26})C(NR^{25})N(R^{23})(R^{24})$
 when Q^{ss} is $(CR^{37}R^{38})_f$ wherein f is other than the integer 1:
 10 Y^0 is optionally Q^b-Q^{sss} wherein Q^{sss} is $(CH(R^{38}))_r-W^3$, r is an
 integer selected from 1 through 3, W^3 is selected from the group consisting of
 1,1-cyclopropyl, 1,2-cyclopropyl, 1,1-cyclobutyl, 1,2-cyclobutyl, 1,2-cyclohexyl,
 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-
 morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4-
 15 morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl,
 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl,
 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl,
 3,4-piperidinyl, 3,5-piperidinyl, 3,6-piperidinyl, 1,2-pyrrolidinyl, 1,3-
 pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl,
 20 2H-2,3-pyranyl, 2H-2,4-pyranyl, 2H-2,5-pyranyl, 4H-2,3-pyranyl, 4H-2,4-
 pyranyl, 4H-2,5-pyranyl, 2H-pyran-2-one-3,4-yl, 2H-pyran-2-one-4,5-yl, 4H-
 pyran-4-one-2,3-yl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-
 tetrahydrofuranyl, 3,4-tetrahydrofuranyl, 2,3-tetrahydropyranyl, 2,4-
 tetrahydropyranyl, 2,5-tetrahydropyranyl, 2,6-tetrahydropyranyl, 3,4-
 25 tetrahydropyranyl, and 3,5-tetrahydropyranyl, and each carbon and hyrido
 containing nitrogen member of the ring of the W^3 other than the points of
 attachment is optionally substituted with one or more of the group consisting of

R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that $(CH(R^{38}))_r$ is bonded to E^0 and Q^b is bonded to lowest numbered substituent position of each W^3 ;

Y^0 is optionally Q^b-Q^{ssr} wherein Q^{ssr} is $(CH(R^{38}))_r-W^4$, r is an

integer selected from 1 through 3, W^4 is selected from the group consisting of

- 5 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl,
- 10 2,6-piperidinyl, 3,4-piperidinyl, 3,5-piperidinyl, 3,6-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2H-2,3-pyranyl, 2H-2,4-pyranyl, 2H-2,5-pyranyl, 4H-2,3-pyranyl, 4H-2,4-pyranyl, 4H-2,5-pyranyl, 2H-pyran-2-one-3,4-yl, 2H-pyran-2-one-4,5-yl, 4H-pyran-4-one-2,3-yl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl,
- 15 3,4-tetrahydrofuranyl, 2,3-tetrahydropyranyl, 2,4-tetrahydropyranyl, 2,5-tetrahydropyranyl, 2,6-tetrahydropyranyl, 3,4-tetrahydropyranyl, and 3,5-tetrahydropyranyl, and each carbon and hydrido containing nitrogen member of the ring of the W^4 other than the points of attachment is optionally substituted with one or more of the group consisting of
- 20 R^9 , R^{10} , R^{11} , and R^{12} , with the provisos that $(CH(R^{38}))_r$ is bonded to E^0 and Q^b is bonded to highest number substituent position of each W^4 ;


Y^0 is optionally Q^b-Q^{ssss} wherein Q^{ssss} is $(CH(R^{38}))_r-W^5$, r is an

integer selected from 1 through 3, W^5 is selected from the group consisting of

- 25 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-

- benzothiophenyl, 3,7-benzothiophenyl, 2,4-imidazo(1,2-a)pyridinyl, 2,5-imidazo(1,2-a)pyridinyl, 2,6-imidazo(1,2-a)pyridinyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl, and
- each carbon and hydrido containing nitrogen member of the ring of the W^5 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is bonded to lowest number substituent position of each W^5 and that $(CH(R^{38}))_r$ is bonded to E^0 ;
- Y^0 is optionally Q^b-Q^{ssssr} wherein Q^{ssssr} is $(CH(R^{38}))_r-W^6$, r is an integer selected from 1 through 3, W^6 is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-

- benzothiophenyl, 3,7-benzothiophenyl, 2,4-imidazo(1,2-a)pyridinyl, 2,5-imidazo(1,2-a)pyridinyl, 2,6-imidazo(1,2-a)pyridinyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl, and
- each carbon and hydrido containing nitrogen member of the ring of the W^6 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is bonded to highest number substituent position of each W^6 and that $(CH(R^{38}))_r$ is bonded to E^0 .
- In an embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,
- J^a and J^b are independently selected from the group consisting of O and S;
- B is formula (V):



(V)

- wherein D^1, D^2, J^1, J^2 and K^1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1, D^2, J^1, J^2 and K^1 is O,
- 5 no more than one of D^1, D^2, J^1, J^2 and K^1 is S, one of D^1, D^2, J^1, J^2 and K^1 must be a covalent bond when two of D^1, D^2, J^1, J^2 and K^1 are O and S, and no more than four of D^1, D^2, J^1, J^2 and K^1 are N, with the provisos that D^1, D^2, J^1, J^2 and K^1 are selected to maintain an aromatic ring system and that $R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are each independently selected to maintain the
- 10 tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;
- $R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{16}, R^{17}, R^{18}, R^{19}, R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are independently selected from the group consisting of
- heterocyclalkoxy, N-alkyl-N-arylamino, heterocyclalamino,
- 15 heterocyclalkylamino, hydrido, acetamido, haloacetamido, amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aryloylalkoxy, heterocycloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl,
- 20 aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, heteroarylamino, N-heteroarylamino-N-alkylamino,

5 halocycloalkenyloxyalkyl, hydroxy, amino, alkoxyamino, thio, nitro,
alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio,
arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl,
arylsulfinylalkyl, arylsulfonylalkyl, heteroarylsulfinylalkyl,
heteroarylsulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl,
10 haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsulfonamido,
alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl
amidosulfonyl, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl,
monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio,
heteroarylsulfinyl, heteroarylsulfonyl, heterocyclisulfonyl, heterocyclylthio,
15 alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,
haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalkyl,
alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl,
cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, halo, haloalkyl, haloalkenyl,
haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, alkylenylamino,
20 hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy,
aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl,
heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl,
heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido,
alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl,
25 carboalkoxyalkenyl, carboxy, carboaralkoxy, carboxamido, carboxamidoalkyl,
cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono,
and diaralkoxyphosphonoalkyl;

 $Q^b;$

independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a

5 consisting of spacer pairs R³² and R³³, R³³ and R³⁴, R³⁴ and R³⁵, and R³⁵
and R³⁶ can be used at the same time;

independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 3 through 6 contiguous atoms connecting the points of bonding of said spacer pair members to form a ring selected from the group consisting of a cycloalkenyl ring having 5 through 8 contiguous members, a partially saturated heterocyclcyl ring having 5 through 8 contiguous members, a heteroaryl ring having 5 through 6 contiguous members, and an aryl with the proviso that no more than one of the group

B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B may be optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R³², R³³, R³⁴, R³⁵, and R³⁶;

32

nitrogen three atoms from the point of attachment and adjacent to the R¹⁰ position is optionally substituted with R¹¹, a ring carbon or nitrogen atom three from the point of attachment and adjacent to the R¹² position is optionally substituted with R³³, and a ring carbon or nitrogen four atoms from the point of attachment and adjacent to the R¹¹ and R³³ positions is optionally substituted with R³⁴;

A is selected from the group consisting of single covalent bond, $(W^7)_{rr}-(CH(R^{15}))_{pa}$ and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is an integer selected from 0 through 1, pa is an integer selected from 0 through 6, and W^7 is selected from the group consisting of O, S, C(O), C(S), C(O)S, C(S)O, C(O)N(R⁷), C(S)N(R⁷), (R⁷)NC(O), (R⁷)NC(S), S(O), S(O)₂, S(O)₂N(R⁷), (R⁷)NS(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), C(NR⁷)N(R⁷), (R⁷)NC(NR⁷), (R⁷)NC(NR⁷)NR⁷, and N(R⁷) with the proviso that no more than one of the group consisting of rr and pa can be 0 at the same time;

R⁷ and R⁸ are independently selected from the group consisting of
20 hydrido, hydroxy, alkyl, acyl, aroyl, heteroaroyl, and alkoxyalkyl;

R¹⁴, R¹⁵, R³⁷, and R³⁸ are independently selected from the group consisting of hydrido, hydroxy, halo, cyano, hydroxyalkyl, alkoxy, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, haloalkoxy, haloalkoxyalkyl, haloalkenyloxyalkyl,

halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;

- R^{14} and R^{38} are independently optionally selected from the group consisting of acyl, aroyl, and heteroaroyl with the proviso that acyl is selected from other than formyl and 2-oxoacyl and R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;

Ψ is selected from the group consisting of NR^5 , O, C(O), C(S), S, S(O), S(O)₂, ON(R^5), P(O)(R^8), and CR³⁹R⁴⁰;

- R^5 is selected from the group consisting of hydrido, hydroxy, amino, alkyl, alkoxy, alkoxyalkyl, haloalkyl, acyl, aroyl, and heteroaroyl;
- R^{39} and R^{40} are independently selected from the group consisting of hydrido, hydroxy, halo, cyano, hydroxyalkyl, acyl, aroyl, heteroaroyl, acylamido, alkoxy, alkyl, alkoxyalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, alkylsulfonyl, haloalkylsulfonyl, carboxy, carboxyalkyl, carboalkoxy, carboxamide, and carboxamidoalkyl;

M is selected from the group consisting of N and R^1 -C;

R^2 and R^1 are independently selected from the group consisting of Z^0 -Q, hydrido, alkyl, alkenyl, and halo;


- R^1 is optionally selected from the group consisting of amino, aminoalkyl, alkylamino, amidino, guanidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, alkylthio, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, heteroaryl amino, nitro, aryl amino, aralkyl amino, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, hydroxyhaloalkyl, cyano, and phosphono;

Z^0 is selected from the group consisting of covalent single bond, $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 6, $(CH(R^{41}))_g^-$

- $W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R⁴¹), (R⁴¹)NC(O), C(S)N(R⁴¹), (R⁴¹)NC(S), OC(O)N(R⁴¹), (R⁴¹)NC(O)O, SC(S)N(R⁴¹), (R⁴¹)NC(S)S, SC(O)N(R⁴¹), (R⁴¹)NC(O)S, OC(S)N(R⁴¹), (R⁴¹)NC(S)O, N(R⁴²)C(O)N(R⁴¹), (R⁴¹)NC(O)N(R⁴²), N(R⁴²)C(S)N(R⁴¹), (R⁴¹)NC(S)N(R⁴²), S(O), S(O)₂, S(O)₂N(R⁴¹), N(R⁴¹)S(O)₂, Se, Se(O), Se(O)₂, Se(O)₂N(R⁴¹), N(R⁴¹)Se(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R⁴¹), ON(R⁴¹), and SiR²⁸R²⁹, and (CH(R⁴¹))_e-W²².
- 5 $(CH(R^{42}))_h$ wherein e and h are integers independently selected from 0 through 2 and W^{22} is selected from the group consisting of CR⁴¹=CR⁴², CR⁴¹R⁴²=C; vinylidene), ethynylidene (C≡C; 1,2-ethynyl), 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the
- 10 provisos that R⁴¹ and R⁴² are selected from other than halo and cyano when directly bonded to N, Z⁰ is directly bonded to the pyrazinone ring, and W²² is optionally substituted with one or more substituents selected from the group consisting of R⁹, R¹⁰, R¹¹, R¹², and R¹³;
- 15 R⁴¹ and R⁴² are independently selected from the group consisting of
- 20 amidino, hydroxyamino, hydrido, hydroxy, amino, halo, cyano, aryloxy,

- hydroxyalkyl, acyl, aroyl, heteroaroyl, heteroaryloxyalkyl, alkoxy, alkyl, aryl, aralkyl, aryloxyalkyl, aralkoxyalkylalkoxy, alkoxyalkyl, heteroaryloxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkenyl, cycloalkenylalkyl, haloalkyl, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxy,
- 5 haloalkoxyalkyl, haloalkenyloxyalkyl, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaralkyl, heteroarylthioalkyl, heteroaralkylthioalkyl, alkylsulfonyl, haloalkylsulfonyl, arylsulfonyl, arylsulfonylalkyl, aralkylsulfonyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl,
- 10 heteroarylsulfonylalkyl, heteroarylsulfonyl, and aralkylsulfonylalkyl;

Q is formula (II):



- wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is O,
- 15 no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is S, one of D^1 , D^2 , J^1 , J^2 and K^1 must be a covalent bond when two of D^1 , D^2 , J^1 , J^2 and K^1 are O and S, and no more than four of D^1 , D^2 , J^1 , J^2 and K^1 are N, with the proviso that R^9 , R^{10} , R^{11} , R^{12} , and R^{13} are each independently selected to maintain the
- 20 tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen and that D^1 , D^2 , J^1 , J^2 and K^1 are selected to maintain an aromatic ring system;

Q is optionally selected from formula (III):



consisting of C, N, O, and S, no more than one of D^3 , D^4 , J^3 , and J^4 is O, no more than one of D^3 , D^4 , J^3 , and J^4 is S, and no more than three of D^1 , D^2 , J^1 ,

10 Q is optionally selected from the group consisting of hydrido, alkyl, alkoxy, alkylamino, alkylthio, haloalkylthio, alkenyl, alkynyl, saturated heterocyclyl, partially saturated heterocyclyl, acyl, aroyl, heteroaroyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkylalkenyl, haloalkyl, haloalkoxy, haloalkenyl, halocycloalkyl, halocycloalkenyl, haloalkoxyalkyl, 15 haloalkenyloxyalkyl, halocycloalkoxyalkyl, and halocycloalkenyloxyalkyl with the proviso that Z⁰ is selected from other than a single covalent bond when Q is hydrido;

R^{4a} and R^{4b} are independently selected from the group consisting of

E⁰ is E¹, when K is (CR^{4a}R^{4b})_n, wherein E¹ is selected from the group consisting of a covalent single bond, O, S, C(O), C(S), C(O)O, C(S)O, C(O)S,

$C(S)S$, $C(O)N(R^7)$, $(R^7)NC(O)$, $C(S)N(R^7)$, $(R^7)NC(S)$, $OC(O)N(R^7)$,
 $(R^7)NC(O)O$, $SC(S)N(R^7)$, $(R^7)NC(S)S$, $SC(O)N(R^7)$, $(R^7)NC(O)S$.
 $OC(S)N(R^7)$, $(R^7)NC(S)O$, $N(R^8)C(O)N(R^7)$, $(R^7)NC(O)N(R^8)$,
 $N(R^8)C(S)N(R^7)$, $(R^7)NC(S)N(R^8)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^7)$, $N(R^7)S(O)_2$,
5 $S(O)_2N(R^7)C(O)$, $C(O)N(R^7)S(O)_2$, $P(O)(R^8)$, $N(R^7)P(O)(R^8)$,
 $P(O)(R^8)N(R^7)$, $N(R^7)$, $ON(R^7)$, $CR^{4a}=CR^{4b}$, ethynylidene ($C\equiv C$; 1,2-
ethynyl), and $C=CR^{4a}R^{4b}$;


K is optionally $(CH(R^{14}))_j-T$ wherein j is selected from a integer from
0 through 2 and T is selected from the group consisting of single covalent
10 bond, O, S, and $N(R^7)$ with the proviso that $(CH(R^{14}))_j$ is bonded to the uracil
ring;

E^0 is optionally E^2 , when K is $(CH(R^{14}))_j-T$, wherein E^2 is selected
from the group consisting of a covalent single bond, $C(O)$, $C(S)$, $C(O)O$,
 $C(S)O$, $C(O)S$, $C(S)S$, $C(O)N(R^7)$, $(R^7)NC(O)$, $C(S)N(R^7)$, $(R^7)NC(S)$,
15 $(R^7)NC(O)O$, $(R^7)NC(S)S$, $(R^7)NC(O)S$, $(R^7)NC(S)O$, $N(R^8)C(O)N(R^7)$,
 $(R^7)NC(O)N(R^8)$, $N(R^8)C(S)N(R^7)$, $(R^7)NC(S)N(R^8)$, $S(O)$, $S(O)_2$,
 $S(O)_2N(R^7)$, $N(R^7)S(O)_2$, $S(O)_2N(H)C(O)$, $C(O)N(H)S(O)_2$, $P(O)(R^8)$,
 $N(R^7)P(O)(R^8)$, $P(O)(R^8)N(R^7)$, and $N(R^7)$;

K is optionally $G-(CH(R^{15}))_k$ wherein k is selected from an integer
20 from 1 through 2 and G is selected from the group consisting of O, S, and
 $N(R^7)$ with the proviso that R^{15} is other than hydroxy, cyano, halo, amino,
alkylamino, dialkylamino, and sulfhydryl when k is 1;

E^0 is optionally E^3 when K is $G-(CH(R^{15}))_k$, wherein E^3 is selected from the group consisting of a covalent single bond, O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R⁷), (R⁷)NC(O), C(S)N(R⁷), (R⁷)NC(S), OC(O)N(R⁷), (R⁷)NC(O)O, SC(S)N(R⁷), (R⁷)NC(S)S, SC(O)N(R⁷), (R⁷)NC(O)S, OC(S)N(R⁷), (R⁷)NC(S)O, N(R⁸)C(O)N(R⁷), (R⁷)NC(O)N(R⁸), N(R⁸)C(S)N(R⁷), (R⁷)NC(S)N(R⁸), S(O), S(O)₂, S(O)₂N(R⁷), N(R⁷)S(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R⁷), ON(R⁷), CR^{4a}=CR^{4b}, ethynylidene (C≡C; 1,2-ethynyl), and C=CR^{4a}R^{4b};

10 Y^0 is formula (IV):



wherein D⁵, D⁶, J⁵, and J⁶ are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K² is independently selected from the group consisting of C and N⁺, no more than one of D⁵, D⁶, J⁵, and J⁶ is O, no more than one of D⁵, D⁶, J⁵, and J⁶ is S, one of D⁵, D⁶, J⁵, and J⁶ must be a covalent bond when two of D⁵, D⁶, J⁵, and J⁶ are O and S, no more than three of D⁵, D⁶, J⁵, and J⁶ is N when K² is N⁺, and no more than four of D⁵, D⁶,

J^5 , and J^6 are N when K^2 is carbon, with the provisos that R^{16} , R^{17} , R^{18} , and R^{19} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen and that D^5 , D^6 , J^5 , and J^6 are selected to maintain an aromatic ring system;

R^{16} and R^{17} are optionally independently taken together to form a linear moiety spacer having from 3 through 6 contiguous atoms connected to form a ring selected from the group consisting of a cycloalkenyl ring having from 5 through 8 contiguous members, a partially saturated heterocyclyl ring having from 5 through 8 contiguous members, a heteroaryl having from 5 through 6 contiguous members, and an aryl;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, $+NR^{20}R^{21}R^{22}$, oxy, alkyl, aminoalkyl, alkylamino, dialkylamino, dialkylsulfoniumalkyl, acylamino and hydrido, wherein R^{20} , R^{21} , and R^{22} are independently selected from the group consisting of hydrido, amino, alkyl, hydroxy, alkoxy, aminoalkyl, alkylamino, dialkylamino, and hydroxyalkyl with the provisos that no more than one of R^{20} , R^{21} , and R^{22} is hydroxy, alkoxy, alkylamino, amino, and dialkylamino at the same time and that R^{20} , R^{21} , and R^{22} must be other than be hydroxy, alkoxy, alkylamino, amino, and dialkylamino when K^2 is N^+ ;

R^{20} and R^{21} , R^{20} and R^{22} , and R^{21} and R^{22} are independently optionally selected to form a spacer pair wherein a spacer pair is taken together to form a linear moiety having from 4 through 7 contiguous atoms connecting the points of bonding of said spacer pair members to form a heterocyclyl ring having 5 through 8 contiguous members with the proviso that no more than one of the group consisting of spacer pairs R^{20} and R^{21} , R^{20} and R^{22} , and R^{21} and R^{22} is used at the same time;

Q^b is optionally selected from the group consisting of $N(R^{26})SO_2N(R^{23})(R^{24})$, $N(R^{26})C(O)OR^5$, $N(R^{26})C(O)SR^5$, $N(R^{26})C(S)OR^5$ and $N(R^{26})C(S)SR^5$ with the proviso that no more than one of R^{23} , R^{24} , and R^{26} is hydroxy, alkoxy, alkylamino, amino, and dialkylamino when two of the group consisting of R^{23} , R^{24} , and R^{26} are bonded to the same atom;

Q^b is optionally selected from the group consisting of dialkylsulfonium, trialkylphosphonium, $C(NR^{25})NR^{23}R^{24}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $N(R^{26})C(O)N(R^{23})(R^{24})$, $N(R^{26})C(S)N(R^{23})(R^{24})$, $C(NR^{25})OR^5$, $C(O)N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $C(S)N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $N(R^{26})N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $ON(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $N(R^{26})N(R^{26})SO_2N(R^{23})(R^{24})$, $C(NR^{25})SR^5$, $C(O)NR^{23}R^{24}$, and $C(O)NR^{23}R^{24}$ with the provisos that no more than one of R^{23} , R^{24} , and R^{26} can be hydroxy, alkoxy, alkylamino, amino, or dialkylamino when two of the group consisting of R^{23} , R^{24} , and R^{26} are bonded to the same atom and that said Q^b group is bonded directly to a carbon atom;

R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, alkoxy, aminoalkyl, alkylamino, dialkylamino, amino, and hydroxyalkyl;

R^{23} and R^{24} are optionally taken together to form a linear spacer moiety having from 4 through 7 contiguous atoms connecting the points of bonding to form a heterocyclyl ring having 5 through 8 contiguous members;

- Q^s is selected from the group consisting of a single covalent bond,
 $(CR^{37}R^{38})_b-(W^0)_{az}$ wherein az is an integer selected from 0 through 1, b is an
integer selected from 1 through 4, and W^0 is selected from the group consisting
of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴),
5 (R¹⁴)NC(O), C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), SC(S)N(R¹⁴),
SC(O)N(R¹⁴), OC(S)N(R¹⁴), N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵),
N(R¹⁵)C(S)N(R¹⁴), (R¹⁴)NC(S)N(R¹⁵), S(O), S(O)₂, S(O)₂N(R¹⁴),
N(R¹⁴)S(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R¹⁴),
ON(R¹⁴), (CH(R¹⁴))_c-W¹-(CH(R¹⁵))_d wherein c and d are integers
10 independently selected from 1 through 4, and W^1 is selected from the group
consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴),
(R¹⁴)NC(O), C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), (R¹⁴)NC(O)O,
SC(S)N(R¹⁴), (R¹⁴)NC(S)S, SC(O)N(R¹⁴), (R¹⁴)NC(O)S, OC(S)N(R¹⁴),
(R¹⁴)NC(S)O, N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵),
15 N(R¹⁵)C(S)N(R¹⁴), (R¹⁴)NC(S)N(R¹⁵), S(O), S(O)₂, S(O)₂N(R¹⁴),
N(R¹⁴)S(O)₂, P(O)(R⁸), N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R¹⁴),
ON(R¹⁴), and (CH(R¹⁴))_e-W²²-(CH(R¹⁵))_h wherein e and h are integers
independently selected from 0 through 2 and W^{22} is selected from the group
consisting of CR⁴¹=CR⁴², CR⁴¹R⁴²=C; vinylidene), ethynylidene (C≡C; 1,2-
20 ethynyl), 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-
cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-
morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl,
2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl,

2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the provisos that R^{14} and R^{15} are selected from other

- 5 than halo and cyano when directly bonded to N and that $(CR^{37}R^{38})_b$, $(CH(R^{14}))_c$, $(CH(R^{14}))_e$ and are bonded to E^0 ;

Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b-Q^s ;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is selected from the group

consisting of $(CR^{37}R^{38})_f$ wherein f is an integer selected from 1 through 6,

- 10 $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 4, and W^1 is selected from the group consisting of W^1 is selected from the group consisting of O, S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R^{14}), (R^{14})NC(O), C(S)N(R^{14}), (R^{14})NC(S), OC(O)N(R^{14}), (R^{14})NC(O)O, SC(S)N(R^{14}), (R^{14})NC(S)S, SC(O)N(R^{14}),
15 (R^{14})NC(O)S, OC(S)N(R^{14}), (R^{14})NC(S)O, N(R^{15})C(O)N(R^{14}), (R^{14})NC(O)N(R^{15}), N(R^{15})C(S)N(R^{14}), (R^{14})NC(S)N(R^{15}), S(O), S(O)₂, S(O)₂N(R^{14}), N(R^{14})S(O)₂, P(O)(R^8), N(R^7)P(O)(R^8), P(O)(R^8)N(R^7), N(R^{14}), ON(R^{14}), and $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$ wherein e and h are
integers independently selected from 0 through 2 and W^2 is selected from the
20 group consisting of $CR^{4a}=CR^{4b}$, ethynylidene ($C\equiv C$; 1,2-ethynyl), and $C=CR^{4a}R^{4b}$ with the provisos that R^{14} and R^{15} are selected from other than halo and cyano when directly bonded to N and that $(CR^{37}R^{38})_f$, $(CH(R^{14}))_c$, and $(CH(R^{14}))_e$ are bonded to E^0 ;

- Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{38}))_r-W^3$, r is an integer selected from 1 through 3, W^3 is selected from the group consisting of 1,1-cyclopropyl, 1,2-cyclopropyl, 1,1-cyclobutyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 3,5-piperidinyl, 3,6-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2H-2,3-pyranyl, 2H-2,4-pyranyl, 2H-2,5-pyranyl, 4H-2,3-pyranyl, 4H-2,4-pyranyl, 4H-2,5-pyranyl, 2H-pyran-2-one-3,4-yl, 2H-pyran-2-one-4,5-yl, 4H-pyran-4-one-2,3-yl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, 3,4-tetrahydrofuranyl, 2,3-tetrahydropyranyl, 2,4-tetrahydropyranyl, 2,5-tetrahydropyranyl, 2,6-tetrahydropyranyl, 3,4-tetrahydropyranyl, and 3,5-tetrahydropyranyl, and each carbon and hydride containing nitrogen member of the ring of the W^3 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that $(CH(R^{38}))_r$ is bonded to E^0 and Q^b is bonded to lowest numbered substituent position of each W^3 ;

- Y^0 is optionally Q^b-Q^{ssr} wherein Q^{ssr} is $(CH(R^{38}))_r-W^4$, r is an integer selected from 1 through 3, W^4 is selected from the group consisting of 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 3,5-piperidinyl, 3,6-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2H-2,3-pyranyl, 2H-2,4-pyranyl, 2H-2,5-pyranyl, 4H-2,3-pyranyl, 4H-2,4-pyranyl, 4H-2,5-pyranyl, 2H-pyran-2-one-3,4-yl, 2H-pyran-2-one-4,5-

yl, 4H-pyran-4-one-2,3-yl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, 3,4-tetrahydrofuranyl, 2,3-tetrahydropyranyl, 2,4-tetrahydropyranyl, 2,5-tetrahydropyranyl, 2,6-tetrahydropyranyl, 3,4-tetrahydropyranyl, and 3,5-tetrahydropyranyl, and each carbon and hydrido

- 5 containing nitrogen member of the ring of the W^4 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the provisos that $(CH(R^{38}))_r$ is bonded to E^0 and Q^b is bonded to highest number substituent position of each W^4 ;

Y^0 is optionally Q^b-Q^{ssss} wherein Q^{ssss} is $(CH(R^{38}))_r-W^5$, r is an

- 10 integer selected from 1 through 3, W^5 is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-

isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl, and each carbon and hydrido containing nitrogen member of the ring of the W^5 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is bonded to lowest number substituent position of each W^5 and that $(CH(R^{38}))_r$ is bonded to E^0 ;

Y^0 is optionally Q^b-Q^{sssr} wherein Q^{sssr} is $(CH(R^{38}))_r-W^6$, r is an integer selected from 1 through 3, W^6 is selected from the group consisting of

1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-

cinnoliny, 4,5-cinnoliny, 4,6-cinnoliny, 4,7-cinnoliny, and 4,8-cinnoliny, and each carbon and hydrido containing nitrogen member of the ring of the W^6 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is


- 5 bonded to highest number substituent position of each W^6 and that $(CH(R^{38}))_r$ is bonded to E^0 .

In another embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,

J^a and J^b are independently selected from the group consisting of O

- 10 and S;

B is formula (V):



wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group

- 15 consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is O,

no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is S, one of D^1 , D^2 , J^1 , J^2 and K^1

must be a covalent bond when two of D^1 , D^2 , J^1 , J^2 and K^1 are O and S, and

no more than four of D^1 , D^2 , J^1 , J^2 and K^1 are N, with the provisos that D^1 ,

D^2 , J^1 , J^2 and K^1 are selected to maintain an aromatic ring system and that

- 20 R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are each independently selected to maintain the

tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

$R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{16}, R^{17}, R^{18}, R^{19}, R^{32}, R^{33}, R^{34}, R^{35}$, and

R^{36} are independently selected from the group consisting of

- 5 heterocyclalkoxy, N-alkyl-N-arylamino, heterocyclalamino, heterocyclalkylamino, hydrido, acetamido, haloacetamido, amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aryloylalkoxy, heterocyclloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl,
- 10 heterocycl, perhaloaralkyl, aralkylsulfonfyl, aralkylsulfonfylalkyl, aralkylsulfynyl, aralkylsulfynylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfynyl, cycloalkylsulfynylalkyl, cycloalkylsulfonfyl, cycloalkylsulfonfylalkyl, heteroarylamino, N-heteroarylamino-N-alkylamino, heteroarylaminoalkyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl,
- 15 haloalkoxylalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyalkyl, cycloalkylalkoxy, cycloalkenyloxyalkyl, cycloalkylenedioxy, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxy, halocycloalkenyloxyalkyl, hydroxy, amino, alkoxyamino, thio, nitro, alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio,
- 20 arylthioalkyl, heteroaralkoxyalkyl, alkylsulfynyl, alkylsulfynylalkyl, arylsulfynylalkyl, arylsulfonfylalkyl, heteroaryl sulfynylalkyl, heteroaryl sulfonfylalkyl, alkylsulfonfyl, alkylsulfonfylalkyl, haloalkylsulfynylalkyl, haloalkylsulfonfylalkyl, alkylsulfonamido, alkylaminosulfonfyl, amidosulfonfyl, monoalkyl amidosulfonfyl, dialkyl
- 25 amidosulfonfyl, monoaryl amidosulfonfyl, arylsulfonamido, diarylamidosulfonfyl, monoalkyl monoaryl amidosulfonfyl, arylsulfynyl, arylsulfonfyl, heteroarylthio, heteroaryl sulfynyl, heteroaryl sulfonfyl, heterocyclylsulfonfyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalkyl,
- 30 alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, alkylenylamino, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocycl, partially saturated heterocycl, heteroaryl,

heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarboxamido, alkylamidocarbonylamido, arylamidocarbonylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboxy, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl;

R^{16} , R^{19} , R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently optionally

Q^b ;

10 B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, C2-C8 haloalkyl, and C3-C8 haloalkenyl wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

15 B is optionally selected from the group consisting of C3-C12 cycloalkyl, C5-C10 cycloalkenyl, and C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen

20

25

four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

A is selected from the group consisting of single covalent bond, $(W^7)_{rr}-(CH(R^{15}))_{pa}$ and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is an integer

- 5 selected from 0 through 1, pa is an integer selected from 0 through 6, and W^7 is selected from the group consisting of O, S, C(O), C(O)N(R^7), C(S)N(R^7), (R^7)NC(O), (R^7)NC(S), and N(R^7) with the proviso that no more than one of the group consisting of rr and pa can be 0 at the same time;

- R^7 and R^8 are independently selected from the group consisting of
10 hydrido, hydroxy, alkyl, and alkoxyalkyl;

R^{14} , R^{15} , R^{37} , and R^{38} are independently selected from the group consisting of hydrido, hydroxy, halo, alkyl, alkoxyalkyl, haloalkyl, haloalkoxy, and haloalkoxyalkyl;

- R^{14} and R^{38} are independently optionally selected from the group
15 consisting of aroyl and heteroaroyl, wherein R^{38} is optionally substituted at from with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;

Ψ is selected from the group consisting of NR^5 , C(O), and S(O)₂;

- R^5 is selected from the group consisting of hydrido, hydroxy, alkyl, and
20 alkoxy;

R^{39} and R^{40} are independently selected from the group consisting of hydrido, hydroxy, halo, hydroxyalkyl, alkyl, alkoxyalkyl, haloalkyl, haloalkoxy, and haloalkoxyalkyl;

M is selected from the group consisting of N and R^1 -C;

R^1 is selected from the group consisting of hydrido, alkyl, alkenyl, cyano, halo, haloalkyl, haloalkoxy, haloalkylthio, amino, aminoalkyl, alkylamino, amidino, guanidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, alkylthio, and phosphono;


5 R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of covalent single bond, $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 3, $(CH(R^{41}))_g^-$ $W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), S(O),
 10 $S(O)_2$, $N(R^{41})$, and $ON(R^{41})$, and $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are integers independently selected from 0 through 2 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl,
 15 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the
 20 proviso that Z^0 is directly bonded to the uracil ring and W^{22} is optionally substituted with one or more substituents selected from the group consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} ;

R^{41} and R^{42} are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl;

25

Q is selected from the group consisting of hydrido, with the proviso that Z^0 is other than a covalent single bond, the formula (II):




wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is O, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is S, one of D^1 , D^2 , J^1 , J^2 and K^1 must be a covalent bond when two of D^1 , D^2 , J^1 , J^2 and K^1 are O and S, and no more than four of D^1 , D^2 , J^1 , J^2 and K^1 is N, with the provisos that D^1 , D^2 , J^1 , J^2 and K^1 are selected to maintain an aromatic ring system and that R^9 , R^{10} , R^{11} , R^{12} , and R^{13} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

K is $(CR^{4a}R^{4b})_n$ wherein n is an integer selected from 1 through 2;

R^{4a} and R^{4b} are independently selected from the group consisting of halo, hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

E^0 is selected from the group consisting of a covalent single bond, $C(O)$, $C(S)$, $C(O)N(R^7)$, $(R^7)NC(O)$, $S(O)_2$, $(R^7)NS(O)_2$, and $S(O)_2N(R^7)$;

Y^0 is formula (IV):



- wherein D^5 , D^6 , J^5 , and J^6 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K^2 is C, no more than one of D^5 , D^6 , J^5 , and J^6 is O, no more than one of D^5 , D^6 , J^5 , and J^6 is S, one of D^5 , D^6 , J^5 , and J^6 must be a covalent bond when two of D^5 , D^6 , J^5 , and J^6 are O and S, and no more than four of D^5 , D^6 , J^5 , and J^6 are N when K^2 is carbon, with the provisos that R^{16} , R^{17} , R^{18} , and R^{19} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen and that D^5 , D^6 , J^5 , and J^6 are selected to maintain an aromatic ring system;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, $NR^{20}R^{21}R^{22}$, aminoalkyl, and hydrido, wherein R^{20} , R^{21} , and R^{22} are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, aminoalkyl, dialkylamino, alkylamino, and hydroxyalkyl with the proviso that no more than one of R^{20} and R^{21} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;

- Q^b is optionally selected from the group consisting of $C(NR^{25})NR^{23}R^{24}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$,

$C(O)N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, $N(R^{26})N(R^{26})C(NR^{25})N(R^{23})(R^{24})$,
and $ON(R^{26})C(NR^{25})N(R^{23})(R^{24})$ with the provisos that no more than one

of R^{23} , R^{24} , and R^{26} is hydroxy, alkylamino, amino, or dialkylamino when
two of the group consisting of R^{23} , R^{24} , and R^{26} are bonded to the same

5 atom;

R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group
consisting of hydrido, alkyl, hydroxy, amino, aminoalkyl, dialkylamino, alkylamino,
and hydroxyalkyl;

Q^5 is selected from the group consisting of a single covalent bond,

10 $(CR^{37}R^{38})_b(W^0)_{az}$ wherein az is an integer selected from 0 through 1, b is an
integer selected from 1 through 5, and W^0 is selected from the group consisting
of O, C(O), S(O), S(O)₂, S(O)₂N(R¹⁴), N(R¹⁴)S(O)₂, and N(R¹⁴),

$(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently
selected from 1 through 4 and W^1 is selected from the group consisting of O,

15 S, C(O), C(S), C(O)O, C(S)O, C(O)S, C(S)S, C(O)N(R¹⁴), (R¹⁴)NC(O),
C(S)N(R¹⁴), (R¹⁴)NC(S), OC(O)N(R¹⁴), (R¹⁴)NC(O)O, SC(S)N(R¹⁴),
(R¹⁴)NC(S)S, SC(O)N(R¹⁴), (R¹⁴)NC(O)S, OC(S)N(R¹⁴), (R¹⁴)NC(S)O,
N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵), N(R¹⁵)C(S)N(R¹⁴),
(R¹⁴)NC(S)N(R¹⁵), S(O), S(O)₂, S(O)₂N(R¹⁴), N(R¹⁴)S(O)₂, P(O)(R⁸),

20 N(R⁷)P(O)(R⁸), P(O)(R⁸)N(R⁷), N(R¹⁴), ON(R¹⁴), and $(CH(R^{14}))_e-W^{22}-$
 $(CH(R^{15}))_h$ wherein e and h are integers independently selected from 0
through 2 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$,

10 directly bonded to N and that $(\text{CR}^{37}\text{R}^{38})_{\text{b}}$, $(\text{CH}(\text{R}^{14}))_{\text{c}}$, and $(\text{CH}(\text{R}^{14}))_{\text{e}}$ are
bonded to E^0 ;

Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b - Q^s ;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is selected from the group consisting of $(CR^{37}R^{38})_f$ wherein f is an integer selected from 1 through 4, $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 2, and W^1 is selected from the group consisting of W^1 is selected from the group consisting of O, S, C(O), C(O)N(R¹⁴), (R¹⁴)NC(O), N(R¹⁵)C(O)N(R¹⁴), (R¹⁴)NC(O)N(R¹⁵), N(R¹⁴), ON(R¹⁴), and $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$ wherein e and h are integers independently selected from 0 through 2 and W^2 is selected from the group consisting of $CR^{4a}=CR^{4b}$, ethynylidene ($C\equiv C$; 1,2-ethynyl), and $C=CR^{4a}R^{4b}$ with the provisos that R^{14} and R^{15} are selected from other than halo when directly bonded to N and that $(CR^{37}R^{38})_f$, $(CH(R^{14}))_c$, and $(CH(R^{14}))_e$ are bonded to E^0 ;

integer selected from 1 through 2, W^3 is selected from the group consisting of 1,1-cyclopropyl, 1,2-cyclopropyl, 1,1-cyclobutyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-

containing nitrogen member of the ring of the W^3 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that $(CH(R^{38}))_r$ is bonded to E^0 and

Y^0 is optionally Q^b-Q^{sssr} wherein Q^{sssr} is $(CH(R^{38}))_r-W^4$, r is an

1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,4-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,5-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 1,4-piperazinyl, 2,3-piperazinyl, 2,5-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 1,4-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,5-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 3,5-piperidinyl, 3,6-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-

56

yl, 4H-pyran-4-one-2,3-yl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, 3,4-tetrahydrofuranyl, 2,3-tetrahydropyranyl, 2,4-tetrahydropyranyl, 2,5-tetrahydropyranyl, 2,6-tetrahydropyranyl, 3,4-tetrahydropyranyl, and 3,5-tetrahydropyranyl, and each carbon and hyrido

- 5 containing nitrogen member of the ring of the W^4 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the provisos that $(CH(R^{38}))_r$ is bonded to E^0 and Q^b is bonded to highest number substituent position of each W^4 ;

Y^0 is optionally Q^b-Q^{ssss} wherein Q^{ssss} is $(CH(R^{38}))_r-W^5$, r is an

- 10 integer selected from 1 through 2, W^5 is selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-

isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl, and each carbon and hyrido containing nitrogen member of the ring of the W^5 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is bonded to lowest number substituent position of each W^5 and that $(CH(R^{38}))_r$ is bonded to E^0 ;

Y^0 is optionally Q^b-Q^{sssr} wherein Q^{sssr} is $(CH(R^{38}))_r-W^6$, r is an integer selected from 1 through 2, W^6 is selected from the group consisting of

1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-


cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl, and each carbon and hyrido containing nitrogen member of the ring of the W^6 other than the points of attachment is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is

- 5 bonded to highest number substituent position of each W^6 and that $(CH(R^{38}))_r$ is bonded to E^0 .

In a preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,

J^a and J^b are each O;

- 10 B is formula (V):



wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is O,

- 15 no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is S, one of D^1 , D^2 , J^1 , J^2 and K^1 must be a covalent bond when two of D^1 , D^2 , J^1 , J^2 and K^1 are O and S, and no more than four of D^1 , D^2 , J^1 , J^2 and K^1 are N;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are

- 20 independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylendioxy, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxylalkyl, hydroxy, amino, alkoxyamino, nitro,

alkylamino, alkylthio, alkylthioalkyl, alkylsulfinyl, alkylsulfonyl, alkylsulfonylalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyalkyl, aminoalkyl, haloalkoxyalkyl, carboxyalkyl, carboalkoxy, carboxy, carboxamido, carboxamidoalkyl, and cyano;

R^{16} , R^{19} , R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently optionally

Q^b with the proviso that no more than one of R^{16} and R^{19} is Q^b at the same time and that Q^b is Q^{be} ;

B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylene, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

B is optionally selected from the group consisting of C3-C12 cycloalkyl and C4-C9 saturated heterocyclyl, wherein each ring carbon may be optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment may be optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the

5 A is selected from the group consisting of single covalent bond, $(W^7)_{rr}-(CH(R^{15}))_{pa}$ and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is an integer selected from 0 through 1, pa is an integer selected from 0 through 6, and W^7 is selected from the group consisting of O, S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$ with the proviso that no more than one of the group consisting of rr and pa is 0 at the same time;

R¹⁵ is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;

15 M is selected from the group consisting of N and R¹-C;

20 R^2 is Z^0 -Q;


$$(\text{CR}^{41}\text{R}^{42})_q$$
 wherein q is an integer selected from 1 through 3, $(\text{CH}(\text{R}^{41}))_{q-}$

25 $\text{N}(\text{R}^{41})$, and $\text{ON}(\text{R}^{41})$, and $(\text{CH}(\text{R}^{41}))_e\text{-W}^{22}\text{-(CH}(\text{R}^{42}))_h$ wherein e and h

- are integers independently selected from 0 through 1 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-
- 5 piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the proviso that Z^0 is directly
- 10 bonded to the uracil ring;

R^{41} and R^{42} are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl;

Q is selected from the group consisting of hydrido, with the proviso that Z^0 is other than a covalent single bond, and the formula (II):



- 15 wherein D^1 , D^2 , J^1 , J^2 and K^1 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is O, no more than one of D^1 , D^2 , J^1 , J^2 and K^1 is S, one of D^1 , D^2 , J^1 , J^2 and K^1
- 20 must be a covalent bond when two of D^1 , D^2 , J^1 , J^2 and K^1 are O and S, and no more than four of D^1 , D^2 , J^1 , J^2 and K^1 are N, with the proviso that R^9 , R^{10} , R^{11} , R^{12} , and R^{13} are each independently selected to maintain the

K is $(\text{CR}^{4a}\text{R}^{4b})_n$ wherein n is an integer selected from 1 through 2;

5 halo, hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

consisting of a covalent single bond, C(O), C(S), C(O)N(R⁷), (R⁷)NC(O),

Y^0 is formula (IV):



15

consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, nitro, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkylenylamino, haloalkoxyalkyl, carboalkoxy, and cyano;

Q^{be} wherein Q^{be} is hydrido, N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), and C(NR²⁵)NR²³R²⁴, with the proviso that no more than one of R²⁰ and R²¹ is hydroxy, amino, alkylamino, or dialkylamino at the same time and that no more than one of R²³ and R²⁴ is hydroxy, amino, alkylamino, or dialkylamino at the same time;

group consisting of hydrido, alkyl, hydroxy, aminoalkylenyl, amino, dialkylamino, alkylamino, and hydroxyalkyl;

(CR³⁷R³⁸)_b wherein b is an integer selected from 1 through 4, and

selected from 1 through 3 and W^1 is selected from the group consisting of

20 $N(R^{14})$, with the provisos that R^{14} is selected from other than halo when

R¹⁴ is selected from the group consisting of hydrido, halo, alkyl, and aryl;

25 hydrido, alkyl, and haloalkyl;

R³⁸ is optionally selected from the group consisting of aroyl and

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$,

wherein e and h are integers independently selected from 1 through 2 and W^2

5 is $\text{CR}^{4a}=\text{CR}^{4b}$ with the proviso that $(\text{CH}(\text{R}^{14}))_e$ is bonded to E^0 ;

Y^0 is optionally selected from the group consisting of Q^b-Q^{ssss} and Q^b-Q^{ssssr} wherein Q^{ssss} is $(CH(R^{38}))_r-W^5$ and Q^{ssssr} is $(CH(R^{38}))_r-W^6$, r is an integer selected from 1 through 2, and W^5 and W^6 are independently

selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl, 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl, 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl, 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl, 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl, 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-

cinnoliny, 4,5-cinnoliny, 4,6-cinnoliny, 4,7-cinnoliny, and 4,8-cinnoliny, and each carbon and hyrido containing nitrogen member of the ring of the W^5 and of the ring of the W^6 , other than the points of attachment of W^5 and W^6 , is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the provisos that Q^b is bonded to lowest number substituent position of each W^5 , Q^b is bonded to highest number substituent position of each W^6 , and $(CH(R^{38}))_r$ is bonded to E^0 .

In another preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,

10 J^a and J^b are each O;

B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a nitrogen with a removable hydrogen or a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , a nitrogen with a removable hydrogen or a carbon at the other position adjacent to the point of attachment is optionally substituted by R^{36} , a nitrogen with a removable hydrogen or a carbon adjacent to R^{32} and two atoms from the point of attachment is optionally substituted by R^{33} , a nitrogen with a removable hydrogen or a carbon adjacent to R^{36} and two atoms from the point of attachment is optionally substituted by R^{35} , and a nitrogen with a removable hydrogen or a carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylendioxy, haloalkylthio, alkanoyloxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy,

heteroaralkoxy, heterocycloxy, heterocyclalkoxy, alkoxyalkyl,
haloalkoxylalkyl, hydroxy, amino, alkoxyamino, nitro, alkylamino,
N-alkyl-N-aryl amino, aryl amino, aralkyl amino, heteroaryl amino,
heteroaralkyl amino, heterocycl amino, heterocyclalkyl amino, alkylthio,
5 alkylthioalkyl, alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl,
heteroaryl sulfinyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl,
cycloalkylsulfonyl, heteroaryl sulfonyl, alkylsulfonylalkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heterocycl, alkylsulfonamido,
amidosulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl,
10 haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyalkyl, aminoalkyl,
haloalkoxyalkyl, carboxyalkyl, carboalkoxy, carboxy, carboxamido,
carboxamidoalkyl, and cyano;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently optionally Q^b ;

B is optionally selected from the group consisting of hydrido,
15 trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and
C2-C8 haloalkyl, wherein each member of group B is optionally substituted at
any carbon up to and including 6 atoms from the point of attachment of B to A
with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

B is optionally a C3-C12 cycloalkyl or C4-C9 saturated heterocycl,
20 wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other
than the ring carbon at the point of attachment of B to A is optionally
substituted with oxo provided that no more than one ring carbon is substituted
by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon
atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring
25 carbon or nitrogen atom adjacent to the R^9 position and two atoms from the
point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen
adjacent to the R^{13} position and two atoms from the point of attachment is
optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the
point of attachment and adjacent to the R^{10} position is optionally substituted

5 A is selected from the group consisting of a bond, $(W^7)_{rr}$ -
 $(CH(R^{15}))_{pa}$, and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer
selected from 0 through 6, and W^7 is selected from the group consisting of O,
S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$ with the proviso that no more
than one of the group consisting of rr and pa is 0 at the same time;
10 R^7 is selected from the group consisting of hydrido, hydroxy, and
alkyl;
 R^{15} is selected from the group consisting of hydrido, hydroxy, halo,
alkyl, and haloalkyl;
 Ψ is NH or NOH;
15 M is N or R^1-C ;
 R^1 is selected from the group consisting of hydrido, alkyl, alkenyl,
cyano, halo, haloalkyl, haloalkoxy, haloalkylthio, amino, aminoalkyl, alkylamin
amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol,
and alkylthio;
20 R^2 is Z^0-Q ;
 Z^0 is selected from the group consisting of a bond,
 $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 3, and
 $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently
selected from 0 through 3 and W^0 is selected from the group consisting of O,
25 S, C(O), S(O), $N(R^{41})$, and $ON(R^{41})$;

independently 0 or 1 and W^{22} is selected from the group consisting of

1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl,
2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl,
1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl,
2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl,
1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl,
3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl,

R⁴¹ and R⁴² are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl;

69

Q is optionally hydrido with the proviso that Z^0 is selected from other than a bond;

K is $(CR^{4a}R^{4b})_n$ wherein n is 1 or 2;

- 5 R^{4a} and R^{4b} are independently selected from the group consisting of halo, hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;
- E^0 is E^1 , when K is $(CR^{4a}R^{4b})_n$, wherein E^1 is selected from the group consisting of a bond, C(O), C(S), C(O)N(R^7), (R^7)NC(O), S(O)₂, (R^7)NS(O)₂, and S(O)₂N(R^7);

- Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon
- 10 of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a
- 15 carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

- R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, nitro, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl,
- 20 alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, haloalkoxyalkyl, carboalkoxy, and cyano;

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, aminoalkyl, hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time, with the further proviso that no more than one of R^{23} and R^{24} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;
- R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, aminoalkyl, amino, dialkylamino, alkylamino, and hydroxyalkyl;
- Q^s is selected from the group consisting of bond, $(CR^{37}R^{38})_b$ wherein b is an integer selected from 1 through 4, and $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 3 and W^1 is selected from the group consisting of $C(O)N(R^{14})$, $(R^{14})NC(O)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, and $N(R^{14})$, with the proviso that R^{14} is selected from other than halo when directly bonded to N, with the further provision that Q^s is selected from other than a bond when Y^0 is $2-Q^b-5-Q^s-6-R^{17}-4-R^{18}-3-R^{19}$ pyridine or $2-Q^b-4-Q^s-3-R^{16}-5-R^{18}-6-R^{19}$ pyridine, and with the additional proviso that $(CR^{37}R^{38})_b$ and $(CH(R^{14}))_c$ are bonded to E^0 ;
- R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R^{37} and R^{38} are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;

R^{38} is optionally aroyl or heteroaroyl, wherein R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;

Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b-Q^s ;

5 Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$,

wherein e and h are independently 1 or 2 and W^2 is $CR^{4a}=CR^{4b}$, with the proviso that $(CH(R^{14}))_e$ is bonded to E^0 ;

Y^0 is optionally Q^b-Q^{ssss} or Q^b-Q^{sssr} wherein Q^{ssss} is $(CH(R^{38}))_r-W^5$, Q^{sssr} is $(CH(R^{38}))_r-W^6$, r is 1 or 2, W^5 and W^6 are independently

- 10 selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl,
- 15 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl,
- 20 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl,
- 25 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl,
- 30 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl,

- 3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl, 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl, 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl, 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl,
- 5 and each carbon and hyrido containing nitrogen member of the ring of the W^5 and of the ring of the W^6 , other than the points of attachment of W^5 and W^6 , is optionally substituted with one or more of the group consisting of R^9 , R^{10} , R^{11} , and R^{12} , with the proviso that Q^b is bonded to lowest number substituent position of each W^5 , with the further proviso that Q^b is bonded to highest
- 10 number substituent position of each W^6 , and with the additional proviso that $(CH(R^{38}))_r$ is bonded to E^0 .

In a more preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,

J^a and J^b are each O;

- 15 B is selected from the group consisting of aryl and heteroaryl wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon
- 20 adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

- R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino,
- 25 alkylenedioxy, haloalkylthio, alkanoyloxy, alkoxy, hydroxy, amino,

alkoxyamino, alkanoyl, haloalkanoyl, nitro, alkylamino, alkylthio, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyalkyl, alkylenylamino,

- 5 carboalkoxy, carboxy, carboxamido, cyano, and Q^b :

B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A

- 10 with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

B is optionally selected from the group consisting of C3-C12 cycloalkyl and C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo

15 provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment is

- optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13}
- 20 position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen
- 25 four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

R^9 , R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from the group

consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl, haloalkanoyl, amidino, guanidino, alkylendioxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl,

- 5 alkylsulfonamido, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, carboalkoxy, carboxyalkyl, carboxy, carboxamido, and cyano;

A is selected from the group consisting of single covalent bond and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is an integer selected from 0 through 1, pa is

- 10 an integer selected from 0 through 3, and W^7 is selected from the group consisting of O, S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$;

R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;

- 15 Ψ is NH;

M is selected from the group consisting of N and R^1-C ;

R^1 is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

- 20 R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of covalent single bond and $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 2, $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, and $N(R^{41})$,

- 25 and $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are integers independently selected from 0 through 1 and W^{22} is selected from the group consisting of

CR⁴¹=CR⁴², 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 5 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, with the proviso that Z⁰ is directly bonded to the uracil ring;


R⁴¹ and R⁴² are independently selected from the group consisting of
 10 hydrido, hydroxy, and amino;
 Q is selected from the group consisting of hydrido, with the proviso that Z⁰ is other than a covalent single bond, aryl, and heteroaryl, wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two atoms from the carbon at
 15 the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

20 K is CHR^{4a} wherein R^{4a} is selected from the group consisting of hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

E⁰ is selected from the group consisting of a covalent single bond, C(O)N(H), (H)NC(O), (R⁷)NS(O)₂, and S(O)₂N(R⁷):

25

Y^0 is formula (IV):



wherein D^5 , D^6 , J^5 , and J^6 are independently selected from the group consisting of C, N, O, S and a covalent bond with the provisos that no more than one is a covalent bond, K^2 is C, no more than one of D^5 , D^6 , J^5 , and J^6 is O, no more than one of D^5 , D^6 , J^5 , and J^6 is S, one of D^5 , D^6 , J^5 , and J^6 must be a covalent bond when two of D^5 , D^6 , J^5 , and J^6 are O and S, and no more than four of D^5 , D^6 , J^5 , and J^6 are N, with the provisos that R^{16} , R^{17} , R^{18} , and R^{19} are each independently selected to maintain the tetravalent nature of carbon, trivalent nature of nitrogen, the divalent nature of sulfur, and the divalent nature of oxygen;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} and R^{19} are optionally Q^b with the proviso that no more than one of R^{16} and R^{19} is Q^b at the same time and that Q^b is Q^{be} ;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, Q^{be} wherein Q^{be} is hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the provisos

that no more than one of R^{20} and R^{21} is hydroxy, amino, alkylamino, or dialkylamino at the same time and that no more than one of R^{23} and R^{24} is hydroxy, amino, alkylamino, or dialkylamino at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the

5 group consisting of hydrido, alkyl, hydroxy, amino, alkylamino and dialkylamino:

Q^s is selected from the group consisting of a single covalent bond,

$(CR^{37}R^{38})_b$ wherein b is an integer selected from 1 through 4, and

$(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently

selected from 1 through 3 and W^1 is selected from the group consisting of

10 $C(O)N(R^{14})$, $(R^{14})NC(O)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, and $N(R^{14})$, with the provisos that R^{14} is selected from other than halo when

directly bonded to N and that $(CR^{37}R^{38})_b$ and $(CH(R^{14}))_c$ are bonded to E^0 ;

R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

15 R^{37} and R^{38} are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;

R^{38} is optionally selected from the group consisting of aroyl and heteroaroyl;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$,

20 wherein e and h are integers independently selected from 1 through 2 and W^2 is $CR^{4a}=CH$ with the proviso that $(CH(R^{14}))_e$ is bonded to E^0 .

In another more preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof,

J^a and J^b are each O;

B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylenedioxy, haloalkylthio, alkanoyloxy, alkoxy, hydroxy, amino, alkoxyamino, haloalkanoyl, nitro, alkylamino, alkylthio, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, amidosulfonyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

B is optionally a C3-C12 cycloalkyl or a C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring

carbon or nitrogen atom adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen atom adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen atom three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen atom three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen atom four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

$R^9, R^{10}, R^{11}, R^{12}$, and R^{13} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl, haloalkanoyl, amidino, guanidino, alkylenedioxy, haloalkylthio, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, alkylamino, N-alkyl-N-aryl amino, arylamino, aralkylamino, heteroaryl amino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylthio, alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, alkylsulfamido, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, amidosulfonyl, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, and cyano;

A is bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is selected from the group consisting of O, S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$;

R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;

Ψ is NH;

5 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

R^2 is Z^0-Q ;

10 Z^0 is selected from the group consisting of a bond, $(CR^{41}R^{42})_q$ wherein q is 1 or 2, and $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), S(O), $N(R^{41})$, and $ON(R^{41})$;

Z^0 is optionally $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are

15 independently 0 or 1 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 20 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, wherein Z^0 is directly bonded to the uracil ring and W^{22} is optionally substituted with one or more

25 substituents selected from the group consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} ;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z⁰ is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two atoms from the carbon at the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

K is CHR^{4a} wherein R^{4a} is selected from the group consisting of
o, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

15 C(O)N(H) , (H)NC(O) , $(\text{R}^7)_7\text{NS(O)}_2$, and $\text{S(O)}_2\text{N(R}^7)$;

82

consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy,

R¹⁶ or R¹⁹ is optionally selected from the group consisting of

proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of NR²⁰R²¹, hydrido,

15 R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, alkylamino and dialkylamino;

Q^s is selected from the group consisting of a bond, $(CR^{37}R^{38})_b$

wherein b is an integer selected from 1 through 4, and

$$(\text{CH}(\text{R}^{14}))_c\text{-W}^1\text{-(CH}(\text{R}^{15}))_d$$
 wherein c and d are integers independently

83

R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

R^{37} and R^{38} are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;

- 5 R^{38} is optionally aroyl or heteroaroyle, wherein R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;


Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b-Q^s ;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$, wherein

- 10 e and h are integers independently selected from 1 through 2 and W^2 is

$CR^{4a}=CH$ with the proviso that $(CH(R^{14}))_e$ is bonded to E^0 .

In an even more preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:



- 15 wherein;

B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon

- 20 adjacent to R^{32} and two atoms from the carbon at the point of attachment is

$R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are independently selected from the

A is a bond or $(\text{CH}(\text{R}^{15}))_{\text{pa}}-(\text{W}^7)_{\text{rr}}$ wherein rr is 0 or 1, pa is an

R⁷ is selected from the group consisting of hydrido, hydroxy and alkyl;

$$M \text{ is } N \text{ or } R^1\text{-}C;$$
$$R^2 \text{ is } Z^0\text{-}Q;$$

20 $(\text{CH}(\text{R}^{42}))_p$ wherein p is 0 or 1 and W^0 is selected from the group consisting of O, S, and $\text{N}(\text{R}^{41})$;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl

85

5 carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

10 carboxamido, and cyano;

15 heteroaralkoxy, heterocycloxy, heterocyclylalkoxy, hydroxy, amino, alkoxyamino, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylsulfonamido, amidosulfonyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, arylsulfonyl, aralkylsulfonyl,

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S, a carbon two or three

86

attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

- 5 consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the

- 10 proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;


- 15 R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

20

25

In another even more preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:



wherein;

- 5 B is selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

- 10 R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

- 15 A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $(R^7)NC(O)$ or $N(R^7)$;

R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

- 20 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0 -Q;

- 5 Z^0 is selected from the group consisting of a bond, CH_2 , CH_2CH_2 , W^0 - $(CH(R^{42}))_p$ wherein p is 0 or 1 and W^0 is selected from the group consisting of O, S, and $N(R^{41})$;

R^{41} and R^{42} are independently hydrido or alkyl;

- 10 Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the
- 15 carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

- R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboxy, carboxamido, and cyano;
- 20

- R^{10} and R^{12} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, alkoxyamino, alkylamino, arylamino, aralkylamino, heteroarylamino,
- 25

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^s, a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b, a carbon adjacent to the point of attachment of Q^s is optionally substituted by R¹⁷, another carbon adjacent to the point of attachment of Q^s is optionally substituted by R¹⁸, a carbon adjacent to Q^b is optionally substituted by R¹⁶, and another carbon adjacent to Q^b is optionally substituted by R¹⁹;

20 R¹⁶ or R¹⁹ is optionally selected from the group consisting of NR²⁰R²¹, N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), and C(NR²⁵)NR²³R²⁴, with the proviso that R¹⁶, R¹⁹, and Q^b are not simultaneously hydrido;


Q^b is selected from the group consisting of NR²⁰R²¹, hydrido,
C(NR²⁵)NR²³R²⁴, and N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), with the proviso that
no more than one of R²⁰ and R²¹ is hydroxy at the same time and with the

further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

- 5 Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

In still another even more preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:



10

wherein;

- B is a C3-C7 cycloalkyl or a C4-C6 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring
- 15
- 20

5 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboxy, carboxamido, and cyano;

R³³ and R³⁴ are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, and cyano;

A is a bond or $(\text{CH}(\text{R}^{15}))_{\text{pa}}\text{-(W}^7\text{)}_{\text{rr}}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $(\text{R}^7)\text{NC}(\text{O})$ or $\text{N}(\text{R}^7)$;

R¹⁵ is selected from the group consisting of hydrido, halo, alkyl, and aryl;

$$M \text{ is } N \text{ or } R^1\text{-}C:$$

5 R¹ is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

$$R^2 \text{ is } Z^0\text{-}Q;$$

Z^0 is selected from the group consisting of a bond, CH_2 , CH_2CH_2 ,

10 $W^0-(CH(R^{42}))_p$ wherein p is 0 or 1 and W^0 is selected from the group consisting of O, S, and $N(R^{41})$;

R⁴¹ and R⁴² are independently hydrido or alkyl;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;


Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S , a carbon two or three atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^S is

5 R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23}

$R^{20}, R^{21}, R^{23}, R^{24}$, and R^{25} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

20 In a most preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:

[illegible][illegible][illegible][illegible][illegible][illegible]

M is N or R¹-C;

R¹ is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

5 R² is Z⁰-Q;

Z⁰ is a bond;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z⁰ is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two atoms from the carbon at the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

15 R⁹, R¹¹, and R¹³ are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkoxy, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;

R¹⁰ and R¹² are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, alkoxyamino, hydroxy, amino, alkylamino, alkylsulfonamido, amidosulfonyl, hydroxyalkyl, aminoalkyl, halo, haloalkyl, carboalkoxy, carboxy, carboxamido, carboxyalkyl, and cyano;

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S, a carbon two or three atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is

substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;


R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$;

R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently hydrido or alkyl;

Q^s is CH_2 .

In another most preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:



wherein;

B is selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} ,

5 R^{33} , R^{34} , R^{35} , and R^{36} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $N(R^7)$;

R^7 is hydrido or alkyl;

15 R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

20 R^2 is Z^0-Q ;

Z^0 is a bond;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the

25 carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is

R^9, R^{11} , and R^{13} are independently selected from the group consisting

R^{10} and R^{12} are independently selected from the group consisting of

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon


R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

99

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido,
 5 $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$;
 R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently hydrido or alkyl;
 Q^s is CH_2 .

In still another most preferred embodiment of compounds of Formula I or a pharmaceutically acceptable salt thereof, said compound is the formula:



10

wherein;

- B is a C3-C7 cycloalkyl or a C4-C6 saturated heterocyclyl, wherein
 each ring carbon is optionally substituted with R^{33} , a ring carbon other than the
 ring carbon at the point of attachment of B to A is optionally substituted with
 15 oxo provided that no more than one ring carbon is substituted by oxo at the
 same time, ring carbons and a nitrogen adjacent to the carbon atom at the point
 of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or
 nitrogen adjacent to the R^9 position and two atoms from the point of attachment
 is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13}
 20 position and two atoms from the point of attachment is optionally substituted

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0 -Q;

5 Z^0 is a bond;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon

10 adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon
15 of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is
20 optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl,

haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;


- 5 Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$;

R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently hydrido or alkyl;

Q^s is CH_2 .

In a preferred specific embodiment of Formula I, compounds have the

- 10 Formula I-S:



or a pharmaceutically acceptable salt thereof, wherein;






- 15 B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-3-yl, 1,3,4-oxadiazol-5-yl, 3-isothiazolyl, 5-isothiazolyl, 2-oxazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl, 1,2,4-triazin-5-yl,
- 20 1,2,4-triazin-6-yl, 1,2,3-triazin-4-yl, and 1,2,3-triazin-5-yl, wherein a carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the











methoxymethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoromethyl, methylthiomethyl, and hydrido;


E^0 is a covalent single bond, $C(O)N(H)$, $(H)NC(O)$, and $S(O)_2N(H)$;

Y^0 is selected from the group of formulas consisting of:

5







R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

- consisting of hydrido, methyl, ethyl, isopropyl, propyl, amidino, guanidino,
 5 carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino,
 methoxyamino, ethoxyamino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-N-
 methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio,
 isopropylthio, trifluoromethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl,
 ethylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-
 10 pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro,
 bromo, amidosulfonyl, N-methylamid sulfonyl, N,N-dimethylamid sulfonyl,
 acetyl, propanoyl, trifluoroacetyl, pentafluoropropanoyl, hydroxymethyl, 1-
 hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, and cyano;

- R^{16} and R^{19} are optionally Q^b with the proviso that no more than one
 15 of R^{16} and R^{19} is Q^b at the same time and that Q^b is Q^{be} ;


Q^b is selected from the group consisting of $NR^{20}R^{21}$, Q^{be} wherein
 Q^{be} is hydrido, $C(NR^{25})NR^{23}R^{24}$ and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, with
 the proviso that no more than one of R^{20} and R^{21} is hydroxy, N-methylamino,
 and N,N-dimethylamino at the same time and that no more than one of R^{23}

and R^{24} is hydroxy, N-methylamino, and N,N-dimethylamino at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, isopropyl, hydroxy, 2-aminoethyl, 2-(N-methylamino)ethyl, and 2-(N,N-dimethylamino)ethyl;

Q^s is selected from the group consisting of a single covalent bond, CH_2 , CH_2CH_2 , CH_3CH , CF_3CH , CH_3CHCH_2 , CF_3CHCH_2 , $CH_2(CH_3)CH$, $CH=CH$, $CF=CH$, $C(CH_3)=CH$, $CH=CHCH_2$, $CF=CHCH_2$, $C(CH_3)=CHCH_2$, $CH_2CH=CH$, $CH_2CF=CH$, $CH_2C(CH_3)=CH$, $CH_2CH=CHCH_2$, $CH_2CF=CHCH_2$, $CH_2C(CH_3)=CHCH_2$, $CH_2CH=CHCH_2CH_2$, $CH_2CF=CHCH_2CH_2$, and $CH_2C(CH_3)=CHCH_2CH_2$.

In a more preferred specific embodiment of Formula I, compounds have the Formula I-MPS wherein B is an aromatic:



(I-MPS wherein B is aromatic)
or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the

point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon

- 5 adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

- group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, 15 amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, cyano, and Q^b ;

A is selected from the group consisting of a bond, NH, $N(CH_3)$,

$N(OH)$, CH_2 , CH_3CH , CF_3CH , $NHC(O)$, $N(CH_3)C(O)$, $C(O)NH$,

$C(O)N(CH_3)$, CH_2CH_2 , $CH_2CH_2CH_2$, CH_3CHCH_2 , and CF_3CHCH_2 ;


- 20 R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino, guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio, 25 methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;

R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido, with the proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

- 5 R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, methyl, ethyl, and hydroxy.

In another more preferred specific embodiment of Formula I, compounds have the Formula I-MPS wherein B is a non-cyclic substituent:



- 10 wherein B is a non-cyclic substituent) or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butenyl, 3-butenyl, 2-butyryl, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 1-pentyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-pentynyl, 3-pentynyl, 2-pentyl, 1-methyl-2-butenyl, 1-methyl-3-butenyl, 1-methyl-2-butyryl, 3-pentyl, 1-ethyl-2-propenyl, 2-methylbutyl, 2-methyl-2-butenyl, 2-methyl-3-butenyl, 2-methyl-3-butyryl, 3-methylbutyl, 3-methyl-2-butenyl, 3-methyl-3-butenyl, 1-hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 2-hexyl, 1-methyl-2-pentenyl, 1-methyl-3-pentenyl, 1-methyl-4-pentenyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 3-hexyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 1-propyl-2-propenyl, 1-ethyl-2-butyryl, 1-heptyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 2-heptyl, 3-heptyl, 4-heptyl, 5-heptyl, 2-heptyl, 1-methyl-2-hexenyl, 1-methyl-3-hexenyl, 1-methyl-4-hexenyl, 1-methyl-5-hexenyl, 1-methyl-2-hexynyl, 1-methyl-3-hexynyl, 1-methyl-4-hexynyl, 3-
- 15
20
25

heptyl, 1-ethyl-2-pentenyl, 1-ethyl-3-pentenyl, 1-ethyl-4-pentenyl, 1-butyl-2-propenyl, 1-ethyl-2-pentynyl, 1-ethyl-3-pentynyl, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 4-trifluoromethyl-5,5,5-trifluoropentyl, 4-trifluoromethylpentyl, 5,5,6,6,6-pentafluorohexyl, and 3,3,3-trifluoropropyl, wherein each member of
 5 group B is optionally substituted at any carbon up to and including 5 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy,
 10 isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl, N-
 15 methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, cyano, and Q^b ;

A is selected from the group consisting of single covalent bond, NH,
 20 $N(CH_3)$, $N(OH)$, CH_2 , CH_3CH , CF_3CH , $NHC(O)$, $N(CH_3)C(O)$, $C(O)NH$, $C(O)N(CH_3)$, CH_2CH_2 , $CH_2CH_2CH_2$, CH_3CHCH_2 , and CF_3CHCH_2 ;

A is optionally selected from the group consisting of $CH_2N(CH_3)$, $CH_2N(CH_2CH_3)$, $CH_2CH_2N(CH_3)$, and $CH_2CH_2N(CH_2CH_3)$ with the proviso that B is hydrido;
 25 R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino, guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio,
 30 methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl,


pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;

- R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $C(NR^{25})NR^{23}R^{24}$, and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, $C(NR^{25})NR^{23}R^{24}$, and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, isopropyl, and hydroxy.

- In still another more preferred specific embodiment of Formula I, compounds have the Formula I-MPS wherein B is a non-aromatic cyclic substituent:



wherein B is a non-aromatic cyclic substituent) or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of cyclopropyl, cyclobutyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, thiaetan-3-yl, cyclopentyl, cyclohexyl, norbornyl, 7-oxabicyclo[2.2.1]heptan-2-yl, bicyclo[3.1.0]hexan-6-yl, cycloheptyl, 2-morpholinyl, 3-morpholinyl,

- 4-morpholinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-dioxanyl, 4H-2-pyranyl, 4H-3-pyranyl, 4H-4-pyranyl, 4H-pyran-4-one-2-yl, 4H-pyran-4-one-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 5 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl, wherein each ring carbon is optionally substituted with R^{33} , ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from 10 the point of attachment is optionally substituted with R^{10} , and a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} ;

- A is selected from the group consisting of single covalent bond, NH, $N(CH_3)$, $N(OH)$, CH_2 , CH_3CH , CF_3CH , $NHC(O)$, $N(CH_3)C(O)$, $C(O)NH$, 15 $C(O)N(CH_3)$, CH_2CH_2 , $CH_2CH_2CH_2$, CH_3CHCH_2 , and CF_3CHCH_2 ;

- R^{33} is selected from the group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, 20 trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, 25 amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, cyano, and Q^b ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino,

guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;


R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} ,

R^{19} , and Q^b are not simultaneously hydrido;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido, with the proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, methyl, ethyl, and hydroxy.

The more preferred specific embodiment (I-MPS) compounds of the present invention having the Formula:



or a pharmaceutically acceptable salt thereof, have common structural units, wherein;

M is N or R^1 -C;

R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino, dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy,

1,1,2,2-tetrafluoroethoxy, fluoro, chloro, and bromo;

R^2 is Z^0 -Q;

Z^0 is selected from the group consisting of a bond, CH_2 , CH_2CH_2 , O, S, NH, $N(CH_3)$, OCH_2 , SCH_2 , $N(H)CH_2$, and $N(CH_3)CH_2$;

- 5 Q is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to
10 the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of
15 attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;


- R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, N-methylamino,
20 N,N-dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, methanesulfonamido, amidosulfonyl, N-methylamidodisulfonyl, N,N-dimethylamidodisulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl,
25 2,2,2-trifluoro-1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, carboxymethyl, methyl, ethyl, propyl,


- isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methanesulfonamido, amidosulfonyl, N-methylamidosulfonyl,
- 5 N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl, N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl,
- 10 N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl, N-benzylamidosulfonyl, N-(2-chlorobenzyl)amidosulfonyl, N-ethylamidocarbonyl, N-isopropylamidocarbonyl, N-propylamidocarbonyl, N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl, N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl,
- 15 N-cyclohexylamidocarbonyl, fluoro, chloro, bromo, cyano, cyclobutoxy, cyclohexoxy, cyclohexylmethoxy, 4-trifluoromethylcyclohexylmethoxy, cyclopentoxy, benzyl, benzyloxy, 4-bromo-3-fluorophenoxy, 3-bromobenzyloxy, 4-bromobenzyloxy, 4-bromobenzylamino, 5-bromopyrid-2-ylmethylamino, 4-butoxyphenamino, 3-chlorobenzyl,
- 20 4-chlorophenoxy, 4-chloro-3-ethylphenoxy, 4-chloro-3-ethylbenzylamino, 4-chloro-3-ethylphenylamino, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 4-chlorobenzylsulfonyl, 4-chlorophenylamino, 4-chlorophenylsulfonyl, 5-chloropyrid-3-yloxy, 2-cyanopyrid-3-yloxy, 2,3-difluorobenzyloxy, 2,4-difluorobenzyloxy, 3,4-difluorobenzyloxy, 2,5-difluorobenzyloxy,
- 25 3,5-difluorophenoxy, 3,5-difluorobenzyloxy, 4-difluoromethoxybenzyloxy, 2,3-difluorophenoxy, 2,4-difluorophenoxy, 2,5-difluorophenoxy, 5-dimethylphenoxy, 3,4-dimethylphenoxy, 3,4-dimethylbenzyloxy, 3,5-dimethylbenzyloxy, 4-ethoxyphenoxy, 4-ethylbenzyloxy, 3-ethylphenoxy, 4-ethylaminophenoxy, 3-ethyl-5-methylphenoxy, 4-fluorobenzyloxy,
- 30 2-fluoro-3-trifluoromethylbenzyloxy, 3-fluoro-5-trifluoromethylbenzyloxy, 4-fluoro-2-trifluoromethylbenzyloxy, 4-fluoro-3-trifluoromethylbenzyloxy, 2-fluorophenoxy, 4-fluorophenoxy, 2-fluoro-3-trifluoromethylphenoxy, 2-fluorobenzyloxy, 4-fluorophenylamino, 2-fluoro-4-trifluoromethylphenoxy, 4-isopropylbenzyloxy, 3-isopropylphenoxy, 4-isopropylphenoxy,
- 35 4-isopropyl-3-methylphenoxy, 4-isopropylbenzyloxy, 3-isopropylphenoxy,

- 4-isopropylphenoxy, 4-isopropyl-3-methylphenoxy, phenylamino,
 1-phenylethoxy, 2-phenylethoxy, 2-phenylethyl, 2-phenylethylamino,
 phenylsulfonyl, 3-trifluoromethoxybenzyloxy, 4-trifluoromethoxybenzyloxy,
 3-trifluoromethoxyphenoxy, 4-trifluoromethoxyphenoxy,
 5 3-trifluoromethylbenzyloxy, 4-trifluoromethylbenzyloxy,
 2,4-bis-trifluoromethylbenzyloxy, 3-trifluoromethylbenzyl,
 3,5-bis-trifluoromethylbenzyloxy, 4-trifluoromethylphenoxy,
 3-trifluoromethylphenoxy, 3-trifluoromethylthiobenzyloxy,
 4-trifluoromethylthiobenzyloxy, 2,3,4-trifluorophenoxy, 2,3,5-trifluorophenoxy,
 10 3-pentafluoroethylphenoxy, 3-(1,1,2,2-tetrafluoroethoxy)phenoxy, and
 3-trifluoromethylthiophenoxy;

Y^0 is selected from the group of formulas consisting of:




1- Q^b -4- Q^s -2- R^{16} -3- R^{17} -5- R^{18} -6- R^{19} benzene,




2- Q^b -5- Q^s -6- R^{17} -4- R^{18} -3- R^{19} pyridine,


15



3- Q^b -6- Q^s -2- R^{16} -5- R^{18} -4- R^{19} pyridine,




2- Q^b -5- Q^s -3- R^{16} -6- R^{18} pyrazine,




5


3- Q^b -6- Q^s -2- R^{18} -5- R^{19} -4- R^{19} pyridazine,




2- Q^b -5- Q^s -4- R^{17} -6- R^{18} pyrimidine,



5- Q^b -2- Q^s -4- R^{16} -6- R^{19} pyrimidine,




3- Q^b -5- Q^s -4- R^{16} -2- R^{19} thiophene,




2- Q^b -5- Q^s -3- R^{16} -4- R^{17} thiophene,


5




3- Q^b -5- Q^s -4- R^{16} -2- R^{19} furan,



2- Q^b -5- Q^s -3- R^{16} -4- R^{17} furan,





3- Q^b -5- Q^s -4- R^{16} -2- R^{19} pyrrole,





2- Q^b -5- Q^s -3- R^{16} -4- R^{17} pyrrole,


5

4-Q^b-2-Q^s-5-R¹⁹ imidazole,2-Q^b-4-Q^s-5-R¹⁷ imidazole,


5

3-Q^b-5-Q^s-4-R¹⁶ isoxazole,5-Q^b-3-Q^s-4-R¹⁶ isoxazole,


10



2- Q^b -5- Q^s -4- R^{16} pyrazole,




4- Q^b -2- Q^s -5- R^{19} thiazole, and



2- Q^b -5- Q^s -4- R^{17} thiazole;

Q^s is selected from the group consisting of a bond, CH_2 and CH_2CH_2 .

In a most preferred specific embodiment of Formula I, compounds have the Formula I-EMPS wherein B is an aromatic:



(I-EMPS wherein B is aromatic)

or a pharmaceutically acceptable salt thereof, wherein;


- B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, and 5-isoxazolyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl
- 5 ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any
- 10 carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;
- R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,
- 15 fluoro, chloro, bromo, amidosulfonyl, N-methylamidodisulfonyl, hydroxymethyl, amidocarbonyl, carboxy, cyano, and Q^b ;

A is selected from the group consisting of a bond, NH, $N(CH_3)$, CH_2 , CH_3CH , and CH_2CH_2 ;

- Q^b is $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$;
- 20 R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, methyl, and ethyl.

25

In another most preferred specific embodiment of Formula I, compounds have the Formula I-EMPS wherein B is a non-cyclic substituent:



wherein B is a non-cyclic substituent)

5 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butenyl, 2-butyryl, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 1-pentyl, 2-pentenyl, 3-pentenyl, 2-pentynyl, 3-pentynyl, 2-pentyl, 3-pentyl, 2-methylbutyl, 2-methyl-2-butenyl, 10 3-methylbutyl, 3-methyl-2-butenyl, 1-hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 2-hexyl, 1-methyl-2-pentenyl, 1-methyl-3-pentenyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 3-hexyl, 1-ethyl-2-butenyl, 1-heptyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 2-heptyl, 3-heptyl, 4-heptyl, 5-heptyl, 2-heptyl, 1-methyl-2-hexenyl, 15 1-methyl-3-hexenyl, 1-methyl-4-hexenyl, 1-methyl-2-hexynyl, 1-methyl-3-hexynyl, 1-methyl-4-hexynyl, 3-heptyl, 1-ethyl-2-pentenyl, 1-ethyl-3-pentenyl, 1-ethyl-2-pentynyl, 1-ethyl-3-pentynyl, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 4-trifluoromethyl-5,5,5-trifluoropentyl, 4-trifluoromethylpentyl, 5,5,6,6,6-pentafluorohexyl, and 3,3,3-trifluoropropyl, 20 wherein each member of group B is optionally substituted at any carbon up to and including 5 atoms from the point of attachment of B to A with one or more of the group consisting of R³², R³³, R³⁴, R³⁵, and R³⁶;

R³², R³³, R³⁴, R³⁵, and R³⁶ are independently selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, 25 ethoxy, hydroxy, amino, N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,

fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, carboxy, cyano, and Q^b ;


A is selected from the group consisting of a bond, NH, N(CH₃), CH₂, CH₃CH, and CH₂CH₂;

- 5 A is optionally selected from the group consisting of CH₂N(CH₃), CH₂N(CH₂CH₃), CH₂CH₂N(CH₃), and CH₂CH₂N(CH₂CH₃) with the proviso that B is hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, $C(NR^{25})NR^{23}R^{24}$, and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$;

- 10 R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, methyl, and ethyl.

In still another most preferred specific embodiment of Formula I, compounds have the Formula I-EMPS wherein B is a non-aromatic cyclic substituent:



- 15 (I-EMPS wherein B is a non-aromatic cyclic substituent)

or a pharmaceutically acceptable salt thereof, wherein;

- 20 B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, bicyclo[3.1.0]hexan-6-yl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-pyrrolidinyl,

2-pyrrolidinyl, 3-pyrrolidinyl, 2-dioxanyl, 2-tetrahydrofuranyl,
3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl,
4-tetrahydropyranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl, wherein each
ring carbon is optionally substituted with R^{33} , ring carbons and a nitrogen

- 5 adjacent to the carbon atom at the point of attachment are optionally substituted
with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two
atoms from the point of attachment are optionally substituted with R^{10} , and a
ring carbon or nitrogen atom adjacent to the R^{13} position and two atoms from
the point of attachment is optionally substituted with R^{12} ;

- 10 R^{33} is selected from the group consisting of hydrido, amidino,
guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, carboxy, amino,
N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio,
trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo,
amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, cyano,
15 and Q^b ;


A is selected from the group consisting of a bond, NH, $N(CH_3)$, CH_2 ,

CH_3CH , CH_2CH_2 , and $CH_2CH_2CH_2$;

Q^b is $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$;

- R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently selected from the group
20 consisting of hydrido, methyl, and ethyl.

The most preferred specific embodiment (I-EMPS) compounds of the
present invention having the Formula:



or a pharmaceutically acceptable salt thereof, have common structural units, wherein;

M is N or R^1 -C;

- 5 R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, methylthio, trifluoromethoxy, fluoro, and chloro;

- R^2 is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-pyrrolyl, 2-imidazolyl, 2-thiazolyl, 3-isoxazolyl, 2-pyridyl, and 3-pyridyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to the uracil ring is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;
- 10
- 15

- R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, methylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamid sulfonyl, N,N-dimethylamid sulfonyl, hydroxymethyl,
- 20

1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, carboxy, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of

hydrido, amidino, amidocarbonyl, N-methylamidocarbonyl,

N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl,

5 N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl,

N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl,

N-benzylamidosulfonyl, N-(2-chlorobenzyl)amidosulfonyl,

N-ethylamidocarbonyl, N-isopropylamidocarbonyl, N-propylamidocarbonyl,

N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl,

10 N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl,

N-cyclohexylamidocarbonyl, guanidino, methyl, ethyl, methoxy, ethoxy,

hydroxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxy,

carboxymethyl, amino, acetamido, trifluoromethyl, pentafluoroethyl,


2,2,2-trifluoroethyl, trifluoroacetamido, aminomethyl, N-methylamino,

15 dimethylamino, methoxyamino, amidosulfonyl, N-methylamidosulfonyl,


N,N-dimethylamidosulfonyl, methanesulfonamido, methoxycarbonyl, fluoro,

chloro, bromo, and cyano;


Y^0 is selected from the group of formulas consisting of:



20 $1-Q^b-4-Q^s-2-R^{16}-3-R^{17}-5-R^{18}-6-R^{19}$ benzene,




3- Q^b -5- Q^s -4- R^{16} -2- R^{19} furan,




2- Q^b -5- Q^s -3- R^{16} -4- R^{17} furan,


5




3- Q^b -5- Q^s -4- R^{16} -2- R^{19} pyrrole,



2- Q^b -5- Q^s -3- R^{16} -4- R^{17} pyrrole,



4- Q^b -2- Q^s -5- R^{19} thiazole, and



2- Q^b -5- Q^s -4- R^{17} thiazole;

- 5 R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, methyl, ethyl, amidino, guanidino, methoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, methylthio, ethylthio, trifluoromethylthio, methylsulfinyl, methylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 10 trifluoromethoxy, fluoro, chloro, hydroxymethyl, carboxy, and cyano;

Q^s is CH_2 .

- The compounds of this invention can be used in anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular disease. The compounds of this invention 15 can be used to inhibit serine protease associated with the coagulation cascade and factors II, VII, VIII, IX, X, XI, or XII. The compounds of the invention can inhibit the formation of blood platelet aggregates, inhibit the formation of fibrin, inhibit thrombus formation, and inhibiting embolus formation in a mammal, in blood, in blood products, and in mammalian organs. The compounds also can 20 be used for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels in a mammal. The compounds can also be used in prophylactic treatment of

subjects who are at risk of developing such disorders. The compounds can be used to lower the risk of atherosclerosis. The compounds of Formula (I) would also be useful in prevention of cerebral vascular accident (CVA) or stroke.

5 Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

10 In yet another embodiment of the present invention, the novel compounds are selected from the compounds set forth in **Examples 1** through **Example 7**.

 The use of generic terms in the description of the compounds are herein defined for clarity.

15 Standard single letter elemental symbols are used to represent specific types of atoms unless otherwise defined. The symbol "C" represents a carbon atom. The symbol "O" represents an oxygen atom. The symbol "N" represents a nitrogen atom. The symbol "P" represents a phosphorus atom. The symbol "S" represents a sulfur atom. The symbol "H" represents a hydrido atom. Double letter elemental symbols are used as defined for the elements of the periodical table
20 (i.e., Cl represents chlorine, Se represents selenium, etc.).

 As utilized herein, the term "alkyl", either alone or within other terms such as "haloalkyl" and "alkylthio", means an acyclic alkyl radical containing from 1 to about 10, preferably from 3 to about 8 carbon atoms and more preferably 3 to about 6 carbon atoms. Said alkyl radicals may be optionally substituted with groups as
25 defined below. Examples of such radicals include methyl, ethyl, chloroethyl, hydroxyethyl, n-propyl, oxopropyl, isopropyl, n-butyl, cyanobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, aminopentyl, iso-amyl, hexyl, octyl and the like.

 The term "alkenyl" refers to an unsaturated, acyclic hydrocarbon radical in so much as it contains at least one double bond. Such alkenyl radicals contain
30 from about 2 to about 10 carbon atoms, preferably from about 3 to about 8 carbon atoms and more preferably 3 to about 6 carbon atoms. Said alkenyl radicals may be optionally substituted with groups as defined below. Examples of suitable alkenyl radicals include propenyl, 2-chloropropenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, 3-hydroxyhexen-1-yl, hepten-1-yl, and octen-1-yl, and the like.
35

5

10

15

The term “cyano” radical denotes a carbon radical having three of four covalent bonds shared by a nitrogen atom.

20

25

30

The term “alkenylene” radical denotes linear or branched radicals having from 2 to about 10 carbon atoms, at least one double bond, and having

attachment points for two or more covalent bonds. Examples of such radicals are 1,1-vinylidene ($\text{CH}_2=\text{C}$), 1,2-vinylidene ($-\text{CH}=\text{CH}-$), and 1,4-butadienyl ($-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$).

5 The term "halo" means halogens such as fluorine, chlorine, bromine or iodine atoms.

The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either a bromo, chloro or a
 10 fluoro atom within the radical. Dihalo radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhaloalkyl radicals may have more than two of the same halo atoms or a combination of different halo radicals. More preferred haloalkyl radicals are "haloalkyl" radicals having one to about six carbon atoms. Examples of such haloalkyl
 15 radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trifluoroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

The term "hydroxyhaloalkyl" embraces radicals wherein any one or
 20 more of the haloalkyl carbon atoms is substituted with hydroxy as defined above. Examples of "hydroxyhaloalkyl" radicals include hexafluorohydroxypropyl.

The term "haloalkylene radical" denotes alkylene radicals wherein any one or more of the alkylene carbon atoms is substituted with halo as defined
 25 above. Dihalo alkylene radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhaloalkylene radicals may have more than two of the same halo atoms or a combination of different halo radicals. More preferred haloalkylene radicals are "haloalkylene" radicals having one to about six carbon atoms. Examples of "haloalkylene" radicals
 30 include difluoromethylene, tetrafluoroethylene, tetrachloroethylene, alkyl substituted monofluoromethylene, and aryl substituted trifluoromethylene.

The term "haloalkenyl" denotes linear or branched radicals having from 1 to about 10 carbon atoms and having one or more double bonds wherein any one or more of the alkenyl carbon atoms is substituted with halo as
 35 defined above. Dihaloalkenyl radicals may have two or more of the same halo

The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-
5 containing radicals each having alkyl portions of one to about ten carbon atoms,
such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals
having one or more alkoxy radicals attached to the alkyl radical, that is, to form
monoalkoxyalkyl and dialkoxyalkyl radicals. More preferred alkoxy radicals
are "alkoxy" radicals having one to six carbon atoms. Examples of such
10 radicals include methoxy, ethoxy, propoxy, butoxy, isopropoxy and *tert*-butoxy
alkyls. The "alkoxy" radicals may be further substituted with one or more halo
atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" and
"haloalkoxyalkyl" radicals. Examples of such haloalkoxy radicals include
fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy,
15 trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and
fluoropropoxy. Examples of such haloalkoxyalkyl radicals include
fluoromethoxymethyl, chloromethoxyethyl, trifluoromethoxymethyl,
difluoromethoxyethyl, and trifluoroethoxymethyl.

The terms "alkenyloxy" and "alkenyloxyalkyl" embrace linear or branched oxy-containing radicals each having alkenyl portions of two to about ten carbon atoms, such as ethenyloxy or propenyloxy radical. The term "alkenyloxyalkyl" also embraces alkenyl radicals having one or more alkenyloxy radicals attached to the alkyl radical, that is, to form monoalkenyloxyalkyl and dialkenyloxyalkyl radicals. More preferred alkenyloxy radicals are "alkenyloxy" radicals having two to six carbon atoms. Examples of such radicals include ethenyloxy, propenyloxy, butenyloxy, and isopropenyloxy alkyls. The "alkenyloxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkenyloxy" radicals. Examples of such radicals include trifluoroethenyloxy, fluoroethenyloxy, difluoroethenyloxy, and fluoropropenyloxy.

35 "haloalkenyloxy" also embraces oxygen radicals having one or more

haloalkenyloxy radicals attached to the oxygen radical, that is, to form monohaloalkenyloxy and dihaloalkenyloxy radicals. The term "haloalkenyloxyalkyl" also embraces alkyl radicals having one or more haloalkenyloxy radicals attached to the alkyl radical, that is, to form monohaloalkenyloxyalkyl and dihaloalkenyloxyalkyl radicals.

The term "alkylenedioxy" radicals denotes alkylene radicals having at least two oxygens bonded to a single alkylene group. Examples of "alkylenedioxy" radicals include methylenedioxy, ethylenedioxy, alkylsubstituted methylenedioxy, and arylsubstituted methylenedioxy. The term "haloalkylenedioxy" radicals denotes haloalkylene radicals having at least two oxy groups bonded to a single haloalkyl group. Examples of "haloalkylenedioxy" radicals include difluoromethylenedioxy, tetrafluoroethylenedioxy, tetrachloroethylenedioxy, alkylsubstituted monofluoromethylenedioxy, and arylsubstituted monofluoromethylenedioxy.

The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused. The term "fused" means that a second ring is present (ie, attached or formed) by having two adjacent atoms in common (ie, shared) with the first ring. The term "fused" is equivalent to the term "condensed". The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.

The term "perhaloaryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl wherein the aryl radical is substituted with 3 or more halo radicals as defined below.

The term "heterocyclyl" embraces saturated and partially saturated heteroatom-containing ring-shaped radicals having from 4 through 15 ring members, herein referred to as "C4-C15 heterocyclyl", selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom. Heterocyclyl radicals may contain one, two or three rings wherein such rings may be attached in a pendant manner or may be fused. Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl, etc.]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2

sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl, etc.]. Examples of partially saturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Non-limiting examples of heterocyclic radicals include 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, 1,3-dioxolanyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, and the like. Said "heterocyclyl" group may be substituted as defined herein. Preferred heterocyclic radicals include five to twelve membered fused or unfused radicals.

The term "heteroaryl" embraces fully unsaturated heteroatom-containing ring-shaped aromatic radicals having from 4 through 15 ring members selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom. Heteroaryl radicals may contain one, two or three rings wherein such rings may be attached in a pendant manner or may be fused. Examples of "heteroaryl" radicals, include the unsaturated heteromonocyclyl group of 5 to 6 contiguous members containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.] tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizynyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5-b]pyridazinyl, etc.], etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl, etc.]; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.] and the like. The term also embraces radicals where heterocyclic radicals are fused with

09717051.112000

The term "aralkyl" embraces aryl-substituted alkyl radicals. Preferable aralkyl radicals are " aralkyl" radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Examples of such radicals include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl and diphenylethyl. The terms benzyl and phenylmethyl are interchangeable.

The term "heteroaralkyl" embraces heteroaryl-substituted alkyl radicals wherein the heteroaralkyl radical may be additionally substituted with three or more substituents as defined above for aralkyl radicals. The term "perhaloaralkyl" embraces aryl-substituted alkyl radicals wherein the aralkyl radical is substituted with three or more halo radicals as defined above.

The term "aralkylsulfinyl", embraces aralkyl radicals attached to a sulfinyl radical, where aralkyl is defined as above. "Aralkylsulfinylalkyl", embraces aralkylsulfinyl radicals attached to an alkyl radical, where alkyl is defined as above.

The term "aralkylsulfonyl", embraces aralkyl radicals attached to a sulfonyl radical, where aralkyl is defined as above. "Aralkylsulfonylalkyl", embraces aralkylsulfonyl radicals attached to an alkyl radical, where alkyl is defined as above.

The term "cycloalkyl" embraces radicals having three to 15 carbon atoms. More preferred cycloalkyl radicals are " cycloalkyl" radicals having three to seven carbon atoms. Examples include radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term cycloalkyl embraces radicals having seven to 15 carbon atoms and having two to four rings. Exmaples incude radicals such as norbornyl (i.e., bicyclo[2.2.1]heptyl) and adamantyl. The term "cycloalkylalkyl" embraces cycloalkyl-substituted alkyl radicals. Preferable cycloalkylalkyl radicals are " cycloalkylalkyl" radicals having cycloalkyl radicals attached to alkyl radicals having one to six carbon atoms. Examples of such radicals include cyclohexylhexyl. The term "cycloalkenyl" embraces radicals having three to ten carbon atoms and one or more carbon-carbon double bonds. Preferred cycloalkenyl radicals are " cycloalkenyl" radicals having three to seven carbon atoms. Examples include radicals such as cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. The term "halocycloalkyl" embraces radicals wherein any one or more of the cycloalkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohalocycloalkyl, dihalocycloalkyl and polyhalocycloalkyl

radicals. A monohalocycloalkyl radical, for one example, may have either a bromo, chloro or a fluoro atom within the radical. Dihalo radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhalocycloalkyl radicals may have more than two of the same halo atoms or a combination of different halo radicals. More preferred halocycloalkyl radicals are "halocycloalkyl" radicals having three to about eight carbon atoms. Examples of such halocycloalkyl radicals include fluorocyclopropyl, difluorocyclobutyl, trifluorocyclopentyl, tetrafluorocyclohexyl, and dichlorocyclopropyl. The term "halocycloalkenyl" embraces radicals wherein any one or more of the cycloalkenyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohalocycloalkenyl, dihalocycloalkenyl and polyhalocycloalkenyl radicals.

The term "cycloalkoxy" embraces cycloalkyl radicals attached to an oxy radical. Examples of such radicals includes cyclohexoxy and cyclopentoxy. The term "cycloalkoxyalkyl" also embraces alkyl radicals having one or more cycloalkoxy radicals attached to the alkyl radical, that is, to form monocycloalkoxyalkyl and dicycloalkoxyalkyl radicals. Examples of such radicals include cyclohexoxyethyl. The "cycloalkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "halocycloalkoxy" and "halocycloalkoxyalkyl" radicals.

The term "cycloalkylalkoxy" embraces cycloalkyl radicals attached to an alkoxy radical. Examples of such radicals includes cyclohexylmethoxy and cyclopentylmethoxy.

The term "cycloalkenyloxy" embraces cycloalkenyl radicals attached to an oxy radical. Examples of such radicals includes cyclohexenyloxy and cyclopentenylloxy. The term "cycloalkenyloxyalkyl" also embraces alkyl radicals having one or more cycloalkenyloxy radicals attached to the alkyl radical, that is, to form monocycloalkenyloxyalkyl and dicycloalkenyloxyalkyl radicals. Examples of such radicals include cyclohexenyloxyethyl. The "cycloalkenyloxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "halocycloalkenyloxy" and "halocycloalkenyloxyalkyl" radicals.

The term "cycloalkylenedioxy" radicals denotes cycloalkylene radicals having at least two oxygens bonded to a single cycloalkylene group. Examples of "alkylenedioxy" radicals include 1,2-dioxycyclohexylene.

The term "cycloalkylsulfinyl", embraces cycloalkyl radicals attached to a sulfinyl radical, where cycloalkyl is defined as above. "Cycloalkylsulfinylalkyl", embraces cycloalkylsulfinyl radicals attached to an alkyl radical, where alkyl is defined as above. The term "Cycloalkylsulfonyl", embraces cycloalkyl radicals
 5 attached to a sulfonyl radical, where cycloalkyl is defined as above. "Cycloalkylsulfonylalkyl", embraces cycloalkylsulfonyl radicals attached to an alkyl radical, where alkyl is defined as above.

The term "cycloalkylalkanoyl" embraces radicals wherein one or more of the cycloalkyl carbon atoms are substituted with one or more carbonyl
 10 radicals as defined below. Specifically embraced are monocarbonylcycloalkyl and dicarbonylcycloalkyl radicals. Examples of monocarbonylcycloalkyl radicals include cyclohexylcarbonyl, cyclohexylacetyl, and cyclopentylcarbonyl. Examples of dicarbonylcycloalkyl radicals include 1,2-dicarbonylcyclohexane.

The term "alkylthio" embraces radicals containing a linear or branched
 15 alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. More preferred alkylthio radicals are "alkylthio" radicals having one to six carbon atoms. An example of "alkylthio" is methylthio ($\text{CH}_3\text{-S-}$). The "alkylthio" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkylthio" radicals. Examples
 20 of such radicals include fluoromethylthio, chloromethylthio, trifluoromethylthio, difluoromethylthio, trifluoroethylthio, fluoroethylthio, tetrafluoroethylthio, pentafluoroethylthio, and fluoropropylthio.

The term "alkyl aryl amino" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, and one aryl radical both
 25 attached to an amino radical. Examples include N-methyl-4-methoxyaniline, N-ethyl-4-methoxyaniline, and N-methyl-4-trifluoromethoxyaniline.

The term alkylamino denotes "monoalkylamino" and "dialkylamino" containing one or two alkyl radicals, respectively, attached to an amino radical. One or two alkyl radicals of the alkylamino may be optionally substituted with
 30 hydrogen bonding substituents selected from the group consisting of hydroxy, amino, monoalkylamino, dialkylamino, amidino, guanidino, thiol, and alkoxy provided the alkyl radicals comprises two or more carbons.

The terms arylamino denotes "monoarylamino" and "diarylamino" containing one or two aryl radicals, respectively, attached to an amino radical.
 35 Examples of such radicals include N-phenylamino and N-naphthylamino.

The term "aralkanoyl" embraces aralkyl radicals, as defined herein, attached to an carbonyl radical as defined above. Examples of such radicals include, for example, phenylacetyl.

5 The term "aralkoxy" embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are " aralkoxy" radicals having phenyl radicals attached to alkoxy radical as described above. Examples of such radicals include benzyloxy, 1-phenylethoxy, 3-trifluoromethoxybenzyloxy, 3-trifluoromethylbenzyloxy, 3,5-difluorobenzyloxy, 3-bromobenzyloxy, 4-propylbenzyloxy, 2-fluoro-3-
10 trifluoromethylbenzyloxy, and 2-phenylethoxy.

The term "aryloxyalkyl" embraces aryloxy radicals, as defined above, attached to an alkyl group. Examples of such radicals include phenoxymethyl.

The term "haloaryloxyalkyl" embraces aryloxyalkyl radicals, as defined above, wherein one to five halo radicals are attached to an aryloxy group.

15 The term "heteroaroyl" embraces heteroaryl radicals, as defined above, attached to an carbonyl radical as defined above. Examples of such radicals include furoyl and nicotinyl.

The term "heteroaralkanoyl" embraces heteroaralkyl radicals, as defined herein, attached to an carbonyl radical as defined above. Examples of such
20 radicals include, for example, pyridylacetyl and furylbutyryl.

The term "heteroaralkoxy" embraces oxy-containing heteroaralkyl radicals attached through an oxygen atom to other radicals. More preferred heteroaralkoxy radicals are " heteroaralkoxy" radicals having heteroaryl radicals attached to alkoxy radical as described above. The term
25 "heterocyclalkoxy" embraces oxy-containing heterocyclalkyl radicals attached through an oxygen atom to other radicals.

The term "haloheteroaryloxyalkyl" embraces heteroaryloxyalkyl radicals, as defined above, wherein one to four halo radicals are attached to an heteroaryloxy group.

30 The term "heteroarylamino" embraces heteroaryl radicals, as defined above, attached to an amino group. Examples of such radicals include pyridylamino. The term "heterocycllamino" embraces heterocycll radicals, as defined above, attached to an amino group.

The term "heteroaralkylamino" embraces heteroaralkyl radicals, as
35 defined above, attached to an amino group. Examples of such radicals include

pyridylmethylamino. The term "heterocyclylalkylamino" embraces heterocyclylalkyl radicals, as defined above, attached to an amino group.

The term "heteroaryloxy" embraces heteroaryl radicals, as defined above, attached to an oxy group. Examples of such radicals include 2-thiophenyloxy, 2-pyrimidyloxy, 2-pyridyloxy, 3-pyridyloxy, and 4-pyridyloxy. The term "heterocyclyloxy" embraces heterocyclyl radicals, as defined above, attached to an oxy group.

The term "heteroaryloxyalkyl" embraces heteroaryloxy radicals, as defined above, attached to an alkyl group. Examples of such radicals include 2-pyridyloxymethyl, 3-pyridyloxyethyl, and 4-pyridyloxymethyl. The term "heterocyclyloxyalkyl" embraces heterocyclyloxy radicals, as defined above, attached to an alkyl group.

The term "arylthio" embraces aryl radicals, as defined above, attached to an sulfur atom. Examples of such radicals include phenylthio.

The term "arylthioalkyl" embraces arylthio radicals, as defined above, attached to an alkyl group. Examples of such radicals include phenylthiomethyl.

The term "alkylthioalkyl" embraces alkylthio radicals, as defined above, attached to an alkyl group. Examples of such radicals include methylthiomethyl. The term "alkoxyalkyl" embraces alkoxy radicals, as defined above, attached to an alkyl group. Examples of such radicals include methoxymethyl.

The term "carbonyl" denotes a carbon radical having two of the four covalent bonds shared with an oxygen atom. The term "carboxy" embraces a hydroxyl radical, as defined above, attached to one of two unshared bonds in a carbonyl group. The term "carboxamido" embraces amino, monoalkylamino, dialkylamino, monocycloalkylamino, alkylcycloalkylamino, dicycloalkylamino, N-alkyl-N-arylamino, arylamino, aralkylamino, nitrogen containing heterocyclyl, heterocyclylamino, N-alkyl-N-heterocyclylamino, heteroarylamino, and heteroaralkylamino radicals, attached to one of two unshared bonds in a carbonyl group. The term "carboxamidoalkyl" embraces carboxamido radicals, as defined above, attached to an alkyl group. The term "carboxyalkyl" embraces a carboxy radical, as defined above, attached to an alkyl group. The term "carboalkoxy" embraces alkoxy radicals, as defined above, attached to one of two unshared bonds in a carbonyl group. The term "carboaralkoxy" embraces aralkoxy radicals, as

defined above, attached to one of two unshared bonds in a carbonyl group. The term "monocarboalkoxyalkyl" embraces one carboalkoxy radical, as defined above, attached to an alkyl group. The term "dicarboalkoxyalkyl" embraces two carboalkoxy radicals, as defined above, attached to an alkylene group. The term

5 "monocyanoalkyl" embraces one cyano radical, as defined above, attached to an alkyl group. The term "dicyanoalkylene" embraces two cyano radicals, as defined above, attached to an alkyl group. The term "carboalkoxycyanoalkyl" embraces one cyano radical, as defined above, attached to an carboalkoxyalkyl group.

The term "acyl", alone or in combination, means a carbonyl or

10 thionocarbonyl group bonded to a radical selected from, for example, hydrido, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkoxyalkyl, haloalkoxy, aryl, heterocyclyl, heteroaryl, alkylsulfinylalkyl, alkylsulfonylalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylthio, arylthio, amino, alkylamino, dialkylamino, aralkoxy, arylthio, and alkylthioalkyl. Examples of "acyl" are formyl, acetyl, benzoyl, trifluoroacetyl,

15 phthaloyl, malonyl, nicotinyl, and the like. The term "haloalkanoyl" embraces one or more halo radicals, as defined herein, attached to an alkanoyl radical as defined above. Examples of such radicals include, for example, chloroacetyl, trifluoroacetyl, bromopropanoyl, and heptafluorobutanoyl.

The term "phosphono" embraces a pentavalent phosphorus attached with

20 two covalent bonds to an oxygen radical. The term "dialkoxyposphono" denotes two alkoxy radicals, as defined above, attached to a phosphono radical with two covalent bonds. The term "diaralkoxyposphono" denotes two aralkoxy radicals, as defined above, attached to a phosphono radical with two covalent bonds. The term "dialkoxyposphonoalkyl" denotes dialkoxyposphono radicals, as defined

25 above, attached to an alkyl radical. The term "diaralkoxyposphonoalkyl" denotes diaralkoxyposphono radicals, as defined above, attached to an alkyl radical.

The term "amino" denotes a nitrogen atom containing two substituents such as hydrido, hydroxy or alkyl and having one covalent bond available for bonding to a single atom such as carbon. Examples of such amino radicals include,

30 for example, -NH_2 , -NHCH_3 , -NHOH , and -NHOCH_3 . The term "imino" denotes a nitrogen atom containing one substituent such as hydrido, hydroxy or alkyl and having two covalent bonds available for bonding to a single atom such as carbon. Examples of such imino radicals include, for example, =NH , =NCH_3 , =NOH , and =NOCH_3 . The term "imino carbonyl" denotes a carbon radical

having two of the four covalent bond sites shared with an imino group. Examples of such imino carbonyl radicals include, for example, $C=NH$, $C=NCH_3$, $C=NOH$, and $C=NOCH_3$. The term "amidino" embraces a substituted or unsubstituted amino group bonded to one of two available bonds of an iminocarbonyl radical.

- 5 Examples of such amidino radicals include, for example, $NH_2-C=NH$, $NH_2-C=NCH_3$, $NH_2-C=NOCH_3$ and $CH_3NH-C=NOH$. The term "guanidino" denotes an amidino group bonded to an amino group as defined above where said amino group can be bonded to a third group. Examples of such guanidino radicals include, for example, $NH_2-C(NH)-NH-$, $NH_2-C(NCH_3)-NH-$, $NH_2-C(NOCH_3)-NH-$, and $CH_3NH-C(NOH)-NH-$.

The term "sulfonium" denotes a positively charged trivalent sulfur atom where said sulfur is substituted with three carbon based groups such as alkyl, alkenyl, aralkyl, or aryl. The term "dialkyl sulfonium" denotes a sulfonium group where said sulfur is substituted with two alkyl groups. Examples of such

- 15 dialkylsulfonium radicals include, for example, $(CH_3)_2S^+$. The term "dialkyl sulfonium alkyl" denotes a dialkyl sulfonium group where said group is bonded to one bond of an alkylene group as defined above. Examples of such dialkylsulfoniumalkyl radicals include $(CH_3)_2S^+-CH_2CH_2-$.

- 20 The term "phosphonium" denotes a positively charged tetravalent phosphorus atom where said phosphorus is substituted with four carbon based groups such as alkyl, alkenyl, aralkyl, or aryl. The term "trialkyl phosphonium" denotes a phosphonium group where said phosphorus is substituted with three alkyl groups. Examples of such trialkylphosphonium radicals include, for example, $(CH_3)_3P^+$.

- 25 Said "alkyl", "alkenyl", "alkynyl", "alkanoyl", "alkylene", "alkenylene", "hydroxyalkyl", "haloalkyl", "haloalkylene", "haloalkenyl", "alkoxy", "alkenyloxy", "alkenyloxyalkyl", "alkoxyalkyl", "aryl", "perhaloaryl", "haloalkoxy", "haloalkoxyalkyl", "haloalkenyloxy", "haloalkenyloxyalkyl", "alkylenedioxy", "haloalkylenedioxy", "heterocyclyl", "heteroaryl", "hydroxyhaloalkyl", "alkylsulfonyl", "haloalkylsulfonyl", "alkylsulfonylalkyl", "haloalkylsulfonylalkyl", "alkylsulfinyl",
- 30

150

- heteroarylsulfinyl, heteroarylsulfonyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalkyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, aminoalkyl, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroaralkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, alkoxycarbonyl, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl.

- The term "spacer" can include a covalent bond and a linear moiety having a backbone of 1 to 7 contiguous atoms. The spacer may have 1 to 7 atoms of a univalent or multi-valent chain. Univalent chains may be constituted by a radical selected from $=C(H)-$, $=C(R^{2a})-$, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-NH-$, $-N(R^{2a})-$, $-N=$, $-CH(OH)-$, $=C(OH)-$, $-CH(OR^{2a})-$, $=C(OR^{2a})-$, and $-C(O)-$ wherein R^{2a} is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, aryloxyalkyl, alkoxyalkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, perhaloaralkyl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylthioalkyl, and heteroarylalkenyl. Multi-valent chains may consist of a straight chain of 1 or 2 or 3 or 4 or 5 or 6 or 7 atoms or a straight chain of 1 or 2 or 3 or 4 or 5 or 6 atoms with a side chain. The chain may be constituted of one or more radicals selected from: alkylene, alkenyl, $-O-$, $-O-CH_2-$, $-S-CH_2-$, $-CH_2CH_2-$, ethenyl, $-CH=CH(OH)-$, $-OCH_2O-$, $-O(CH_2)_2O-$, $-NHCH_2-$, $-OCH(R^{2a})O-$, $-O(CH_2CHR^{2a})O-$, $-OCF_2O-$, $-O(CF_2)_2O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-N(H)-$, $-N(H)O-$, $-N(R^{2a})O-$, $-N(R^{2a})-$, $-C(O)-$, $-C(O)NH-$, $-C(O)NR^{2a}-$, $-N=$, $-OCH_2-$, $-SCH_2-$, $S(O)CH_2-$, $-CH_2C(O)-$, $-CH(OH)-$, $=C(OH)-$, $-CH(OR^{2a})-$, $=C(OR^{2a})-$, $S(O)_2CH_2-$, and $-NR^{2a}CH_2-$ and many other radicals defined above

- or generally known or ascertained by one of skill-in-the art. Side chains may include substituents such as 1 or more non-hydrido substituents such as amidino, guanidino, dialkylsulfonium, trialkylphosphonium, dialkylsulfoniumalkyl, perhaloaralkyl, aralkylsulfonyl, aralkylsulfonylalkyl, aralkylsulfinyl, aralkylsulfinylalkyl, halocycloalkyl, halocycloalkenyl, cycloalkylsulfinyl, cycloalkylsulfinylalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, heteroarylamino, N-heteroarylamino-N-alkylamino, heteroaralkylamino, heteroaryloxy, heteroaryloxyalkyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, heteroaralkoxy, cycloalkoxy, cycloalkenyloxy, cycloalkoxyalkyl, cycloalkylalkoxy, cycloalkenyloxyalkyl, cycloalkylenedioxy, halocycloalkoxy, halocycloalkoxyalkyl, halocycloalkenyloxy, halocycloalkenyloxyalkyl, hydroxy, amino, thio, nitro, alkylamino, alkylthio, alkylthioalkyl, arylamino, aralkylamino, arylthio, arylthioalkyl, heteroaralkoxyalkyl, alkylsulfinyl, alkylsulfinylalkyl, arylsulfinylalkyl, arylsulfonylalkyl, heteroarylsulfinylalkyl, heteroarylsulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, haloalkylsulfinylalkyl, haloalkylsulfonylalkyl, alkylsulfonamido, alkylaminosulfonyl, amidosulfonyl, monoalkyl amidosulfonyl, dialkyl amidosulfonyl, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoalkyl monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkenyloxyalkyl, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyaralkyl, hydroxyalkyl, aminoalkyl, hydroxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, carboxyalkyl, carboalkoxy, carboaralkoxy, carboxamido, carboxamidoalkyl, cyano, carbohaloalkoxy, phosphono, phosphonoalkyl, diaralkoxyphosphono, and diaralkoxyphosphonoalkyl.
- 30 Compounds of the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d-isomers, l-isomers, the racemic mixtures thereof and other mixtures thereof, as falling within the scope of the invention. Pharmaceutically

acceptable sales of such tautomeric, geometric or stereoisomeric forms are also included within the invention.

The terms "cis" and "trans" denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond ("cis") or on opposite sides of the double bond ("trans").

Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or "E" and "Z" geometric forms.

Some of the compounds described contain one or more stereocenters and are meant to include R, S, and mixtures of R and S forms for each stereocenter present.


Some of the compounds described herein may contain one or more ketonic or aldehydic carbonyl groups or combinations thereof alone or as part of a heterocyclic ring system. Such carbonyl groups may exist in part or principally in the "keto" form and in part or principally as one or more "enol" forms of each aldehyde and ketone group present. Compounds of the present invention having aldehydic or ketonic carbonyl groups are meant to include both "keto" and "enol" tautomeric forms.

Some of the compounds described herein may contain one or more amide carbonyl groups or combinations thereof alone or as part of a heterocyclic ring system. Such carbonyl groups may exist in part or principally in the "keto" form and in part or principally as one or more "enol" forms of each amide group present. Compounds of the present invention having amidic carbonyl groups are meant to include both "keto" and "enol" tautomeric forms. Said amide carbonyl groups may be both oxo ($C=O$) and thiono ($C=S$) in type.

Some of the compounds described herein may contain one or more imine or enamine groups or combinations thereof. Such groups may exist in part or principally in the "imine" form and in part or principally as one or more "enamine" forms of each group present. Compounds of the present invention having said imine or enamine groups are meant to include both "imine" and "enamine" tautomeric forms.

The present invention also comprises a treatment and prophylaxis in anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular disease in a subject,

comprising administering to the subject having such disorder a therapeutically-effective amount of a compound of Formula (I):



or a pharmaceutically-acceptable salt thereof.

- 5 As a further embodiment, compounds of the present invention of Formula (I) or a pharmaceutically-acceptable salt thereof as defined above, comprise a treatment and prophylaxis of coronary artery disease, cerebrovascular disease and other coagulation cascade related disorders in a subject, comprising administering to the subject having such disorder a therapeutically-effective amount of compounds of formula (I) of the present invention or a pharmaceutically-acceptable salt thereof.

- 10 Compounds of the present invention of Formula (I) or a pharmaceutically-acceptable salt thereof can also be used whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus coagulation inhibitors of the present invention can be added to or contacted with stored whole blood and any medium containing or suspected of containing plasma coagulation factors and in which it is desired that blood coagulation be inhibited, e.g. when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.

- 20 Compounds of Formula (I) are capable of inhibiting activity of serine proteases related to the coagulation cascade, and thus could be used in the manufacture of a medicament, a method for the prophylactic or therapeutic treatment of diseases mediated by coagulation cascade serine proteases, such as inhibiting the formation of blood platelet aggregates, inhibiting the formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, in blood, in blood products, and in mammalian organs. The

compounds also can be used for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and

5 reocclusion or restenosis of recanalized vessels in a mammal. The compounds also can be used to study the mechanism of action of coagulation cascade serine proteases to enable the design of better inhibitors and development of better assay methods. The compounds of Formula (I) would be also useful in prevention of cerebral vascular accident (CVA) or stroke.

10 Also included in the family of compounds of Formula (I) are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salt" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable

15 pharmaceutically-acceptable acid addition salts of compounds of Formula (I) may be prepared from inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and

20 sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethylsulfonic, benzenesulfonic, sulfanilic, stearic,

25 cyclohexylaminosulfonic, algenic, galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula (I) include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, choline, chlorprocaine, diethanolamine, ethylenediamine, meglumine (N-

30 methylglucamine) and procain. All of these salts may be prepared by conventional means from the corresponding compound of Formula (I) by reacting, for example, the appropriate acid or base with the compound of Formula (I).

The present invention also comprises a pharmaceutical composition

35 comprising a therapeutically-effective amount of a compound of Formulas (I)

5 (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.

15 The compounds can be administered in the form of a depot injection or
implant preparation which may be formulated in such a manner as to permit a
sustained release of the active ingredient. The active ingredient can be
compressed into pellets or small cylinders and implanted subcutaneously or
intramuscularly as depot injections or implants. Implants may employ inert
20 materials such as biodegradable polymers or synthetic silicones, for example,
Silastic, silicone rubber or other silicon containing polymers.

The compounds may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters,

For oral administration, the pharmaceutical composition may be in the form of, for example, tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, liquids including syrups, and emulsions. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 2000 mg, and preferably in the range of about 0.5 to 500 mg. A daily dose of about 0.01 to 100 mg/kg body weight, and preferably between about 0.5 and about 20 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of

09717051.112000

this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

10 The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others.

20 The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

30 For therapeutic purposes, the active compounds of the present invention are ordinarily combined with one or more adjuvants appropriate to the indicated

route of administration. If administered *per os*, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

In practicing the methods of the present invention for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular disease, the compounds and pharmaceutical compositions of the present invention are administered alone or in combination with one another, or in combination with other therapeutics or in vivo diagnostic agents. The coagulation cascade inhibitors of the present invention can also be co-administered with suitable anti-platelet aggregation agents, including, but not limited to ticlopidine or clopidogrel, fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis), anti-coagulants such as aspirin, warfarin or heparins, thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various pathologies, lipid lowering agents including antihypercholesterolemics (e.g. HMG CoA reductase inhibitors such as mevastatin, lovastatin, simvastatin, pravastatin, and fluvastatin, HMG CoA synthetase inhibitors, etc.), anti-diabetic drugs, or other cardiovascular agents (loop diuretics, thiazide type diuretics, nitrates, aldosterone antagonists (i.e., spironolactone and epoxymexlerenone), angiotensin converting enzyme (e.g. ACE) inhibitors, angiotensin II receptor antagonists, beta-blockers,

antiarrhythmics, anti-hypertension agents, and calcium channel blockers) to treat or prevent atherosclerosis. For example, patients suffering from coronary artery disease, and patients subjected to angioplasty procedures, would benefit from coadministration of fibrinogen receptor antagonists and coagulation cascade inhibitors of the present invention. Also, coagulation cascade inhibitors could enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion.

Typical doses of coagulation cascade inhibitors of the present invention with other suitable anti-platelet agents, anticoagulation agents, cardiovascular therapeutic agents, or thrombolytic agents may be the same as those doses of coagulation cascade inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, cardiovascular therapeutic agents, or thrombolytic agents, or may be substantially less than those doses of coagulation cascade inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, cardiovascular therapeutic agents, or thrombolytic agents, depending on a patient's therapeutic needs.

The present novel methods preferably employ compounds which selectively inhibit human TF-VIIA over the inhibition of both human Thrombin II and human factor Xa. Preferably, the compounds have a human TF-VIIA IC_{50} of less than 0.5 μM and also have a selectivity ratio of TF-VIIA inhibition over both human Thrombin II and human factor Xa inhibition of at least 10, and more preferably at least 100. Even more preferably, the compounds have a human TF-VIIA IC_{50} of less than 0.1 μM and also have a selectivity ratio of TF-VIIA inhibition over both human Thrombin II and human factor Xa inhibition of at least 1000, and most preferably at least 10,000.

All mentioned references are incorporated by reference as if here written.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations. The following examples are provided to illustrate the present invention and are not intended to limit the scope thereof. Without further elaboration, it is believed that one skilled in the art can, using the preceding descriptions, utilize the present invention to its fullest extent. Therefore the following preferred specific embodiments are to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way

whatsoever. Compounds containing multiple variations of the structural modifications illustrated in the schemes or the following Examples are also contemplated. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.

One skilled in the art may use these generic methods to prepare the following specific examples, which have been or may be properly characterized by ^1H NMR, mass spectrometry, elemental composition, and similar procedures. These compounds also may be formed in vivo.


- 10 The following examples contain detailed descriptions of the methods of preparation of compounds of Formula (I). These detailed descriptions fall within the scope and are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are Degrees centigrade unless otherwise indicated.
- 15 The following general synthetic sequences are useful in making the present invention. Abbreviations used in the schemes and tables include: "AA" represents amino acids, "AcCN" represents acetonitrile, "AcOH" represents acetic acid, "BINAP" represents 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, "BnOH" represents benzyl alcohol, "BnCHO" represents 2-phenylethanal, "BnSO₂Cl" represents benzylsulfonyl chloride, "Boc" represents tert-butylloxycarbonyl, "BOP" represents benzotriazol-1-yl-oxy-tris-(dimethylamino), "bu" represents butyl, "dba" represents dibenzylidene-acetone, "DCC" represents 1,3-dicyclohexylcarbodiimide, "DCM" represents dichloromethane or methylene chloride, "DIBAH" or "DIBAL" represents diisobutylaluminum hydride, "DMF" represents dimethylformamide.
- 25 "DMSO" represents dimethylsulfoxide, "DPPA" represents diphenylphosphoryl azide, "EDC" represents 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, "Ex. No." represents Example Number, "Fmoc" represents 9-fluorenylmethoxycarbonyl, "HOBt" represents hydroxybenzotriazole, "LDA" represents lithium diisopropylamide, "MW" represents molecular weight, "NMM" represents N-methylmorpholine, "Ph" represents phenyl or aryl, "PHTH" represents a phthaloyl group, "pnZ" represents 4-nitrobenzyloxy-carbonyl, "PTC" represents a phase transfer catalyst, "py" represents pyridine, "RNH₂" represents a primary organic
- 35 amine, "SEM" represents 2-(trimethylsilyl)ethoxy-methyl chloride, "p-

- TsOH" represents paratoluenesulfonic acid, "TBAF" represents tetrabutylammonium fluoride, "TBTU" represents 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, "TEA" represents triethylamine, "TFA" represents trifluoroacetic acid, "THF" represents tetrahydrofuran, "TMS" represents trimethylsilyl, "TMSCN" represents trimethylsilyl cyanide, and "Cbz" or "Z" represents benzyloxycarbonyl.

GENERAL SYNTHETIC PROCEDURES AND SPECIFIC EXAMPLES


- 10 The general synthetic approach to substituted uracils (i.e., pyrimidinediones) is shown in **Scheme 1** below. Several N-1 substituted pyrimidinediones have been previously prepared, disclosed, and are useful intermediates for the preparation of the compounds of this invention. Stirring a solution of such a N-1 substituted pyrimidinedione and an α -haloacetate in dimethylsulfoxide, in the presence of
- 15 potassium carbonate results in alkylation of the N-3 nitrogen. Reduction of the nitro functional group to the primary amine is easily accomplished with catalytic palladium on carbon in an atmosphere of hydrogen. The primary amine can then be reacted with a variety of raw materials including, but not limited to, acid chlorides, acid anhydrides, sulfonyl chlorides, alkyl and aromatic halides, aldehydes, and
- 20 ketones. The acetate ester can then be hydrolyzed to the acid with lithium hydroxide. The acid can then be coupled with a wide range of desired amines under standard peptide coupling conditions to give an amide. The amines used in the process of this invention are typically multi-functional and are reacted in protected form. Removal of these protecting groups provides the compounds of the present
- 25 invention.

Scheme 1: General Uracil Procedure



This general uracil (i.e., pyrimidinedione) synthetic scheme is exemplified in **Examples 1** and **2** below.

Example 1



EX-1A) A solution of 1-benzyl-5-nitro-2,4(1H,3H) pyrimidinedione (6.14 g, 24.82 mmol) prepared as described by Vampa, G. and Pecorari P. *Boll. Chim. Farm.* **1987**, 126, 467-469 was dissolved in 100 mL dimethylsulfoxide and potassium dicarbonate (3.78 g, 27.34 mmol) was added in one portion with stirring. After approximately 10 minutes a solution of methyl bromoacetate (2.50 mL, 26.40 mmol) in 20 mL dimethylsulfoxide was added drop wise over a 10 minute period. The reaction mixture was then heated to 40°C and allowed to stir for 18 hours. The reaction mixture was diluted with water (500 mL). The aqueous solution was extracted with ethyl acetate (4 x 100 mL). The combined organic solutions were washed with water (1 x 150 mL), brine (2 x 150 mL). The organic solution was dried (MgSO₄), filtered, and concentrated to give an oil. The crude oil was purified by MPLC (20% ethyl acetate/hexanes) to give pure 1-Benzyl-3-methoxycarbonylmethyl-5-nitro-2,4(1H,3H)pyrimidinedione (**EX-1A**) as a white solid in 81% yield: ¹H NMR (400 MHz, CDCl₃) δ 8.73 (s, 1H) 7.38-7.30 (m, 5H), 5.06 (s, 2H), 4.69 (s, 2H), 3.72 (s, 3H); HRMS (ES) calcd for C₁₄H₁₃N₃O₆ 319.0804, found 319.0797.

EX-1B) A solution of 1-Benzyl-3-methoxycarbonylmethyl-5-nitro-2,4(1H,3H) pyrimidinedione (**EX-1A**; 6.30 g, 19.74 mmol) in 100.0 mL methanol was degassed with hydrogen gas. The solution was then added 5% Pd/C (0.737 g) and allowed to stir under an atmosphere of hydrogen at room temperature for 24 hours. The crude reaction was filtered through a pad of Celite 545 and concentrated under reduced pressure. The oil was purified by MPLC (60% Ethyl acetate/hexanes) to give pure 5-amino-1-Benzyl-3-methoxycarbonylmethyl-2,4(1H,3H)-pyrimidinedione (**EX-1B**) in 63% yield as a tan solid: ¹H NMR (300

MHz, DMSO) δ 7.41-7.28 (m, 5H), 6.93 (s, 1H), 4.93 (s, 2H), 4.66 (s, 2H), 4.32 (s, 2H), 3.69 (s, 3H); HRMS (ES) calcd for $C_{14}H_{16}N_3O_4$ 290.1141, found 290.1138.

EX-1C) A solution of 5-amino-1-Benzyl-3-methoxycarbonylmethyl-2,4(1H,3H) pyrimidinedione (**EX-1B**; 3.12 g, 10.77 mmol) in 18.0 mL of tetrahydrofuran and dimethylformamide (1:1, 0.62M) was added N-methyl morpholine (3.60 mL, 32.74 mmol) in one portion at room temperature. The resulting mixture was cooled to 0°C in an ice bath and was allowed to stir for 15 minutes. A solution of benzylsulfonyl chloride (2.26g, 11.86 mmol) in 18.0 mL tetrahydrofuran was added drop wise over a 30 minute period. After the addition was complete the reaction was stirred for 3 hours at 0°C. The reaction mixture was diluted with ethyl acetate (250.0 mL) and washed with 1N HCl ((2 x 50 mL), saturated NaHCO₃ (2 x 50 mL), and brine (2 x 50 mL). The organic solution was dried (MgSO₄), filtered and concentrated. Trituration with ethyl acetate and hexanes gave pure 1-Benzyl-3-methoxycarbonylmethyl-5-[[[(phenylmethyl)sulfonyl]amino]-2,4(1H,3H)pyrimidinedione (**EX-1C**) in 74 % yield as a white solid: ¹H NMR (300 MHz, DMSO) δ 9.16 (s, 1H), 8.02 (s, 1H), 7.43-7.37 (m, 10H), 5.01 (s, 2H), 4.65 (s, 2H), 4.45 (s, 2H), 3.69 (s, 3H); HRMS (ES) calcd for $C_{21}H_{22}N_3O_6S$ 444.1229, found 444.1242.


EX-1D) A suspension of 1-benzyl-3-methoxycarbonylmethyl-5-[[[(phenylmethyl) sulfonyl]amino]-2,4(1H,3H)pyrimidinedione (**EX-1C**; 3.28 g, 7.40 mmol) in 94.0 mL tetrahydrofuran and methanol (1:1, 0.078 M) was added 30.0 mL of 0.1 M lithium hydroxide in water. The suspension quickly clears and becomes homogeneous. The reaction was stirred for 1 hour, and the volatiles were removed under reduced pressure. The remaining aqueous solution was cooled in an ice bath and acidified to a pH of 1 with 1.0 N HCl which resulted in a white precipitate forming. The precipitate was collected by filtration, washed with 1.0 N HCl and water, and dried under vacuum to give pure 1-Benzyl-3-methylene-carboxy-5-[[[(phenylmethyl) sulfonyl]amino]-2,4(1H,3H)pyrimidinedione (**EX-1D**) in 99 % yield: ¹H NMR (300 MHz, DMSO) δ 9.14 (br s, 1H), 7.98 (s, 1H), 7.44-7.35 (m, 10H), 5.00 (s, 2H), 4.51 (s, 2H), 4.45 (s, 2H); HRMS (ES) calcd for $C_{20}H_{19}N_3O_6S$ 429.0995, found 429.0981.

EX-1E) A solution of 1-Benzyl-3-methylenecarboxy-5-[[[(phenylmethyl)-sulfonyl]amino]-2,4(1H,3H)pyrimidinedione (**EX-1D**; 531.6 mg, 1.238 mmol) in

12.4 mL tetrahydrofuran and dimethylformamide (1:1, 0.1 M) was added N,N-diisopropylethylamine (1.10 mL, 6.315 mmol), N-hydroxybenzotriazole (499.6 mg, 3.697 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (717.2 mg, 3.741 mmol). The resulting mixture was allowed to stir for 30 minutes. The reaction mixture was then added amine (623.3 mg, 2.500 mmol) in one portion. The resulting mixture was allowed to stir over night. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with 5% citric acid (1 x 25 mL), saturated NaHCO₃ (1 x 25 mL), and brine (1 x 25 mL). The organic solution was dried (MgSO₄), filtered and concentrated. The crude reaction was purified by MPLC (75% ethyl acetate/hexanes) to give the product **EX-1E**: ¹H NMR (300 MHz, DMSO) δ 9.13 (br s, 1H), 8.77 (t, *J* = 5.3 Hz, 1H), 7.98 (s, 1H), 7.91 (d, *J* = 7.9 Hz, 1H), 7.45-7.35 (m, 13H), 5.01 (s, 2H), 4.56 (s, 2H), 4.56 (s, 2H), 4.44 (s, 2H), 4.38 (d, *J* = 5.4 Hz, 2H), 1.47 (s, 9H); HRMS (ES) calcd for C₃₃H₃₇N₆O₇S 661.2444, found 661.2448.

A flask of protected pyrimidinedione (**EX-1E**) (238.5 mg, 0.3610 mmol) was added 4.0 ml of 4 M HCl in dioxane. The resulting solution was allowed to stir overnight (approximately 18 hours). The solution was concentrated and the crude product was triturated from ethyl ether. The resulting white solid was collected by filtration, washed with ethyl ether and dried to give pure product: ¹H NMR (300 MHz, DMSO) δ 9.44 (s, 2H), 9.29 (s, 2H), 9.14 (s, 1H), 9.01-8.99 (m, 1H), 7.99 (s, 1H), 7.81 (d, *J* = 7.9 Hz, 1H), 7.51-7.37 (m, 14H), 5.01 (s, 2H), 4.57 (s, 2H), 4.45-4.41 (m, 2H), 3.58 (s, 2H); HRMS (ES) calcd for C₂₈H₂₉N₆O₅S 561.1920, found 561.1917.

Example 2




(**EX-2A**) A solution of 1-Benzyl-3-methylenecarboxy-5-[[[(phenyl-methyl)sulfonyl] amino]-2,4(1H,3H)pyrimidinedione (439.8 mg, 1.024mmol) in 10.0 mL tetrahydrofuran and dimethylformamide (1:1, 0.1 M) was added N,N-diisopropylethylamine (1.80 mL, 10.30 mmol), N-hydroxybenzotriazole (169.3 mg, 1.253 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (238.2 mg, 1.243 mmol). The resulting mixture was allowed to stir for 10 minutes. The reaction mixture was then added amine (648.3 mg, 1.231 mmol) in one portion. The resulting mixture was allowed to stir over night. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with 5% citric acid (1 x 50 mL), saturated NaHCO₃ (1 x 50 mL), and brine (1 x 50 mL). The organic solution was dried (MgSO₄), filtered and concentrated. The crude reaction was purified by MPLC (75% ethyl acetate/hexanes) to give the product **EX-2A**: ¹H NMR (300 MHz, DMSO) δ 9.09 (s, 1H), 8.78 (d, *J* = 7.1 Hz, 1H), 8.28 (d, *J* = 3.0 Hz, 1H), 8.19 (d, *J* = 3.0 Hz, 1H), 7.94 (s, 1H), 7.43-7.31 (m, 10H), 6.68 (s, 1H), 5.44-5.43 (m, 1H), 4.97 (s, 2H), 4.56 (d, *J* = 4.2 Hz, 2H), 4.41 (s, 2H), 3.80 (s, 3H), 3.08 (br d, *J* = 5.4 Hz, 3H), 2.91 (s, 1H), 2.75 (s, 1H), 2.59 (s, 3H), 2.52 (s, 3H), 2.06 (s, 3H), 1.92-1.80 (m, 1H), 1.61-1.51 (m, 3H), 1.37-1.33 (m 1H); HRMS (EI) calcd for C₃₉H₄₅N₈O₉S₃ 865.2472, found 865.2484.

A solution of **EX-2A** (281.3 mg, 0.3252 mmol) in 3.0 mL trifluoroacetic acid (0.1 M) was added thioanisole (0.115 mL, 0.9796 mmol) at room temperature with stirring. The resulting mixture was allowed to stir 6 hours. The reaction mixture was concentrated under reduced pressure. The crude product was purified by trituration from ethyl ether. A light yellow powder was collected by filtration,

washed with ethyl ether to give pure product **2**: ^1H NMR (300 MHz, DMSO) δ 9.07 (s, 1H), 8.82 (d, $J = 7.0$ Hz, 1H), 8.30 (d, $J = 3.0$ Hz, 1H), 8.21 (d, $J = 3.0$ Hz, 1H), 7.95 (s, 1H), 7.55-7.20 (m, 10H), 5.49-5.48 (m, 1H), 4.97 (s, 2H), 4.63-4.51 (m, 2H), 4.42 (s, 2H), 3.13 (br d, $J = 6.0$ Hz, 2H), 2.49 (s, 3H), 1.91 (br s, 1H), 1.67-1.58 (m, 4H); LRMS (EI), (MH⁺) 653.2.

Using the procedures exemplified in **Examples 1** and **2** and the attached **Scheme1**, the following compounds can be prepared.

Example 3



10

Following Steps A and B exemplified in **Example 1** and replacing benzyl bromide with 3-(N-Boc-amino)benzyl bromide (Murakami, Y.; Hagishita, S.; Okada, T.; Kii, M.; Hashizume, H.; Yagami, T.; Fujimoto, M.; *Bioorg. Med. Chem.* **1999**, 7, 1703-1714.), alkylated intermediate, methyl 3-[1-[3-(N-Boc-amino)benzyl]-5-amino-2,4-dioxypyrimidinyl]acetate (**EX-3A**) can be prepared.

15


To a solution of 1 eq. of ester **EX-3A** and 1 eq. of cyclobutanone in tetrahydrofuran is added 1 eq. of sodium cyanoborohydride, and the mixture is stirred for several hours. The solvent is evaporated off to afford the crude product. The crude product is purified by silica gel chromatography to afford purified methyl 2-[3-[1-[3-(N-Boc-amino)benzyl]-5-(N-cyclobutyl)amino-2,4-dioxypyrimidinyl]]-acetate (**EX-3B**).

20

Following the remaining procedure exemplified in **Example 1**, the indicated compound of **Example 3** can be obtained.

25

Example 4



A solution of 1 eq. of the appropriate amide and 1 eq. of 3-nitrophenylisocyanate in DMF is heated to 100°C for several hours. The solvent is evaporated off to afford the crude product. The crude product is purified by silica gel chromatography to afford purified product 1-[3-Nitrophenyl]-5-nitro-2,4-dioxypyrimidine (**EX-4A**)

A solution of 1 eq. of uracil **EX-4A** in dimethylsulfoxide is added to 1.1 eq. of potassium dicarbonate in one portion with stirring. After approximately 10 minutes a solution containing 1.1 eq. of methyl bromoacetate in dimethylsulfoxide is added dropwise over a 10 minute period. The reaction mixture is heated to 40°C and allowed to stir for 18 hours. The reaction mixture is diluted with water. The aqueous solution is extracted with ethyl acetate and the combined organic solution is washed with water and brine. The organic solution is dried over MgSO₄, filtered, and concentrated to give a crude product. The crude product is purified by silica gel chromatography to afford purified methyl 2-[3-[1-[3-nitrophenyl]-5-nitro-2,4-dioxypyrimidinyl]]acetate (**EX-4B**).

A suspension of methyl ester **EX-4B** in tetrahydrofuran and methanol is added excess lithium hydroxide in water. The reaction is stirred for 1 hour, and the volatiles are removed under reduced pressure. The remaining aqueous solution is cooled in an ice bath and acidified to a pH of 1 with 1.0 N HCl which results in a white precipitate forming. The precipitate is collected by filtration, washed with 1.0 N HCl and water, and dried under vacuum to give pure acid, 2-[3-[1-[3-nitrophenyl]-5-nitro-2,4-dioxypyrimidinyl]]acetic acid (**EX-4C**).

09717051.112000

A solution of acid **EX-4C** in dimethylformamide (0.1 M) is added to 5 eq N,N-diisopropylethylamine , 1 eq N-hydroxybenzotriazole mmol), and 1 eq 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride. The resulting mixture is allowed to stir for 30 minutes. To the reaction mixture is then added 1 eq. of 4-(N-Boc-amidino)benzylamine in one portion. The resulting mixture is allowed to stir over night. The reaction mixture is diluted with ethyl acetate and washed with 5% citric acid, saturated NaHCO₃, and brine. The organic solution is dried (MgSO₄), filtered and concentrated. Purification by MPLC pure, N-[4-(N-Boc-amidinobenzyl)]-2-[3-[1-[3-nitrophenyl]-5-nitro-2,4-dioxypyrimidinyl]]acetamide (**EX-4D**).


A solution of bis-nitro compound **EX-4D** in methanol is treated with 5 molar percent of 10% Pd/C under an atmosphere of hydrogen (balloon pressure). The suspension is allowed to stir over night. Filtration through Celite 545 followed by removal of the solvent affords pure, N-[4-(N-Boc-amidinobenzyl)]-2-[3-[1-[3-aminophenyl]-5-amino-2,4-dioxypyrimidinyl]]acetamide (**EX-4E**).

A solution of bis-amine **EX-4E** and 1 eq. of cyclobutanone in tetrahydrofuran is treated with 1 eq of sodium cyanoborohydride followed by a catalytic amount of hydrochloric acid. The reaction mixture is allowed to stir at room temperature for several hour. The reaction is quenched with the cautious addition of water. The aqueous solution is extracted with ethyl acetate. The organic solutions are washed with water and brine. The organic solution is dried (MgSO₄), filtered and concentrated. Purification by MPLC affords pure, N-[4-(N-Boc-amidinobenzyl)]-2-[3-[1-[3-aminophenyl]-5-(N-cyclobutyl-amino)-2,4-dioxypyrimidinyl]]acetamide (**EX-4F**).

A solution of N-Boc amidine **EX-4F** in methanol is treated with 3 eq of 4 M HCl in dioxane. The solution is stirred for five hours. Removal of the solvents under vacuum followed by trituration with ethyl ether affords pure product.

A wide variety of methylene analogs of pyrimidinediones wherein a methylene is present as a replacement for the carbonyl of the acetamide at the N-2 position of the pyrimidinedione can be prepared using the procedure detailed below

Example 5



EX-5A) A solution of 1 eq. of phenyl isocyanate and 1 eq. of 3-ethoxy-2-nitro-propenamide in DMF is heated to 100°C for several hours. The solvent is evaporated off to afford the crude product. The crude product is purified by silica gel chromatography to afford purified product **EX-5A**.

EX-5B) To a solution of 1 eq. of **EX-5A** in dimethylsulfoxide is added to 1.1 eq. of potassium dicarbonate in one portion with stirring. After approximately 10 minutes, a solution containing 1.1 eq. of methyl bromoacetate in dimethylsulfoxide is added dropwise over a 10 minute period. The reaction mixture is heated to 40°C and allowed to stir for 18 hours. The reaction mixture is diluted with water. The aqueous solution is extracted with ethyl acetate and the combined organic solution is washed with water and brine. The organic solution is dried over MgSO₄, filtered, and concentrated to give a crude product. The crude product is purified by silica gel chromatography to afford purified product methyl 2-[3-[5-nitro-2,4-dioxo-1-phenylpyrimidyl]]acetate (**EX-5B**).

EX-5C) Diisobutylaluminum hydride (1.05 equiv.) is added over a period of 15 min to a cooled solution -78 °C of 1 eq. of **EX-5B** in tetrahydrofuran. After stirring for 1 h at -78 °C, the reaction is slowly quenched at -78 °C with cold methanol. The mixture is slowly poured into ice-cold 1N HCl, and the aqueous mixture is extracted with ethyl acetate. The combined organic layers are washed with brine, dried with MgSO₄, filtered, and the solvents are removed under reduced pressure. The crude product is purified by column chromatography to afford purified aldehyde product **EX-5C**.

EX-5D) A suspension of 1.0 eq. of the aldehyde, 2-[3-[5-nitro-2,4-dioxo-1-phenylpyrimidyl]]ethanal (**EX-5C**) and 1.0 eq. of the amine, 4-(N-Boc-

amidino)benzylamine in dichloromethane, and catalytic acetic acid is added 1.2 eq. of sodium triacetoxyborohydride. The suspension quickly clears and becomes homogeneous. The reaction is stirred for several hours. The solution is cooled in an ice bath and is made alkaline with 1.0 N NaOH. The reaction mixture is diluted
5 with dichloromethane and washed with brine. The organic solution is dried (MgSO₄), filtered and concentrated to give the crude product. The crude product is purified by silica gel chromatography to afford purified product 2-[3-2-[2-[2-(4-(N-Boc-amidino)benzyl)amino]ethyl-5-nitro-2,4-dioxo-1-phenylpyrimidine (**EX-5D**):

EX-5E) A solution of 1 eq. of **EX-5D** in methanol is degassed with
10 hydrogen gas. To the solution is added a catalytic amount of 5% Pd/C, and the reaction mixture is allowed to stir under an atmosphere of hydrogen at room temperature for 24 hours. The crude reaction is filtered through a pad of Celite 545 and concentrated under reduced pressure. The crude product is purified by silica gel chromatography to afford purified product amine, 2-[3-2-[2-[2-(4-(N-Boc-
15 amidino)benzyl)amino]ethyl-5-amino-2,4-dioxo-1-phenylpyrimidine (**EX-5E**).


EX-5F) To a suspension of 1.0 eq. of **EX-5E** and 1.0 eq. of the phenylacetaldehyde in dichloromethane and catalytic acetic acid is added 1.2 eq. of sodium triacetoxyborohydride. The suspension quickly clears and becomes
20 homogeneous. The reaction is stirred for several hours. The solution is cooled in an ice bath and basified with 1.0 N NaOH. The reaction mixture is diluted with dichloromethane and washed with brine. The organic solution is dried (MgSO₄), filtered and concentrated to give the crude product. The crude product is purified by silica gel chromatography to afford purified 2-[3-2-[2-[2-(4-(N-Boc-amidino)benzyl)amino]ethyl-5-(N-(2-phenylethyl)amino)-2,4-dioxo-1-
25 phenylpyrimidine (**EX-5F**).

To a flask of 1 eq. of **EX-5F** is added 4 M HCl in dioxane. The resulting solution is allowed to stir overnight. The solution is concentrated and the crude product is triturated from ethyl ether to afford purified product as the dihydrochloride salt.

30 Sulfonfyl analogs of pyrimidinediones wherein a sulfonfyl is present as a replacement for the carbonyl of the acetamide at the N-2 position of the pyrimidinedione can be prepared as detailed below in the specific **Example 6**.

35

Example 6



EX-6A) A solution of 1 eq. of **EX-5A** in dimethylsulfoxide is added to 1.1 eq. of potassium dicarbonate in one portion with stirring. After approximately 10 minutes, a solution containing 1.1 eq. of sodium bromomethylsulfonate in dimethylsulfoxide is added dropwise over a 10 minute period. The reaction mixture is heated to 40°C and allowed to stir for 18 hours. The reaction mixture is diluted with water. The aqueous solution is extracted with ethyl acetate. The combined organic solutions are washed with water and brine. The organic solution is dried over MgSO₄, filtered, and concentrated to give a crude product. The crude product is purified by silica gel chromatography to afford purified product, 3-[5-nitro-2,4-dioxo-1-phenylpyrimidyl]methanesulfonic acid (**EX-6A**).

EX-6B) A solution of 1 eq. of **EX-6A** in methanol is degassed with hydrogen gas. To the solution is added a catalytic amount of 5% Pd/C, and the reaction mixture is allowed to stir under an atmosphere of hydrogen at room temperature for 24 hours. The crude reaction is filtered through a pad of Celite 545 and concentrated under reduced pressure. The crude product is purified by silica gel chromatography to afford purified product, 3-[5-amino-2,4-dioxo-1-phenylpyrimidyl]methanesulfonic acid (**EX-6B**).

EX-6C) To a suspension of 1.0 eq. of **EX-6B** and 1.0 eq. of the phenylacetaldehyde in dichloromethane and catalytic acetic acid is added 1.2 eq. of sodium triacetoxyborohydride. The reaction is stirred for several hours. The solution is cooled in an ice bath and basified with 1.0 N NaOH. The reaction mixture is diluted with dichloromethane and washed with brine. The organic solution is dried (MgSO₄), filtered and concentrated to give the crude product. The


crude product is purified by silica gel chromatography to afford purified product, 3-[5-[N-(2-phenylethyl)amino]-2,4-dioxo-1-phenylpyrimidyl]methanesulfonic acid (**EX-6C**).

EX-6D) A solution of 1 eq. of **EX-6C** in dichloromethane with several drops of dimethylformamide is cooled to 0 °C. Thionyl chloride (1.1 equiv.) is added dropwise, and the solution is slowly warmed to room temperature. After completion of the reaction, the volatile components are removed under reduced pressure, and the sulfonyl chloride product is immediately used. The sulfonyl chloride is dissolved into dichloromethane, and 1 eq. of the appropriate amine, 4-(N-Boc-amidino)benzylamine, in DMF is added with 5 eq. of N-methylmorpholine to the sulfonyl chloride solution. After completion of the reaction, polyaldehyde and/or polyamine resin (10 equiv.) are added to remove any unreacted starting materials. The resins are filtered, rinsed with DMF/DCM (1:1), and the solvents are removed under reduced pressure to give pure N-[4-(N-Boc-amidino)benzyl]-3-[5-[N-(2-phenylethyl)amino]-2,4-dioxo-1-phenylpyrimidyl]methanesulfonamide (**EX-6D**).

A flask of 1 eq. of **EX-6D** is added to 4 M HCl in dioxane. The resulting solution is allowed to stir overnight. The solution is concentrated and the crude product was triturated from ethyl ether to afford purified product of **Example 6**.

Triazinedione (aza analogs) of uracils (i.e., pyrimidinones) wherein a nitrogen is present as a replacement for the carbon at the 5-position of the pyrimidinedione can be prepared as detailed below with the specific **Example 7**.

Example 7



EX-7A) A mixture of aniline (1; 50 mmol), concentrated HCl (10 mL), and water (50 mL) is cooled to 5 °C. Separately, a solution of sodium nitrite (50 mmol)

in water (7.2 mL) is cooled to 5 °C and added to the aniline hydrochloride slurry with the addition tube beneath the liquid surface. The temperature is maintained at 5 °C during the addition and for 1 hour thereafter. This solution of diazotized aniline (**EX-7A**) is used in the next step.

5 **EX-7B**) A mixture of cyanoacetylurethane (59 mmol), pyridine (656 mL), ice (216 g) and water (40 mL) is held at 5 °C while the slurry of **EX-67A** is added over 15 min with stirring. After an additional hour of stirring at 5 °C, the orange solid, N-ethoxycarbonyl-2-cyano-2-(N-phenylhydrazo)acetamide (**EX-7B**) is isolated by filtration.

10 **EX-7C**) A mixture of **EX-7B** (95 mmol), sodium acetate (110 mmol) and acetic acid (140 mL) is refluxed for 75 min. The resulting clear solution is concentrated at reduced pressure, and the solid that separates is removed by filtration and washed with water. Compound, 6-cyano-2-phenyl-3,5-dioxo-1,2,4-triazine (**EX-7C**), is recrystallized from 95% ethanol.

15 **EX-7D**) A mixture of compound **EX-7C** (50 mmol), 6 N HCl (190 mL) and dioxane (500 mL) is refluxed for 12 h. On cooling the crystallized product, 6-(2-phenyl-3,5-dioxo-1,2,4-triazinyl)carboxylic acid (**EX-7D**) is separated by filtration and recrystallized from methanol-water.

20 **EX-7E**) The acid **EX-7D** (8.4 mmol) is dissolved in dry *tert*-butyl alcohol (127 mL) and DPPA (9.3 mmol), and triethyl amine (9.3 mmol) is added. The solution is refluxed for 24h thereafter. At this time the solution is concentrated in vacuo. The residue is dissolved in methylene chloride (150 mL) and washed with 0.5 N citric acid (150 mL), 1 N NaHCO₃ (150 mL) and water (150 mL). The methylene chloride solution is then dried (sodium sulfate). Filtration and
25 concentration gives the Boc-protected compound **EX-7E**. This material can be purified by chromatography if necessary.

30 **EX-7F**) A solution of compound **EX-7E** (50 mmol) in DMF (150 mL) is treated with potassium carbonate (55 mmol) in one portion with stirring. After approximately 10 min, a solution of methyl bromoacetate (50 mmol) in DMF (100 mL) is added dropwise. The reaction mixture is heated to 40 °C and allowed to stir for 18 h. Typical aqueous workup and chromatographic purification provides pure methyl 2-(2-phenyl-3,5-dioxo-6-(N-Boc-amino)-1,2,4-triazinyl)acetate (**EX-7F**).

35 **EX-7G**) A solution of compound **EX-7F** (50 mmol) is dissolved in methylene chloride (400 mL) and is treated with TFA (100 mL). The resulting solution is stirred at room temperature for 4 h thereafter. Concentration and

trituration with ether affords TFA salt of methyl 2-(2-phenyl-3,5-dioxo-6-amino-1,2,4-triazinyl)acetate (**EX-7G**).

EX-7H) A solution of compound **EX-7G** in tetrahydrofuran and methylene chloride (1:1, 0.3 M) is treated with 1 eq. of phenylacetaldehyde and 0.9 eq. of triethyl amine. The solution will be cooled to 0 °C and treated with 1 eq. of sodium triacetoxymethylborohydride. After stirring for 5 minutes, the ice bath is removed, and the reaction mixture is allowed to warm to room temperature and stir there for 2 h. The reaction is quenched by the addition of 1 N NaOH, and the mixture is stirred for 5 min. Typical aqueous workup is followed by chromatographic purification to provide pure product, methyl 2-(2-phenyl-3,5-dioxo-6-(N-(2-phenylethyl)amino)-1,2,4-triazinyl)acetate (**EX-7H**).


EX-7I) A solution of compound **EX-7H** (50 mmol) in THF (250 mL) is treated with LiOH (50 mmol). After the hydrolysis is complete, the volatiles are removed under reduced pressure. The remaining aqueous solution is cooled in an ice bath and acidified to pH 1 with 1.0 N HCl. The aqueous mixture is extracted with EtOAc. The EtOAc solution is dried (sodium sulfate), filtered and concentrated to afford pure 2-(2-phenyl-3,5-dioxo-6-(N-(2-phenylethyl)amino)-1,2,4-triazinyl)acetic acid **EX-7I**.

EX-7J) A solution of compound **EX-7I** (50 mmol) in DMF (250 mL) is treated with N-hydroxybenzotriazole (60 mmol) and EDC hydrochloride (60 mmol). The mixture is stirred at room temperature for 30 min and treated with 4-(N-Cbz-amidinobenzylamine (50 mmol). The resulting mixture is allowed to stir overnight. Typical aqueous workup is followed by chromatographic purification to afford pure product, N-(4-Cbz-amidinobenzyl)-2-(2-phenyl-3,5-dioxo-6-(N-(2-phenylethyl)amino)-1,2,4-triazinyl)acetamide (**EX-7J**).

A solution of compound **EX-7J** (50 mmol) in methanol (300 mL) and 4M HCl-dioxane (100 mL) is degassed with hydrogen. 5% Pd(C) (0.5 g) is added, and the solution is stirred under an atmosphere of hydrogen at room temp for 24 h. The reaction mixture is filtered through a pad of celite 545 and concentrated under reduced pressure. Purification by reverse phase chromatography affords pure product of **Example 7**.

Using these methods and ordinary skill in the art of synthetic numerous novel compounds of the present invention have been or can be prepared.

Examples of additional compounds that can be prepared have the formula:



wherein;

R^2 is 3-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-aminophenyl, B is 2-imidazolyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-dimethylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 2-methylphenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is phenyl, B is 3-aminophenyl, A is $C(O)NH$, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 3-amidinophenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-(N-methylamino)phenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-thienyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-methylsulfonamidophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 4-amidinophenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-methylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 4-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is phenyl, B is 3-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-chlorophenyl, B is 4-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-methylphenyl, B is 4-phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-thienyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

20 R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

25 R^2 is 3-aminophenyl, B is 2-imidazolyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 3-dimethylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is phenyl, B is 3-aminophenyl, A is C(O)NH, Y^0 is 4-amidinobenzyl.
and M is CF;

R² is 3-(N-methylamino)phenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 3-methylsulfonamidophenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

15 R² is 3-methylaminophenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is phenyl, B is 4-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M

R² is 3-chlorophenyl, B is 4-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl,
is CF;

R^2 is 3-thienyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl,
I is CF;

R^2 is 3-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 2-imidazolyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-dimethylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 2-methylphenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is 3-aminophenyl, A is $C(O)NH$, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is phenyl, B is 3-amidinophenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-(N-methylamino)phenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-thienyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-methylsulfonamidophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is 4-amidinophenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

25 R^2 is 3-methylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R² is phenyl, B is 3-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M

R² is 3-methylphenyl, B is 4-phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R^2 is 3-amidocarbonyl-5-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH ;

15 R² is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is
20 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxyphenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH:

181

R² is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)- phenyl, B is 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-carboxyphenyl, B is 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-aminophenyl, B is (S)-2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 5-amino-2-fluorophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 2-methyl-3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-
 20 amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is ethyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is ethyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

25 R² is 3-aminophenyl, B is 2-propenyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is isopropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-aminophenyl, B is (R)-2-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-propynyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-aminophenyl, B is 3-pentyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is hydrido, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is ethyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-aminophenyl, B is 2-methylpropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-propyl, A is CH_3CH , Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-aminophenyl, B is propyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 6-amidocarbonylhexyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is tert-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 3-aminophenyl, B is tert-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 3-hydroxypropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-methoxyethyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

15 R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2,2,2-trifluoroethyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

20 R² is 3-aminophenyl, B is (S)-2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 5-amino-2-fluorophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 2-methyl-3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

25 R² is 3-aminophenyl, B is ethyl, A is single bond, Y⁰ is 4-amidinobenzyl,
and M is N;

R² is 3-aminophenyl, B is ethyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-propynyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is ethyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 2-propyl, A is CH_3CH , Y^0 is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is propyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

25 R² is 3-aminophenyl, B is 6-amidocarbonylhexyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is tert-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 3-hydroxypropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-methoxyethyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-
20 fluorobenzyl, and M is CH;

R² is 3-amino-5-carbomethoxyphenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-carboxamidophenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-benzyl-N-methylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-aminobenzyl, and M is CH;

R² is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-propyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

20 R² is 3,5-diaminophenyl, B is 2,2,2-trifluoroethyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y⁰ is 4-
 25 amidinobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is CH₃;

R² is 3,5-diaminophenyl, B is ethyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-carboxyphenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-carboxyphenyl, B is ethyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 2,2,2-trifluoroethyl,
A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-carbomethoxyphenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carboxamidophenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzyl-N-methylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

25 R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-carboxyphenyl, B is 2-propyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CCl;

R^2 is 3-aminophenyl, B is 2-propyl, A is a bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is N;

25 R^2 is 3,5-diaminophenyl, B is 2,2,2-trifluoroethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is (S)-2-butyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzylbenzyl, and M is N;

5 R^2 is 3,5-diaminophenyl, B is ethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is ethyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is N;

10 R^2 is 3-amino-5-carboxyphenyl, B is 2,2,2-trifluoroethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carboxyphenyl, B is (S)-2-butyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carboxyphenyl, B is isopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzylbenzyl, and M is N;

15 R^2 is 3-amino-5-carboxyphenyl, B is ethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carboxyphenyl, B is ethyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is N;

20 R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 2,2,2-trifluoroethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is (S)-2-butyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzylbenzyl, and M is N;

25 R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is N;

R^2 is 3-aminophenyl, B is cyclopropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

5 R^2 is 3-aminophenyl, B is cyclopropyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclopentyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 5-amino-2-thienyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-aminophenyl, B is cyclopropyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-(2R)-bicyclo[2.2.1]-heptyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-aminophenyl, B is cyclopentyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclohexyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is oxalan-2-yl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 1-piperidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R² is 2-hydroxyphenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is phenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

25 R² is 3-aminophenyl, B is cyclopentyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF₃;

194

R^2 is 3-aminophenyl, B is cyclopropyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 3-aminophenyl, B is 2-(2R)-bicyclo[2.2.1]-heptyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

5 R^2 is 3-aminophenyl, B is cyclopentyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CF;

R^2 is 3-aminophenyl, B is cyclohexyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

10 R^2 is 3-aminophenyl, B is oxalan-2-yl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 3-aminophenyl, B is 1-piperidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

15 R^2 is 3-aminophenyl, B is 1,1-dioxothiolan-3-yl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 2-hydroxyphenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

20 R^2 is 3-aminophenyl, B is 1-pyrrolidinyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is phenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 3-thienyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

25 R^2 is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CF;

R^2 is 3-aminophenyl, B is cyclopropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclopentyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-(2R)-bicyclo[2.2.1]-heptyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclohexyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

25 R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl,
and M is N;

196

R^2 is 3-aminophenyl, B is 1,1-dioxothiolan-3-yl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 2-hydroxyphenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-aminophenyl, B is 1-pyrrolidinyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-thienyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carbomethoxyphenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-carboxyphenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 2-amino-6-carboxy-4-pyridyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carbomethoxyphenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxyphenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 2,6-dichlorophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3,5-diaminophenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3,5-diaminophenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

5 R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

10 R^2 is 3,5-diaminophenyl, B is cyclopentyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

15 R^2 is 3-carboxy-5-aminophenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is cyclopentyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclopentyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is
 20 cyclobutyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclopentyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclopropyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

5 R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

10 R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclopentyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxamidophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxamidophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

25 R^2 is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;


R^2 is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

25 R^2 is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

- R^2 is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N.

Examples of still more compounds that can be prepared have the formula:



wherein;

- R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

- R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

- R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF;

R² is benzyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF;

R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF;

R² is 3-aminophenyl, B is phenyl, A is CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl₄;

15 R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl ;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl₄;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R² is 3-aminophenyl, B is phenyl, A is CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

25 R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R² is benzyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

5 R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3,5-diaminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

10 R^2 is 3-carboxy-5-aminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

15 R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

20 R^2 is 3,5-diaminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3-carboxy-5-aminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

25 R^2 is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3,5-diaminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

5 R^2 is 3-carboxy-5-aminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

10 R^2 is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N.

15

Formula (I) compounds of this invention possessing hydroxyl, thiol, and amine functional groups can be converted to a wide variety derivatives.

Alternatively, derivatized Formula (I) compounds can be obtained by first derivatizing one or more intermediates in the processes of preparation before further transforming the derivatized intermediate to compounds of Formula (I). A hydroxyl group in the form of an alcohol or phenol can be readily converted to esters of carboxylic, sulfonic, carbamic, phosphonic, and phosphoric acids. Acylation to form a carboxylic acid ester is readily effected using a suitable acylating reagent such as an aliphatic acid anhydride or acid chloride. The corresponding aryl and heteroaryl acid anhydrides and acid chlorides can also be used. Such reactions are generally carried out using an amine catalyst such as pyridine in an inert solvent. Similarly, carbamic acid esters (urethanes) can be obtained by reacting a hydroxyl group with isocyanates and carbamoyl chlorides. Sulfonate, phosphonate, and phosphate esters can be prepared using the corresponding acid chloride and similar reagents. Compounds of Formula (I) that have at least one thiol group present can be converted to the corresponding thioesters derivatives analogous to those of alcohols and phenols using the same reagents and comparable reaction conditions.

Compounds of Formula (I) that have at least one primary or secondary amine group present can be converted to the corresponding amide derivatives. Amides of carboxylic acids can be prepared using the appropriate acid chloride or anhydrides with reaction conditions analogous to those used with alcohols and phenols. Ureas of the corresponding primary or secondary amine can be prepared using isocyanates directly and carbamoyl chlorides in the presence of an acid scavenger such as triethylamine or pyridine. Sulfonamides can be prepared from the corresponding sulfonyl chloride in the presence of aqueous sodium hydroxide or a tertiary amine. Suitable procedures and methods for preparing these derivatives can be found in House's Modern Synthetic Reactions, W. A. Benjamin, Inc., Shriner, Fuson, and Curtin in The Systematic Identification of Organic Compounds, 5th Edition, John Wiley & Sons, and Fieser and Fieser in Reagents for Organic Synthesis, Volume 1, John Wiley & Sons. Reagents of a wide variety that can be used to derivatize hydroxyl, thiol, and amines of compounds of Formula (I) are available from commercial sources or the references cited above, which are incorporated herein by reference.

Formula (I) compounds of this invention possessing hydroxyl, thiol, and amine functional groups can be alkylated to a wide variety of derivatives. Alternatively, alkylated Formula (I) compounds can be obtained by first alkylating one or more intermediates in the processes of preparation before further transforming the alkylated intermediate to compounds of Formula (I). A hydroxyl group of compounds of Formula (I) can be readily converted to ethers. Alkylation to form an ether is readily effected using a suitable alkylating reagent such as an alkyl bromide, alkyl iodide or alkyl sulfonate. The corresponding aralkyl, heteroaralkyl, alkoxyalkyl, aralkyloxyalkyl, and heteroaralkyloxyalkyl bromides, iodides, and sulfonates can also be used. Such reactions are generally carried out using an alkoxide forming reagent such as sodium hydride, potassium t-butoxide, sodium amide, lithium amide, and n-butyl lithium using an inert polar solvent such as DMF, DMSO, THF, and similar, comparable solvents. amine catalyst such as pyridine in an inert solvent. Compounds of Formula (I) that have at least one thiol group present can be converted to the corresponding thioether derivatives analogous to those of alcohols and phenols using the same reagents and comparable reaction conditions. Compounds of Formula (I) that have at least one primary, secondary or tertiary amine group present can be converted to the corresponding secondary, tertiary or quaternary ammonium derivative. Quaternary ammonium derivatives can

be prepared using the appropriate bromides, iodides, and sulfonates analogous to those used with alcohols and phenols. Conditions involve reaction of the amine by warming it with the alkylating reagent with a stoichiometric amount of the amine (i.e., one equivalent with a tertiary amine, two with a secondary, and three with a primary). With primary and secondary amines, two and one equivalents, respectively, of an acid scavenger are used concurrently. Secondary or tertiary amines can be prepared from the corresponding primary or secondary amine. A primary amine can be dialkylated by reductive amination using an aldehyde, such as formaldehyde, and sodium cyanoborohydride in the presence of glacial acetic acid. A primary amine can be monoalkylated by first mono-protecting the amine with a ready cleaved protecting group, such as trifluoroacetyl. An alkylating agent, such as dimethylsulfate, in the presence of a non-nucleophilic base, such as Barton's base (2-*tert*-butyl-1,1,3,3-tetramethylguanidine), gives the monomethylated protected amine. Removal of the protecting group using aqueous potassium hydroxide gives the desired monoalkylated amine. Additional suitable procedures and methods for preparing these derivatives can be found in House's Modern Synthetic Reactions, W. A. Benjamin, Inc., Shriner, Fuson, and Curtin in The Systematic Identification of Organic Compounds, 5th Edition, John Wiley & Sons, and Fieser and Fieser in Reagents for Organic Synthesis published by John Wiley & Sons. Perfluoroalkyl derivatives can be prepared as described by DesMarteau in J. Chem. Soc. Chem. Commun. 2241 (1998). Reagents of a wide variety that can be used to derivatize hydroxyl, thiol, and amines of compounds of Formula (I) are available from commercial sources or the references cited above, which are incorporated herein by reference.

25

Assays for Biological Activity

TF-VIIa Assay

In this assay 100 nM recombinant soluble tissue factor and 2nM recombinant human factor VIIa are added to a 96-well assay plate containing 0.4 mM of the substrate, N-Methylsulfonyl-D-phe-gly-arg-p-nitroaniline and either inhibitor or buffer (5 mM CaCl₂, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% BSA). The reaction, in a final volume of 100 μ l is measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by

5

0.3 nM human factor Xa and 0.15 mM N- α -Benzyloxycarbonyl-D-arginyl-L-glycyl-L-arginine-p-nitroaniline-dihydrochloride (S-2765) are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% BSA). The reaction, in a final volume of 100 μ l is measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline. Percent inhibition of Xa activity is calculated from OD_{405nm} value from the experimental and control sample.

Thrombin Assay

0.28 nM human thrombin and 0.06 mM H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline dihydrochloride are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% BSA). The reaction, in a final volume of 100 μ l is measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline. Percent inhibition of thrombin activity is calculated from OD_{405nm} value from the experimental and control sample.

5 ug/ml trypsin, type IX from porcine pancreas and 0.375 mM N- α -Benzoyl-L-arginine-p-nitroanilide (L-BAPNA) are added to a 96-well assay plate containing either inhibitor or buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% BSA). The reactions, in a final volume of 100 μ l are measured immediately at 405 nm to determine background absorbance. The plate is incubated at room temperature for 60 min, at which time the rate of hydrolysis of the substrate is measured by monitoring the reaction at 405 nm for the release of p-nitroaniline.

Percent inhibition of trypsin activity is calculated from OD_{405nm} value from the experimental and control sample.

- Recombinant soluble TF, consisting of amino acids 1-219 of the mature protein sequence was expressed in *E. coli* and purified using a Mono Q Sepharose FPLC. Recombinant human VIIa was purchased from American Diagnostica, Greenwich CT and chromogenic substrate N-Methylsulfonyl-D-phe-gly-arg-p-nitroaniline was prepared by American Peptide Company, Inc., Sunnyvale, CA. Factor Xa was obtained from Enzyme Research Laboratories, South Bend IN, thrombin from Calbiochem, La Jolla, CA, and trypsin and L-BAPNA from Sigma, St. Louis MO. The chromogenic substrates S-2765 and S-2238 were purchased from Chromogenix, Sweden.


The biological activity of the compounds of **Examples 1** through **7** as determined by the bioassay procedures is summarized in the Table 1.

Table 1. Inhibitory Activity of Uracils toward Factor Xa, TF-VIIA, Thrombin II, and Trypsin II.

Example Number	TF-VIIA IC50 (uM)	Thrombin II IC50 (uM)	Factor Xa IC50 (uM)	Trypsin II IC50 (uM)
1	>100	13.0	25.6	0.4
2	12.9	0.3	0.2	0.2

What we claim is:

1. A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

5 B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a nitrogen with a removable hydrogen or a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by

10 R^{32} , a nitrogen with a removable hydrogen or a carbon at the other position adjacent to the point of attachment is optionally substituted by R^{36} , a nitrogen with a removable hydrogen or a carbon adjacent to R^{32} and two atoms from the point of attachment is optionally substituted by R^{33} , a nitrogen with a removable hydrogen or a carbon adjacent to R^{36} and two atoms from the point of attachment is optionally substituted by R^{35} , and a nitrogen with a removable hydrogen or a carbon adjacent to both R^{33} and R^{35} is optionally substituted by

15 R^{34} ;

$R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are

independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylendioxy, haloalkylthio, alkanoyloxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, alkoxyalkyl, haloalkoxylalkyl, hydroxy, amino, alkoxyamino, nitro, alkylamino,

20

- N-alkyl-N-arylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylthio, alkylthioalkyl, alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, alkylsulfonylalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, amidosulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyhaloalkyl, hydroxyalkyl, aminoalkyl, haloalkoxyalkyl, carboxyalkyl, carboalkoxy, carboxy, carboxamido, carboxamidoalkyl, and cyano;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently optionally Q^b ;

- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

- B is optionally a C3-C12 cycloalkyl or C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen atom adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen three atoms from the point of attachment

and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

A is selected from the group consisting of a bond, $(W^7)_{rr}$ -

- 5 $(CH(R^{15}))_{pa}$, and $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 6, and W^7 is selected from the group consisting of O, S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$ with the proviso that no more than one of the group consisting of rr and pa is 0 at the same time;

R^7 is selected from the group consisting of hydrido, hydroxy, and

- 10 alkyl;

R^{15} is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;

Ψ is NH or NOH;

M is N or R^1-C ;

- 15 R^1 is selected from the group consisting of hydrido, alkyl, alkenyl, cyano, halo, haloalkyl, haloalkoxy, haloalkylthio, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

R^2 is Z^0-Q ;

- 20 Z^0 is selected from the group consisting of a bond, $(CR^{41}R^{42})_q$ wherein q is an integer selected from 1 through 3, and $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), S(O), $N(R^{41})$, and $ON(R^{41})$;

Z^0 is optionally $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are independently 0 or 1 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, wherein Z^0 is directly bonded to the uracil ring and W^{22} is optionally substituted with one or more substituents selected from the group consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} .

R⁴¹ and R⁴² are independently selected from the group consisting of amidino, hydroxyamino, hydrido, hydroxy, amino, and alkyl;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a nitrogen with a removable hydrogen or a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z⁰ is optionally substituted by R⁹, a nitrogen with a removable hydrogen or a carbon at the other position adjacent to the point of attachment is optionally substituted by R¹³, a nitrogen with a removable hydrogen or a carbon adjacent to R⁹ and two atoms from the point of attachment is optionally substituted by R¹⁰, a nitrogen with a removable hydrogen or a carbon adjacent to R¹³ and two atoms from the point of attachment is optionally substituted by R¹², and a nitrogen with a removable hydrogen or a carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

Q is optionally hydrido with the proviso that Z^0 is selected from other than a bond;

K is $(CR^{4a}R^{4b})_n$ wherein n is 1 or 2;

R^{4a} and R^{4b} are independently selected from the group consisting of
5 halo, hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

E^0 is E^1 , when K is $(CR^{4a}R^{4b})_n$, wherein E^1 is selected from the group consisting of a bond, C(O), C(S), $C(O)N(R^7)$, $(R^7)NC(O)$, $S(O)_2$, $(R^7)NS(O)_2$, and $S(O)_2N(R^7)$;

Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon
10 of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a
15 carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, nitro, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl,
20 alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, alkenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, haloalkoxyalkyl, carboalkoxy, and cyano;

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, aminoalkyl, hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time, with the further proviso that no more than one of R^{23} and R^{24} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, aminoalkyl, amino, dialkylamino, alkylamino, and hydroxyalkyl;

Q^s is selected from the group consisting of bond, $(CR^{37}R^{38})_b$ wherein b is an integer selected from 1 through 4, and $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 3 and W^1 is selected from the group consisting of $C(O)N(R^{14})$, $(R^{14})NC(O)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, and $N(R^{14})$, with the proviso that R^{14} is selected from other than halo when directly bonded to N, with the further provision that Q^s is selected from other than a bond when Y^0 is $2-Q^b-5-Q^s-6-R^{17}-4-R^{18}-3-R^{19}$ pyridine or $2-Q^b-4-Q^s-3-R^{16}-5-R^{18}-6-R^{19}$ pyridine, and with the additional proviso that $(CR^{37}R^{38})_b$ and $(CH(R^{14}))_c$ are bonded to E^0 ;

R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

R^{37} and R^{38} are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;

R^{38} is optionally aroyl or heteroaroyl, wherein R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;

Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b-Q^s ;

5 Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$,

wherein e and h are independently 1 or 2 and W^2 is $CR^{4a}=CR^{4b}$, with the

proviso that $(CH(R^{14}))_e$ is bonded to E^0 ;


Y^0 is optionally Q^b-Q^{sssr} or Q^b-Q^{sssr} wherein Q^{sssr} is $(CH(R^{38}))_r-$

W^5 , Q^{sssr} is $(CH(R^{38}))_r-W^6$, r is 1 or 2, W^5 and W^6 are independently

- 10 selected from the group consisting of 1,4-indenyl, 1,5-indenyl, 1,6-indenyl, 1,7-indenyl, 2,7-indenyl, 2,6-indenyl, 2,5-indenyl, 2,4-indenyl, 3,4-indenyl, 3,5-indenyl, 3,6-indenyl, 3,7-indenyl, 2,4-benzofuranyl, 2,5-benzofuranyl, 2,6-benzofuranyl, 2,7-benzofuranyl, 3,4-benzofuranyl, 3,5-benzofuranyl, 3,6-benzofuranyl, 3,7-benzofuranyl, 2,4-benzothiophenyl, 2,5-benzothiophenyl,
- 15 2,6-benzothiophenyl, 2,7-benzothiophenyl, 3,4-benzothiophenyl, 3,5-benzothiophenyl, 3,6-benzothiophenyl, 3,7-benzothiophenyl, 2,7-imidazo(1,2-a)pyridinyl, 3,4-imidazo(1,2-a)pyridinyl, 3,5-imidazo(1,2-a)pyridinyl, 3,6-imidazo(1,2-a)pyridinyl, 3,7-imidazo(1,2-a)pyridinyl, 2,4-indolyl, 2,5-indolyl, 2,6-indolyl, 2,7-indolyl,
- 20 3,4-indolyl, 3,5-indolyl, 3,6-indolyl, 3,7-indolyl, 1,4-isoindolyl, 1,5-isoindolyl, 1,6-isoindolyl, 2,4-isoindolyl, 2,5-isoindolyl, 2,6-isoindolyl, 2,7-isoindolyl, 1,3-isoindolyl, 3,4-indazolyl, 3,5-indazolyl, 3,6-indazolyl, 3,7-indazolyl, 2,4-benzoxazolyl, 2,5-benzoxazolyl, 2,6-benzoxazolyl, 2,7-benzoxazolyl, 3,4-benzisoxazolyl, 3,5-benzisoxazolyl, 3,6-benzisoxazolyl, 3,7-benzisoxazolyl,
- 25 1,4-naphthyl, 1,5-naphthyl, 1,6-naphthyl, 1,7-naphthyl, 1,8-naphthyl, 2,4-naphthyl, 2,5-naphthyl, 2,6-naphthyl, 2,7-naphthyl, 2,8-naphthyl, 2,4-quinolinyl, 2,5-quinolinyl, 2,6-quinolinyl, 2,7-quinolinyl, 2,8-quinolinyl, 3,4-quinolinyl, 3,5-quinolinyl, 3,6-quinolinyl, 3,7-quinolinyl, 3,8-quinolinyl, 4,5-quinolinyl, 4,6-quinolinyl, 4,7-quinolinyl, 4,8-quinolinyl, 1,4-isoquinolinyl,
- 30 1,5-isoquinolinyl, 1,6-isoquinolinyl, 1,7-isoquinolinyl, 1,8-isoquinolinyl,

3,4-isoquinolinyl, 3,5-isoquinolinyl, 3,6-isoquinolinyl, 3,7-isoquinolinyl,
 3,8-isoquinolinyl, 4,5-isoquinolinyl, 4,6-isoquinolinyl, 4,7-isoquinolinyl,
 4,8-isoquinolinyl, 3,4-cinnolinyl, 3,5-cinnolinyl, 3,6-cinnolinyl, 3,7-cinnolinyl,
 3,8-cinnolinyl, 4,5-cinnolinyl, 4,6-cinnolinyl, 4,7-cinnolinyl, and 4,8-cinnolinyl,
 5 and each carbon and hyrido containing nitrogen member of the ring of the W^5
 and of the ring of the W^6 , other than the points of attachment of W^5 and W^6 ,
 is optionally substituted with one or more of the group consisting of R^9 , R^{10} ,
 R^{11} , and R^{12} , with the proviso that Q^b is bonded to lowest number substituent
 position of each W^5 , with the further proviso that Q^b is bonded to highest
 10 number substituent position of each W^6 , and with the additional proviso that
 $(CH(R^{38}))_r$ is bonded to E^0 .

2. Compound of Claim 1 of the Formula:



15 or a pharmaceutically acceptable salt thereof, wherein;

B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon
 adjacent to the carbon at the point of attachment of said phenyl or heteroaryl
 ring to A is optionally substituted by R^{32} , the other carbon adjacent to the
 carbon at the point of attachment is optionally substituted by R^{36} , a carbon
 20 adjacent to R^{32} and two atoms from the carbon at the point of attachment is
 optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the

carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} :

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

- 5 group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylenedioxy, haloalkylthio, alkanoyloxy, alkoxy, hydroxy, amino, alkoxyamino, haloalkanoyl, nitro, alkylamino, alkylthio, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, amidosulfonyl, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxamido, cyano, and
- 10 Q^b ;

- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A
- 15 with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

- B is optionally a C3-C12 cycloalkyl or a C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted
- 20 by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen atom adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen atom adjacent to the R^{13} position and two atoms from the point of attachment
- 25 is optionally substituted with R^{12} , a ring carbon or nitrogen atom three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring carbon or nitrogen atom three atoms from the

point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen atom four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

- 5 $R^9, R^{10}, R^{11}, R^{12}$, and R^{13} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl, haloalkanoyl, amidino, guanidino, alkylenedioxy, haloalkylthio, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, 10 alkylamino, N-alkyl-N-arylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylthio, alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, alkylsulfamido, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, amidosulfonyl, alkyl, aryl, aralkyl, cycloalkyl, 15 cycloalkylalkyl, heteroaryl, heterocyclyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, and cyano;

A is bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is selected from the group consisting of O,

- 20 S, $C(O)$, $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$;

R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, hydroxy, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

- 25 R^1 is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of a bond, $(CR^{41}R^{42})_q$ wherein q is 1 or 2, and $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), S(O), $N(R^{41})$, and $ON(R^{41})$;

- 5 Z^0 is optionally $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are independently 0 or 1 and W^{22} is selected from the group consisting of $CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl, 2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl, 1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl, 2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl, 1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl, 3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl, 2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, wherein Z^0 is directly bonded
- 15 to the uracil ring and W^{22} is optionally substituted with one or more substituents selected from the group consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} ;

R^{41} and R^{42} are independently selected from the group consisting of hydrido, hydroxy, alkyl, and amino;

- 20 Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the

Q is optionally hydrido with the proviso that Z^0 is other than a bond;

5 hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S, a carbon two or three

atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is substituted by Q^b, a carbon adjacent to the point of attachment of Q^S is optionally substituted by R¹⁷, another carbon adjacent to the point of attachment of Q^S is optionally substituted by R¹⁸, a carbon adjacent to Q^b is optionally substituted by R¹⁶, and another carbon adjacent to Q^b is optionally substituted by R¹⁹;

R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R¹⁶ or R¹⁹ is optionally selected from the group consisting of NR²⁰R²¹, N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), and C(NR²⁵)NR²³R²⁴, with the proviso that R¹⁶, R¹⁹, and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time, with the further proviso that
- 5 no more than one of R^{23} and R^{24} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;
- R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, alkylamino and dialkylamino;
- Q^s is selected from the group consisting of a bond, $(CR^{37}R^{38})_b$
- 10 wherein b is an integer selected from 1 through 4, and $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently selected from 1 through 3 and W^1 is selected from the group consisting of $C(O)N(R^{14})$, $(R^{14})NC(O)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, and $N(R^{14})$, with the proviso that R^{14} is selected from other than halo when
- 15 directly bonded to N and with the further proviso that $(CR^{37}R^{38})_b$, and $(CH(R^{14}))_c$ are bonded to E^0 ;
- R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;
- R^{37} and R^{38} are independently selected from the group consisting of
- 20 hydrido, alkyl, and haloalkyl;
- R^{38} is optionally aroyl or heteroaroyl, wherein R^{38} is optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} ;
- Y^0 is optionally Y^{AT} wherein Y^{AT} is Q^b-Q^s ;

Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$,

wherein e and h are integers independently selected from 1 through 2 and W^2

is $\text{CR}^{4a}=\text{CH}$ with the proviso that $(\text{CH}(\text{R}^{14}))_e$ is bonded to E^0 .

3. Compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein:
B is selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R³², R³³, R³⁴, R³⁵, and R³⁶;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is $(\text{CH}(\text{R}^{15}))_{\text{pa}}\text{-W}^7$ wherein pa is an integer selected from 0 through 3 and W^7 is selected from the group consisting of O, S, and $\text{N}(\text{R}^7)$ wherein R^7 is hydrido or alkyl;

R¹⁵ is selected from the group consisting of hydrido, hydroxy, halo,
alkyl, and haloalkyl with the proviso that R¹⁵ is other than hydroxy or halo
when R¹⁵ is on the carbon bonded directly to W⁷;

$$M \text{ is } N \text{ or } R^1\text{-}C;$$

R¹ is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

$$R^2 \text{ is } Z^0\text{-}Q;$$

Table 1. Demographic characteristics of the study population	
Age (years)	65.5 ± 10.5
Gender (male/female)	100/100
Education (years)	12.5 ± 2.5
Marital status (married/divorced/widowed)	150/50/50
Occupation (retired/working)	150/50
Income (USD/month)	1,200 ± 300
Comorbidities (hypertension/diabetes/cholesterol)	100/50/50
Medication (antidepressants/antipsychotics)	100/50
Alcohol consumption (yes/no)	50/150
Smoking status (current/former/never)	50/100/50
Family size (number of children)	2.5 ± 1.5
Living arrangement (alone/together)	50/150
Health insurance (yes/no)	150/0
Religious affiliation (Christian/Muslim/Jewish)	100/50/50
Place of birth (urban/rural)	100/50
Duration of illness (years)	10.5 ± 5.5
Previous hospitalizations (yes/no)	100/50
Current symptoms (depression/anxiety)	100/50
Functional status (independent/dependent)	100/50
Social support (strong/weak)	100/50
Stress levels (high/low)	100/50
Life satisfaction (satisfied/dissatisfied)	100/50
Quality of life (good/poor)	100/50
Overall health (good/poor)	100/50
Physical activity (regular/irregular)	100/50
Dietary habits (healthy/unhealthy)	100/50
Sleep patterns (regular/irregular)	100/50
Mental health (stable/unstable)	100/50
Substance use (none/moderate/severe)	100/50
Legal issues (yes/no)	100/50
Financial stability (stable/unstable)	100/50
Employment status (employed/unemployed)	100/50
Retirement status (retired/not retired)	100/50
Spouse status (married/separated/divorced/widowed)	100/50
Children status (living with/not living with)	100/50
Parents status (living with/not living with)	100/50
Siblings status (living with/not living with)	100/50
Friends status (many/few)	100/50
Community involvement (active/passive)	100/50
Volunteer work (yes/no)	100/50
Charitable contributions (yes/no)	100/50
Religious practices (regular/irregular)	100/50
Political views (conservative/liberal)	100/50
Environmental concerns (yes/no)	100/50
Technology use (frequent/infrequent)	100/50
Travel habits (frequent/infrequent)	100/50
Language spoken (Arabic/English/Other)	100/50
Native language (Arabic/English/Other)	100/50
Second language (Arabic/English/Other)	100/50
Third language (Arabic/English/Other)	100/50
Fourth language (Arabic/English/Other)	100/50
Fifth language (Arabic/English/Other)	100/50
Sixth language (Arabic/English/Other)	100/50
Seventh language (Arabic/English/Other)	100/50
Eighth language (Arabic/English/Other)	100/50
Ninth language (Arabic/English/Other)	100/50
Tenth language (Arabic/English/Other)	100/50
Eleventh language (Arabic/English/Other)	100/50
Twelfth language (Arabic/English/Other)	100/50
Thirteenth language (Arabic/English/Other)	100/50
Fourteenth language (Arabic/English/Other)	100/50
Fifteenth language (Arabic/English/Other)	100/50
Sixteenth language (Arabic/English/Other)	100/50
Seventeenth language (Arabic/English/Other)	100/50
Eighteenth language (Arabic/English/Other)	100/50
Nineteenth language (Arabic/English/Other)	100/50
Twentieth language (Arabic/English/Other)	100/50
Twenty-first language (Arabic/English/Other)	100/50
Twenty-second language (Arabic/English/Other)	100/50
Twenty-third language (Arabic/English/Other)	100/50
Twenty-fourth language (Arabic/English/Other)	100/50
Twenty-fifth language (Arabic/English/Other)	100/50
Twenty-sixth language (Arabic/English/Other)	100/50
Twenty-seventh language (Arabic/English/Other)	100/50
Twenty-eighth language (Arabic/English/Other)	100/50
Twenty-ninth language (Arabic/English/Other)	100/50
Thirtieth language (Arabic/English/Other)	100/50
Thirty-first language (Arabic/English/Other)	100/50
Thirty-second language (Arabic/English/Other)	100/50
Thirty-third language (Arabic/English/Other)	100/50
Thirty-fourth language (Arabic/English/Other)	100/50
Thirty-fifth language (Arabic/English/Other)	100/50
Thirty-sixth language (Arabic/English/Other)	100/50
Thirty-seventh language (Arabic/English/Other)	100/50
Thirty-eighth language (Arabic/English/Other)	100/50
Thirty-ninth language (Arabic/English/Other)	100/50
Fortieth language (Arabic/English/Other)	100/50
Forty-first language (Arabic/English/Other)	100/50
Forty-second language (Arabic/English/Other)	100/50
Forty-third language (Arabic/English/Other)	100/50
Forty-fourth language (Arabic/English/Other)	100/50
Forty-fifth language (Arabic/English/Other)	100/50
Forty-sixth language (Arabic/English/Other)	100/50
Forty-seventh language (Arabic/English/Other)	100/50
Forty-eighth language (Arabic/English/Other)	100/50
Forty-ninth language (Arabic/English/Other)	100/50
Fiftieth language (Arabic/English/Other)	100/50

Z^0 is a bond or $(CR^{41}R^{42})_q$ wherein q is 1 or 2;

R^{41} and R^{42} are independently selected from the group consisting of hydrido, hydroxy, and amino;

5 Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the
10 carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

$R^9, R^{10}, R^{11}, R^{12}$, and R^{13} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl, haloalkanoyl, amidino, guanidino, alkylenedioxy, haloalkylthio, alkoxy,
15 cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, alkylamino, N-alkyl-N-aryl amino, arylamino, aralkylamino, heteroaryl amino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylthio, alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl,
20 alkylsulfamido, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, amidosulfonyl, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, and cyano;

25 K is CHR^{4a} wherein R^{4a} is selected from the group consisting of hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

E^0 is selected from the group consisting of a covalent single bond, $C(O)N(H)$, $(H)NC(O)$, $(R^7)NS(O)_2$, and $S(O)_2N(R^7)$;

optionally substituted by R¹⁷, another carbon adjacent to the point of attachment of Q^s is optionally substituted by R¹⁸, a carbon adjacent to Q^b is optionally substituted by R¹⁶, and another carbon adjacent to Q^b is optionally substituted by R¹⁹;

Q^b is selected from the group consisting of NR²⁰R²¹, hydrido, N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), and C(NR²⁵)NR²³R²⁴, with the proviso that no more than one of R²⁰ and R²¹ is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time and with the further proviso that no more than one of R²³ and R²⁴ is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;

20 Q^s is selected from the group consisting of a bond, $(CR^{37}R^{38})_b$
 wherein b is an integer selected from 1 through 3, and
 $(CH(R^{14}))_c-W^1-(CH(R^{15}))_d$ wherein c and d are integers independently
 selected from 1 through 2 and W^1 is selected from the group consisting of

$C(O)N(R^{14})$, $(R^{14})NC(O)$, $S(O)$, $S(O)_2$, $S(O)_2N(R^{14})$, $N(R^{14})S(O)_2$, and $N(R^{14})$, with the proviso that R^{14} is selected from other than halo when directly bonded to N and with the further proviso that $(CR^{37}R^{38})_b$, and $(CH(R^{14}))_c$ are bonded to E^0 ;


5 R^{14} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

R^{37} and R^{38} are independently selected from the group consisting of hydrido, alkyl, and haloalkyl;

R^{38} is optionally aroyl or heteroaroyl;

10 Y^0 is optionally Q^b-Q^{ss} wherein Q^{ss} is $(CH(R^{14}))_e-W^2-(CH(R^{15}))_h$, wherein e and h are independently 1 or 2 and W^2 is $CR^{4a}=CH$ with the proviso that $(CH(R^{14}))_e$ is bonded to E^0 .

4. Compound of Claim 3 of the Formula:



15 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of hydrido, trialkylsilyl, C2-C4 alkyl, C3-C5 alkylenyl, C3-C4 alkenyl, C3-C4 alkynyl, and C2-C4 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 3 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , and R^{34} ;

20

R^{32} , R^{33} , and R^{34} are independently selected from the group

consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, and cyano;

A is $(CH(R^{15}))_{pa}-N(R^7)$ wherein pa is an integer selected from 0

through 2 and R^7 is hydrido or alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

10 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, alkyl, cyano, halo, haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy, hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

R^2 is Z^0-Q ;

15 Z^0 is a bond or CH_2 ;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon

20 adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

R^9 , R^{11} , and R^{13} are independently selected from the group consisting

25 of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy,

R^{10} and R^{12} are independently selected from the group consisting of

15 Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon
of said phenyl or said heteroaryl is substituted by Q^S , a carbon two or three
atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is
substituted by Q^b , a carbon adjacent to the point of attachment of Q^S is
optionally substituted by R^{17} , another carbon adjacent to the point of
20 attachment of Q^S is optionally substituted by R^{18} , a carbon adjacent to Q^b is
optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally
substituted by R^{19} ;

229

Q^b is selected from the group consisting of NR²⁰R²¹, hydrido, C(NR²⁵)NR²³R²⁴, and N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), with the proviso that no more than one of R²⁰ and R²¹ is hydroxy at the same time and with the further proviso that no more than one of R²³ and R²⁴ is hydroxy at the same time;

$R^{20}, R^{21}, R^{23}, R^{24}, R^{25}$, and R^{26} are independently selected from the

Q^S is selected from the group consisting of a bond, CH_2 , and

5. Compound of Claim 4 of the Formula or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, butyl, 2-butenyl, 3-butenyl, 2-butenyl, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, and 2,2-difluoropropyl, wherein each member of group B is optionally substituted at any carbon up to and including 3 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , and R^{34} ;

R^{32} , R^{33} , and R^{34} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,

- trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, 5 amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, and cyano;

A is selected from the group consisting of a bond, NH, and N(CH₃);

M is N or R¹-C;

- R¹ is selected from the group consisting of hydrido, hydroxy, amino, 10 amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino, dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, and bromo;

- 15 R² is Z⁰-Q;

Z⁰ is a bond or CH₂;

- Q is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 20 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z⁰ is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two 25 atoms from the carbon at the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

R^9, R^{11} , and R^{13} are independently selected from the group consisting

of hydrido, amidino, guanidino, carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, methanesulfonamido, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of

hydrido, amidino, guanidino, carboxy, carboxymethyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methanesulfonamido, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl, N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl, N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl, N-benzylamidosulfonyl, N-(2-chlorobenzyl)amidosulfonyl, N-isopropylamidocarbonyl, N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl, fluoro, chloro, bromo, cyano, cyclobutoxy, cyclohexoxy, cyclohexylmethoxy, 4-trifluoromethylcyclohexylmethoxy, cyclopentoxy, benzyl, benzyloxy, 4-bromo-3-fluorophenoxy, 3-bromobenzyloxy, 4-bromobenzyloxy, 4-bromobenzylamino, 5-bromopyrid-2-ylmethylamino, 4-butoxyphenamino, 3-chlorobenzyl, 4-chlorophenoxy, 4-chloro-3-ethylphenoxy, 4-chloro-3-ethylbenzylamino, 4-chloro-3-ethylphenylamino, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 4-chlorobenzylsulfonyl, 4-chlorophenylamino, 4-chlorophenylsulfonyl, 5-chloropyrid-3-ylloxy, 2-cyanopyrid-3-ylloxy, 2,3-difluorobenzyloxy, 2,4-difluorobenzyloxy,

- Y^0 is selected from the group consisting of:

- 233

- $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ furan, $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ furan,
 $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ pyrrole, $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ pyrrole,
 $4-Q^b-2-Q^s-5-R^{19}$ imidazole, $2-Q^b-4-Q^s-5-R^{17}$ imidazole,
 $3-Q^b-5-Q^s-4-R^{16}$ isoxazole, $5-Q^b-3-Q^s-4-R^{16}$ isoxazole,
 5 $2-Q^b-5-Q^s-4-R^{16}$ pyrazole, $4-Q^b-2-Q^s-5-R^{19}$ thiazole, and
 $2-Q^b-5-Q^s-4-R^{17}$ thiazole;

- R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group
 consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino,
 guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino,
 10 aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino,
 N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio,
 methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl,
 pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl,
 trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo,
 15 hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;


R^{16} or R^{19} is optionally selected from the group consisting of
 $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the
 proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido,
 20 $C(NR^{25})NR^{23}R^{24}$, and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, with the proviso that
 no more than one of R^{20} , R^{21} , R^{23} , and R^{24} can be hydroxy, when any two
 of the group consisting of R^{20} , R^{21} , R^{23} , and R^{24} are bonded to the same
 atom and with the further proviso that said Q^b group is bonded directly to a
 carbon atom;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, isopropyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

- 5 6. Compound of Claim 4 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

A is selected from the group consisting of $CH_2N(CH_3)$,

$CH_2N(CH_2CH_3)$, $CH_2CH_2N(CH_3)$, and $CH_2CH_2N(CH_2CH_3)$;

- 10 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino, dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy,

- 15 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, and bromo;

R^2 is Z^0-Q ;

Z^0 is a bond or CH_2 ;

- 20 Q is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is

5

10

15

20

25

- N-cyclopentylamidocarbonyl, fluoro, chloro, bromo, cyano, cyclobutoxy, cyclohexoxy, cyclohexylmethoxy, 4-trifluoromethylcyclohexylmethoxy, cyclopentoxy, benzyl, benzyloxy, 4-bromo-3-fluorophenoxy, 3-bromobenzyloxy, 4-bromobenzyloxy, 4-bromobenzylamino,
- 5 5-bromopyrid-2-ylmethylamino, 4-butoxyphenamino, 3-chlorobenzyl, 4-chlorophenoxy, 4-chloro-3-ethylphenoxy, 4-chloro-3-ethylbenzylamino, 4-chloro-3-ethylphenylamino, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 4-chlorobenzylsulfonyl, 4-chlorophenylamino, 4-chlorophenylsulfonyl, 5-chloropyrid-3-yloxy, 2-cyanopyrid-3-yloxy, 2,3-difluorobenzyloxy,
- 10 2,4-difluorobenzyloxy, 3,4-difluorobenzyloxy, 2,5-difluorobenzyloxy, 3,5-difluorophenoxy, 3,5-difluorobenzyloxy, 4-difluoromethoxybenzyloxy, 2,3-difluorophenoxy, 2,4-difluorophenoxy, 2,5-difluorophenoxy, 3,5-dimethylphenoxy, 3,4-dimethylphenoxy, 3,4-dimethylbenzyloxy, 3,5-dimethylbenzyloxy, 4-ethoxyphenoxy, 4-ethylbenzyloxy, 3-ethylphenoxy,
- 15 4-ethylaminophenoxy, 3-ethyl-5-methylphenoxy, 4-fluorobenzyloxy, 2-fluoro-3-trifluoromethylbenzyloxy, 3-fluoro-5-trifluoromethylbenzyloxy, 4-fluoro-2-trifluoromethylbenzyloxy, 4-fluoro-3-trifluoromethylbenzyloxy, 2-fluorophenoxy, 4-fluorophenoxy, 2-fluoro-3-trifluoromethylphenoxy, 2-fluorobenzyloxy, 4-fluorophenylamino, 2-fluoro-4-trifluoromethylphenoxy,
- 20 4-isopropylbenzyloxy, 3-isopropylphenoxy, 4-isopropylphenoxy, 4-isopropyl-3-methylphenoxy, 4-isopropylbenzyloxy, 3-isopropylphenoxy, 4-isopropylphenoxy, 4-isopropyl-3-methylphenoxy, phenylamino, 1-phenylethoxy, 2-phenylethoxy, 2-phenylethyl, 2-phenylethylamino, phenylsulfonyl, 3-trifluoromethoxybenzyloxy, 4-trifluoromethoxybenzyloxy,
- 25 3-trifluoromethoxyphenoxy, 4-trifluoromethoxyphenoxy, 3-trifluoromethylbenzyloxy, 4-trifluoromethylbenzyloxy, 2,4-bis-trifluoromethylbenzyloxy, 3-trifluoromethylbenzyl, 3,5-bis-trifluoromethylbenzyloxy, 4-trifluoromethylphenoxy, 3-trifluoromethylphenoxy, 3-trifluoromethylthiobenzyloxy,
- 30 4-trifluoromethylthiobenzyloxy, 2,3,4-trifluorophenoxy, 2,3,5-trifluorophenoxy, 3-pentafluoroethylphenoxy, 3-(1,1,2,2-tetrafluoroethoxy)phenoxy, and 3-trifluoromethylthiophenoxy;

Y^0 is selected from the group consisting of:

1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,

atom, and with the further proviso that said Q^b group is bonded directly to a carbon atom;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the

group consisting of hydrido, methyl, ethyl, propyl, butyl, isopropyl, and
5 hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

7. Compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein;

A is selected from the group consisting of $CH_2N(CH_3)$,

10 $CH_2N(CH_2CH_3)$, $CH_2CH_2N(CH_3)$, and $CH_2CH_2N(CH_2CH_3)$;

M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, hydroxymethyl, methoxyamino, methylthio,

15 trifluoromethoxy, fluoro, and chloro;

R^2 is Z^0-Q ;

Z^0 is a bond or CH_2 ;

Q is selected from the group consisting of

3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,

20 3-amino-5-benzylphenyl, 3-amino-5-(2-phenylethyl)phenyl,

3-amino-5-benzylaminophenyl, 3-amino-5-(2-phenylethylamino)phenyl,

3-amino-5-benzyloxyphenyl, 3-amino-5-(2-phenylethoxy)phenyl,

3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,

3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,

25 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,

3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,

3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,

3-amino-5-(N-benzylamidosulfonyl)phenyl,

-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,

30 3-amino-5-(N-ethylamidocarbonyl)phenyl,

- 3-amino-5-(N-isopropylamidocarbonyl)phenyl,
 3-amino-5-(N-propylamidocarbonyl)phenyl,
 3-amino-5-(N-isobutylamidocarbonyl)phenyl,
 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
 5 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl,
 5-amino-2-fluorophenyl, 3-amino-5-hydroxymethylphenyl,
 5-amino-3-methoxycarbonylphenyl, 3-amidinophenyl,
 10 3-amino-2-methylphenyl, 5-amino-2-methylthiophenyl, 3-aminophenyl,
 3-carboxyphenyl, 3-carboxy-5-hydroxyphenyl, 3-amino-5-carboxyphenyl,
 3-chlorophenyl, 2-chlorophenyl, 3-cyanophenyl, 3,5-diaminophenyl,
 3-dimethylaminophenyl, 2-fluorophenyl, 3-fluorophenyl, 2-hydroxyphenyl,
 3-hydroxyphenyl, 3-methanesulfonylaminophenyl, 2-methoxyphenyl,
 15 3-methoxyphenyl, 3-methoxyaminophenyl, 3-methoxycarbonylphenyl,
 2-methylaminophenyl, 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl,
 4-methylphenyl, phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl,
 2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl,
 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;
 20 Y^0 is selected from the group consisting of:
 $1-Q^b-4-Q^s-2-R^{16}-3-R^{17}-5-R^{18}-6-R^{19}$ benzene,
 $2-Q^b-5-Q^s-6-R^{17}-4-R^{18}-3-R^{19}$ pyridine,
 $3-Q^b-6-Q^s-2-R^{16}-5-R^{18}-4-R^{19}$ pyridine,
 $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ thiophene, and $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ thiophene;
 25 R^{16} and R^{19} are independently selected from the group consisting of
 hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy,
 hydroxymethyl, fluoro, chloro, and cyano;
 R^{17} and R^{18} are independently selected from the group consisting of
 hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;
 30 Q^b is $C(NR^{25})NR^{23}R^{24}$;

Q^s is CH_2 .

- 30 2-[3-[1-[3-amino-5-carboxyphenyl]-6-fluoro-5-[N,N-diethylhydrazino]-N-[[4-aminoiminomethylphenyl]methyl]-2,4-dioxo-2(2H,4H)-pyrimidinyl]]acetamide;

2-[4-[2-[3-amino-5-carboxyphenyl]-6-[N-ethyl-N-methylhydrazino]-
5 N-[[4-aminoiminomethylphenyl)methyl]-3,5-dioxo-2(3H,5H)-1,2,4-
triazinyl]]acetamide;

10

O=C1NC(=O)N(C1)C(=O)N2C(=O)N(C2)C(=O)N3C(=O)N(C3)C(=O)N4C(=O)N(C4)C(=O)N5C(=O)N(C5)C(=O)N6C(=O)N(C6)C(=O)N7C(=O)N(C7)C(=O)N8C(=O)N(C8)C(=O)N9C(=O)N(C9)C(=O)N10C(=O)N(C10)C(=O)N11C(=O)N(C11)C(=O)N12C(=O)N(C12)C(=O)N13C(=O)N(C13)C(=O)N14C(=O)N(C14)C(=O)N15C(=O)N(C15)C(=O)N16C(=O)N(C16)C(=O)N17C(=O)N(C17)C(=O)N18C(=O)N(C18)C(=O)N19C(=O)N(C19)C(=O)N20C(=O)N(C20)C(=O)N21C(=O)N(C21)C(=O)N22C(=O)N(C22)C(=O)N23C(=O)N(C23)C(=O)N24C(=O)N(C24)C(=O)N25C(=O)N(C25)C(=O)N26C(=O)N(C26)C(=O)N27C(=O)N(C27)C(=O)N28C(=O)N(C28)C(=O)N29C(=O)N(C29)C(=O)N30C(=O)N(C30)C(=O)N31C(=O)N(C31)C(=O)N32C(=O)N(C32)C(=O)N33C(=O)N(C33)C(=O)N34C(=O)N(C34)C(=O)N35C(=O)N(C35)C(=O)N36C(=O)N(C36)C(=O)N37C(=O)N(C37)C(=O)N38C(=O)N(C38)C(=O)N39C(=O)N(C39)C(=O)N40C(=O)N(C40)C(=O)N41C(=O)N(C41)C(=O)N42C(=O)N(C42)C(=O)N43C(=O)N(C43)C(=O)N44C(=O)N(C44)C(=O)N45C(=O)N(C45)C(=O)N46C(=O)N(C46)C(=O)N47C(=O)N(C47)C(=O)N48C(=O)N(C48)C(=O)N49C(=O)N(C49)C(=O)N50C(=O)N(C50)C(=O)N51C(=O)N(C51)C(=O)N52C(=O)N(C52)C(=O)N53C(=O)N(C53)C(=O)N54C(=O)N(C54)C(=O)N55C(=O)N(C55)C(=O)N56C(=O)N(C56)C(=O)N57C(=O)N(C57)C(=O)N58C(=O)N(C58)C(=O)N59C(=O)N(C59)C(=O)N60C(=O)N(C60)C(=O)N61C(=O)N(C61)C(=O)N62C(=O)N(C62)C(=O)N63C(=O)N(C63)C(=O)N64C(=O)N(C64)C(=O)N65C(=O)N(C65)C(=O)N66C(=O)N(C66)C(=O)N67C(=O)N(C67)C(=O)N68C(=O)N(C68)C(=O)N69C(=O)N(C69)C(=O)N70C(=O)N(C70)C(=O)N71C(=O)N(C71)C(=O)N72C(=O)N(C72)C(=O)N73C(=O)N(C73)C(=O)N74C(=O)N(C74)C(=O)N75C(=O)N(C75)C(=O)N76C(=O)N(C76)C(=O)N77C(=O)N(C77)C(=O)N78C(=O)N(C78)C(=O)N79C(=O)N(C79)C(=O)N80C(=O)N(C80)C(=O)N81C(=O)N(C81)C(=O)N82C(=O)N(C82)C(=O)N83C(=O)N(C83)C(=O)N84C(=O)N(C84)C(=O)N85C(=O)N(C85)C(=O)N86C(=O)N(C86)C(=O)N87C(=O)N(C87)C(=O)N88C(=O)N(C88)C(=O)N89C(=O)N(C89)C(=O)N90C(=O)N(C90)C(=O)N91C(=O)N(C91)C(=O)N92C(=O)N(C92)C(=O)N93C(=O)N(C93)C(=O)N94C(=O)N(C94)C(=O)N95C(=O)N(C95)C(=O)N96C(=O)N(C96)C(=O)N97C(=O)N(C97)C(=O)N98C(=O)N(C98)C(=O)N99C(=O)N(C99)C(=O)N100C(=O)N(C100)C(=O)N101C(=O)N(C101)C(=O)N102C(=O)N(C102)C(=O)N103C(=O)N(C103)C(=O)N104C(=O)N(C104)C(=O)N105C(=O)N(C105)C(=O)N106C(=O)N(C106)C(=O)N107C(=O)N(C107)C(=O)N108C(=O)N(C108)C(=O)N109C(=O)N(C109)C(=O)N110C(=O)N(C110)C(=O)N111C(=O)N(C111)C(=O)N112C(=O)N(C112)C(=O)N113C(=O)N(C113)C(=O)N114C(=O)N(C114)C(=O)N115C(=O)N(C115)C(=O)N116C(=O)N(C116)C(=O)N117C(=O)N(C117)C(=O)N118C(=O)N(C118)C(=O)N119C(=O)N(C119)C(=O)N120C(=O)N(C120)C(=O)N121C(=O)N(C121)C(=O)N122C(=O)N(C122)C(=O)N123C(=O)N(C123)C(=O)N124C(=O)N(C124)C(=O)N125C(=O)N(C125)C(=O)N126C(=O)N(C126)C(=O)N127C(=O)N(C127)C(=O)N128C(=O)N(C128)C(=O)N129C(=O)N(C129)C(=O)N130C(=O)N(C130)C(=O)N131C(=O)N(C131)C(=O)N132C(=O)N(C132)C(=O)N133C(=O)N(C133)C(=O)N134C(=O)N(C134)C(=O)N135C(=O)N(C135)C(=O)N136C(=O)N(C136)C(=O)N137C(=O)N(C137)C(=O)N138C(=O)N(C138)C(=O)N139C(=O)N(C139)C(=O)N140C(=O)N(C140)C(=O)N141C(=O)N(C141)C(=O)N142C(=O)N(C142)C(=O)N143C(=O)N(C143)C(=O)N144C(=O)N(C144)C(=O)N145C(=O)N(C145)C(=O)N146C(=O)N(C146)C(=O)N147C(=O)N(C147)C(=O)N148C(=O)N(C148)C(=O)N149C(=O)N(C149)C(=O)N150C(=O)N(C150)C(=O)N151C(=O)N(C151)C(=O)N152C(=O)N(C152)C(=O)N153C(=O)N(C153)C(=O)N154C(=O)N(C154)C(=O)N155C(=O)N(C155)C(=O)N156C(=O)N(C156)C(=O)N157C(=O)N(C157)C(=O)N158C(=O)N(C158)C(=O)N159C(=O)N(C159)C(=O)N160C(=O)N(C160)C(=O)N161C(=O)N(C161)C(=O)N162C(=O)N(C162)C(=O)N163C(=O)N(C163)C(=O)N164C(=O)N(C164)C(=O)N165C(=O)N(C165)C(=O)N166C(=O)N(C166)C(=O)N167C(=O)N(C167)C(=O)N168C(=O)N(C168)C(=O)N169C(=O)N(C169)C(=O)N170C(=O)N(C170)C(=O)N171C(=O)N(C171)C(=O)N172C(=O)N(C172)C(=O)N173C(=O)N(C173)C(=O)N174C(=O)N(C174)C(=O)N175C(=O)N(C175)C(=O)N176C(=O)N(C176)C(=O)N177C(=O)N(C177)C(=O)N178C(=O)N(C178)C(=O)N179C(=O)N(C179)C(=O)N180C(=O)N(C180)C(=O)N181C(=O)N(C181)C(=O)N182C(=O)N(C182)C(=O)N183C(=O)N(C183)C(=O)N184C(=O)N(C184)C(=O)N185C(=O)N(C185)C(=O)N186C(=O)N(C186)C(=O)N187C(=O)N(C187)C(=O)N188C(=O)N(C188)C(=O)N189C(=O)N(C189)C(=O)N190C(=O)N(C190)C(=O)N191C(=O)N(C191)C(=O)N192C(=O)N(C192)C(=O)N193C(=O)N(C193)C(=O)N194C(=O)N(C194)C(=O)N195C(=O)N(C195)C(=O)N196C(=O)N(C196)C(=O)N197C(=O)N(C197)C(=O)N198C(=O)N(C198)C(=O)N199C(=O)N(C199)C(=O)N200C(=O)N(C200)C(=O)N201C(=O)N(C201)C(=O)N202C(=O)N(C202)C(=O)N203C(=O)N(C203)C(=O)N204C(=O)N(C204)C(=O)N205C(=O)N(C205)C(=O)N206C(=O)N(C206)C(=O)N207C(=O)N(C207)C(=O)N208C(=O)N(C208)C(=O)N209C(=O)N(C209)C(=O)N210C(=O)N(C210)C(=O)N211C(=O)N(C211)C(=O)N212C(=O)N(C212)C(=O)N213C(=O)N(C213)C(=O)N214C(=O)N(C214)C(=O)N215C(=O)N(C215)C(=O)N216C(=O)

B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R³², the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R³⁶, a carbon adjacent to R³² and two atoms from the carbon at the point of attachment is optionally substituted by R³³, a carbon adjacent to R³⁶ and two atoms from the carbon at the point of attachment is optionally substituted by R³⁵, and any carbon adjacent to both R³³ and R³⁵ is optionally substituted by R³⁴;

group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl,

alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $(R^7)NC(O)$ or $N(R^7)$;

5 R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

10 R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of a bond, CH_2 , CH_2CH_2 , $W^0-(CH(R^{42}))_p$ wherein p is 0 or 1 and W^0 is selected from the group consisting

15 of O, S, and $N(R^{41})$;

R^{41} and R^{42} are independently hydrido or alkyl;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the

20 carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboxy,

R^{10} and R^{12} are independently selected from the group consisting of

hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy,

10 heteroaralkoxy, heterocyclioxy, heterocyclialkoxo, hydroxy, amino,
alkoxyamino, alkylamino, arylamino, aralkylamino, heteroarylamino,
heteroaralkylamino, heterocyclilamino, heterocyclialkylamino,
alkylsulfonamido, amidosulfonyl, arylsulfinyl, aralkylsulfinyl,
cycloalkylsulfinyl, heteroarylsulfinyl, arylsulfonyl, aralkylsulfonyl,
15 cycloalkylsulfonyl, heteroarylsulfonyl, hydroxyalkyl, hydroxyhaloalkyl,
aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, halo, haloalkyl,
and cyano;

Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S, a carbon two or three

atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is substituted by Q^b, a carbon adjacent to the point of attachment of Q^S is optionally substituted by R¹⁷, another carbon adjacent to the point of attachment of Q^S is optionally substituted by R¹⁸, a carbon adjacent to Q^b is optionally substituted by R¹⁶, and another carbon adjacent to Q^b is optionally substituted by R¹⁹;

R^{16}, R^{17}, R^{18} , and R^{19} are independently selected from the group

consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl,

haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the

proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- 5 Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

- 10 R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

- 15 10. Compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein;

- 20 B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at
- 25

the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

- 5 group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl, N-methylamidulosulfonyl,
- 10 N,N-dimethylamidulosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, cyano, and Q^b ;

A is selected from the group consisting of a bond, NH, N(CH₃),

- 15 N(OH), CH₂, CH₃CH, CF₃CH, NHC(O), N(CH₃)C(O), C(O)NH, C(O)N(CH₃), CH₂CH₂, CH₂CH₂CH₂, CH₃CHCH₂, and CF₃CHCH₂;

M is N or R^1 -C;

- R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino,
- 20 dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, and bromo;

R^2 is Z^0 -Q;

- 25 Z^0 is selected from the group consisting of a bond, CH₂, CH₂CH₂, O, S, NH, N(CH₃), OCH₂, SCH₂, N(H)CH₂, and N(CH₃)CH₂;

Q is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl,

4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point

5 of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

10 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,

15 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, methanesulfonamido, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, and cyano;

20 R^{10} and R^{12} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, carboxymethyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino,

25 methanesulfonamido, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl,

248

4-trifluoromethylthiobenzyloxy, 2,3,4-trifluorophenoxy, 2,3,5-trifluorophenoxy, 3-pentafluoroethylphenoxy, 3-(1,1,2,2-tetrafluoroethoxy)phenoxy, and 3-trifluoromethylthiophenoxy;

Y^0 is selected from the group consisting of:

- 5 $1-Q^b-4-Q^s-2-R^{16}-3-R^{17}-5-R^{18}-6-R^{19}$ benzene,
- $2-Q^b-5-Q^s-6-R^{17}-4-R^{18}-3-R^{19}$ pyridine,
- $3-Q^b-6-Q^s-2-R^{16}-5-R^{18}-4-R^{19}$ pyridine, $2-Q^b-5-Q^s-3-R^{16}-6-R^{18}$ pyrazine,
- $3-Q^b-6-Q^s-2-R^{18}-5-R^{18}-4-R^{19}$ pyridazine,
- $2-Q^b-5-Q^s-4-R^{17}-6-R^{18}$ pyrimidine, $5-Q^b-2-Q^s-4-R^{16}-6-R^{19}$ pyrimidine,
- 10 $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ thiophene, $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ thiophene,
- $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ furan, $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ furan,
- $3-Q^b-5-Q^s-4-R^{16}-2-R^{19}$ pyrrole, $2-Q^b-5-Q^s-3-R^{16}-4-R^{17}$ pyrrole,
- $4-Q^b-2-Q^s-5-R^{19}$ imidazole, $2-Q^b-4-Q^s-5-R^{17}$ imidazole,
- $3-Q^b-5-Q^s-4-R^{16}$ isoxazole, $5-Q^b-3-Q^s-4-R^{16}$ isoxazole,
- 15 $2-Q^b-5-Q^s-4-R^{16}$ pyrazole, $4-Q^b-2-Q^s-5-R^{19}$ thiazole, and
- $2-Q^b-5-Q^s-4-R^{17}$ thiazole;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

- consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino, guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino,
- 20 aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo,
 - 25 hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;

R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido, with the proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

5 R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, methyl, ethyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 and CH_2CH_2 .

10 11. Compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of 2-aminophenyl, 3-aminophenyl, 3-amidinophenyl, 4-amidinophenyl, 3-carboxyphenyl, 3-carboxy-5-hydroxyphenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 15 3-hydroxyphenyl, 4-hydroxyphenyl, 3-methoxyaminophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, 3-trifluoromethylphenyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, 5-chloro-3-trifluoromethyl-2-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, and 3-trifluoromethyl-2-pyridyl;

20 A is selected from the group consisting of CH_2 , CH_3CH , CF_3CH , $NHC(O)$, CH_2CH_2 , and $CH_2CH_2CH_2$;

M is N or R^1-C ;

25 R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, hydroxymethyl, methoxyamino, methylthio, trifluoromethoxy, fluoro, and chloro;

R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of a bond, CH_2 , O, S, NH,

Q is selected from the group consisting of

- 3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,
5 3-amino-5-benzylphenyl, 3-amino-5-(2-phenylethyl)phenyl,
3-amino-5-benzylaminophenyl, 3-amino-5-(2-phenylethylamino)phenyl,
3-amino-5-benzylloxyphenyl, 3-amino-5-(2-phenylethoxy)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
10 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
3-amino-5-(N-benzylamidodisulfonyl)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidodisulfonyl)phenyl,
15 3-amino-5-(N-ethylamidocarbonyl)phenyl,
3-amino-5-(N-isopropylamidocarbonyl)phenyl,
3-amino-5-(N-propylamidocarbonyl)phenyl,
3-amino-5-(N-isobutylamidocarbonyl)phenyl,
3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
20 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 5-amino-2-fluorophenyl,
3-amino-5-hydroxymethylphenyl, 5-amino-3-methoxycarbonylphenyl,
3-amidinophenyl, 3-amino-2-methylphenyl, 5-amino-2-methylthiophenyl,
25 3-aminophenyl, 3-amino-5-(4-trifluoromethylbenzylamino)phenyl,
3-amino-5-(4-trifluoromethylbenzyloxy)phenyl, 3-carboxyphenyl,
3-carboxy-5-hydroxyphenyl, 3-amino-5-carboxyphenyl, 3-chlorophenyl,
2-chlorophenyl, 3-cyanophenyl, 3,5-diaminophenyl, 3-dimethylaminophenyl,
2-fluorophenyl, 3-fluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl,
30 3-methanesulfonylaminophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
3-methoxyaminophenyl, 3-methoxycarbonylphenyl, 2-methylaminophenyl,
3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,
phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl,
2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl,
35 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;

Y^0 is selected from the group consisting of:

- 1- Q^b -4- Q^s -2- R^{16} -3- R^{17} -5- R^{18} -6- R^{19} benzene,
 2- Q^b -5- Q^s -6- R^{17} -4- R^{18} -3- R^{19} pyridine,
 3- Q^b -6- Q^s -2- R^{16} -5- R^{18} -4- R^{19} pyridine,
 5 3- Q^b -5- Q^s -4- R^{16} -2- R^{19} thiophene, and 2- Q^b -5- Q^s -3- R^{16} -4- R^{17} thiophene;

R^{16} and R^{19} are independently selected from the group consisting of hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy, hydroxymethyl, fluoro, chloro, and cyano;

R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} ,

- 10 R^{19} , and Q^b are not simultaneously hydrido;


R^{17} and R^{18} are independently selected from the group consisting of hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido;

R^{23} , R^{24} , and R^{25} are independently hydrido or methyl;

- 15 Q^s is CH_2 .

12. Compound of Claim 9 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

- 20 B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl

ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $N(R^7)$;

R^7 is hydrido or alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0-Q ;

Z^0 is a bond;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the

- carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any
- 5 carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkoxy, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;

- 10 R^{10} and R^{12} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, alkoxyamino, hydroxy, amino, alkylamino, alkylsulfonamido, amidosulfonyl, hydroxyalkyl, aminoalkyl, halo, haloalkyl, carboalkoxy, carboxy, carboxamido, carboxyalkyl, and cyano;

- 15 Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of
- 20 attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl,

25

R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently hydrido or alkyl;

10 13. Compound of Claim 12 or a pharmaceutically acceptable salt thereof,
wherein;

B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, and 5-isoxazolyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R³², the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R³⁶, a carbon adjacent to R³² and two atoms from the carbon at the point of attachment is optionally substituted by R³³, a carbon adjacent to R³⁶ and two atoms from the carbon at the point of attachment is optionally substituted by R³⁵, and any carbon adjacent to both R³³ and R³⁵ is optionally substituted by R³⁴;

$R^{32}, R^{33}, R^{34}, R^{35}$, and R^{36} are independently selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,

fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, carboxy, cyano, and Q^b ;

A is selected from the group consisting of a bond, NH, $N(CH_3)$, CH_2 , CH_3CH , and CH_2CH_2 ;

5 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, methylthio, trifluoromethoxy, fluoro, and chloro;

10 R^2 is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-pyrrolyl, 2-imidazolyl, 2-thiazolyl, 3-isoxazolyl, 2-pyridyl, and 3-pyridyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to the uracil ring is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

20 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, methylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, carboxy, and cyano;

25 R^{10} and R^{12} are independently selected from the group consisting of hydrido, amidino, amidocarbonyl, N-methylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl,

10

15

20

25

$$O^b \text{ is } NR^{20}R^{21} \text{ or } C(NR^{25})NR^{23}R^{24};$$

consisting of hydrido, methyl, and ethyl;

Q^s is CH_2 .

14. Compound of Claim 13 or a pharmaceutically acceptable salt thereof, wherein;

5 B is selected from the group consisting of 2-aminophenyl, 3-aminophenyl, 3-amidinophenyl, 4-amidinophenyl, 3-carboxyphenyl, 3-carboxy-5-hydroxyphenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-methoxyaminophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, 10 3-trifluoromethylphenyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, 5-chloro-3-trifluoromethyl-2-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, and 3-trifluoromethyl-2-pyridyl;

A is CH_2 or CH_2CH_2 ;

15 M is N or R^1 -C;

R¹ is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and fluoro:

R^2 is selected from the group consisting of

20 3-amidocarbonyl-5-aminophenyl, 3-amidocarbonyl-5-aminophenyl,
3-amino-5-(N-benzylamidocarbonyl)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
25 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
3-amino-5-(N-benzylamidosulfonyl)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
3-amino-5-(N-ethylamidocarbonyl)phenyl,
30 -amino-5-(N-isopropylamidocarbonyl)phenyl,
-amino-5-(N-propylamidocarbonyl)phenyl,
3-amino-5-(N-isobutylamidocarbonyl)phenyl,
3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,

15. Compound of Claim 14 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of 3-aminophenyl, 3-amidinophenyl, 4-amidinophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 4-methylphenyl, phenyl, 2-imidazolyl, 3-pyridyl, 4-pyridyl, and 3-trifluoromethyl-2-pyridyl;

A is CH_2 or CH_2CH_2 ;

M is N or $\text{R}^1\text{-C}$;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and fluoro;

R^2 is selected from the group consisting of

3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl, 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,

15 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl, 3-amino-5-(N-benzylamidodisulfonyl)phenyl,


20 3-amino-5-(N-(2-chlorobenzyl)amidodisulfonyl)phenyl, 3-amino-5-(N-ethylamidocarbonyl)phenyl, 3-amino-5-(N-isopropylamidocarbonyl)phenyl, 3-amino-5-(N-propylamidocarbonyl)phenyl, 3-amino-5-(N-isobutylamidocarbonyl)phenyl,

25 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl, 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 3-aminophenyl, 3-carboxy-5-aminophenyl, 3-chlorophenyl, 3,5-diaminophenyl,

30 3-dimethylaminophenyl, 3-hydroxyphenyl, 3-methanesulfonylaminophenyl, 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, phenyl, 3-trifluoroacetamidophenyl, 3-bromo-2-thienyl, 2-thienyl, and 3-thienyl;

Y^0 is selected from the group consisting of 5-amidino-2-thienylmethyl, 4-amidinobenzyl, 2-fluoro-4-amidinobenzyl, and 3-fluoro-4-amidinobenzyl.

16. Compound of Claim 9 where said compound is selected from the group of
5 the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

R^2 is 3-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

- 10 R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

- 15 R^2 is 3-aminophenyl, B is 2-imidazolyl, A is $CH_2CH_2CH_2$, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-dimethylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 2-methylphenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

- 20 R^2 is phenyl, B is 3-aminophenyl, A is $C(O)NH$, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 3-amidinophenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-thienyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is phenyl, B is 4-amidinophenyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is phenyl, B is phenyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is phenyl, B is 3-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M

R² is 3-chlorophenyl, B is 4-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl,
is CH;

20 R^2 is 3-thienyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl,
and M is CH;

R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M

R² is phenyl, B is 3-chlorophenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, is CF;

R² is 3-dimethylaminophenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF₃;

R^2 is phenyl, B is 3-aminophenyl, A is $C(O)NH$, Y^0 is 4-amidinobenzyl, and M is CF;

R² is 3-(N-methylamino)phenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

15 R^2 is 3-methylsulfonamidophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R² is 3-methylaminophenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-

R^2 is phenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF_3 ;

R^2 is phenyl, B is 3-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M

R² is 3-chlorophenyl, B is 4-pyridyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl,
is CF;

R^2 is 3-thienyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R² is 3-aminophenyl, B is phenyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-imidazolyl, A is CH₂CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

15 R^2 is 2-methylphenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl,
and M is N;

R² is phenyl, B is 3-aminophenyl, A is C(O)NH, Y⁰ is 4-amidinobenzyl, and M is N;

R² is phenyl, B is 3-amidinophenyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and
20 M is N;

R² is 3-(N-methylamino)phenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-thienyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

25 R² is 3-methylsulfonamidophenyl, B is phenyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is phenyl, B is 4-amidinophenyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R^2 is 3-methylaminophenyl, B is phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is phenyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is 4-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is 3-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-chlorophenyl, B is 4-pyridyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-methylphenyl, B is 4-phenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-thienyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amidocarbonyl-5-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3,5-diaminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxyphenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amidocarbonyl-5-aminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-chlorobenzyl)amidodisulfonyl)phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;


10 R^2 is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3,5-diaminophenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-carboxyphenyl, B is 3-chlorophenyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N.

15

17. Compound of Claim 2 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

20 B is selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the

point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

- 5 group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $(R^7)NC(O)$ or $N(R^7)$;

- 10 R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

- 15 R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0-Q ;

Z^0 is selected from the group consisting of a bond, CH_2 , CH_2CH_2 , $W^0-(CH(R^{42}))_p$ wherein p is 0 or 1 and W^0 is selected from the group consisting

- 20 of O, S, and $N(R^{41})$;

R^{41} and R^{42} are independently hydrido or alkyl;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the

- 25 carbon at the point of attachment is optionally substituted by R^{13} , a carbon

adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

5 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboxy, carboxamido, and cyano;

10 R^{10} and R^{12} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, 15 alkoxyamino, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylsulfonamido, amidosulfonyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, hydroxyalkyl, hydroxyhaloalkyl, 20 aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, halo, haloalkyl, and cyano;

Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is 25 optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is

optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} :

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the

proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, $C(NR^{25})NR^{23}R^{24}$, and $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

18. Compound of Claim 17 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of hydrido, ethyl, 2-propynyl, 2-propenyl, propyl, isopropyl, butyl, 2-butenyl, 3-butenyl, 2-butyryl, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 1-pentyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-pentynyl, 3-pentynyl, 2-pentyl, 1-methyl-2-butenyl, 1-methyl-3-butenyl, 1-methyl-2-butyryl, 3-pentyl, 1-ethyl-2-propenyl,

- 2-methylbutyl, 2-methyl-2-butenyl, 2-methyl-3-butenyl, 2-methyl-3-butyryl,
 3-methylbutyl, 3-methyl-2-butenyl, 3-methyl-3-butenyl, 1-hexyl, 2-hexenyl,
 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 2-hexyl,
 1-methyl-2-pentenyl, 1-methyl-3-pentenyl, 1-methyl-4-pentenyl,
 5 1-methyl-2-pentyryl, 1-methyl-3-pentyryl, 3-hexyl, 1-ethyl-2-butenyl,
 1-ethyl-3-butenyl, 1-propyl-2-propenyl, 1-ethyl-2-butyryl, 1-heptyl, 2-heptenyl,
 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 2-heptyryl, 3-heptyryl,
 4-heptyryl, 5-heptyryl, 2-heptyl, 1-methyl-2-hexenyl, 1-methyl-3-hexenyl,
 1-methyl-4-hexenyl, 1-methyl-5-hexenyl, 1-methyl-2-hexynyl,
 10 1-methyl-3-hexynyl, 1-methyl-4-hexynyl, 3-heptyl, 1-ethyl-2-pentenyl,
 1-ethyl-3-pentenyl, 1-ethyl-4-pentenyl, 1-butyl-2-propenyl, 1-ethyl-2-pentyryl,
 1-ethyl-3-pentyryl, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 4-trifluoromethyl-
 5,5,5-trifluoropentyl, 4-trifluoromethylpentyl, 5,5,6,6,6-pentafluorohexyl, and
 3,3,3-trifluoropropyl, wherein each member of group B is optionally substituted
 15 at any carbon up to and including 5 atoms from the point of attachment of B to
 A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the

- group consisting of hydrido, amidino, guanidino, carboxy, methoxy, ethoxy,
 isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino,
 20 acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino,
 methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl,
 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy,
 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, amidosulfonyl,
 N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl,
 25 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl,
 methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl,
 N,N-dimethylamidocarbonyl, cyano, and Q^b ;

A is selected from the group consisting of bond, NH, N(CH₃), N(OH),

CH₂, CH₃CH, CF₃CH, NHC(O), N(CH₃)C(O), C(O)NH, C(O)N(CH₃),

- 30 CH₂CH₂, CH₂CH₂CH₂, CH₃CHCH₂, and CF₃CHCH₂;

$\text{CH}_2\text{N}(\text{CH}_2\text{CH}_3)$, $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)$, and $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_2\text{CH}_3)$ with the proviso that B is hydrido;

5 R¹ is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino, dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy,

$$R^2 \text{ is } Z^0\text{-}Q;$$

S, NH, N(CH₃), OCH₂, SCH₂, N(H)CH₂, and N(CH₃)CH₂;

15 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or

271

R^9 , R^{11} , and R^{13} are independently selected from the group consisting

of hydrido, amidino, guanidino, carboxy, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio.

- 5 trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, methanesulfonamido, amidosulfonyl, N-methylamidodisulfonyl, N,N-dimethylamidodisulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, amidocarbonyl, 10 N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of

hydrido, amidino, guanidino, carboxy, carboxymethyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, aminomethyl,

- 15 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methanesulfonamido, amidosulfonyl, N-methylamidodisulfonyl, N,N-dimethylamidodisulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, 20 N,N-dimethylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl, N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl, N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl, N-benzylamidodisulfonyl, N-(2-chlorobenzyl)amidodisulfonyl, N-ethylamidocarbonyl, 25 N-isopropylamidocarbonyl, N-propylamidocarbonyl, N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl, N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl, N-cyclohexylamidocarbonyl, fluoro, chloro, bromo, cyano, cyclobutoxy, cyclohexoxy, cyclohexylmethoxy, 4-trifluoromethylcyclohexylmethoxy, 30 cyclopentoxo, benzyl, benzyloxy, 4-bromo-3-fluorophenoxy, 3-bromobenzyloxy, 4-bromobenzyloxy, 4-bromobenzylamino, 5-bromopyrid-2-ylmethylamino, 4-butoxyphenamino, 3-chlorobenzyl, 4-chlorophenoxy, 4-chloro-3-ethylphenoxy, 4-chloro-3-ethylbenzylamino, 4-chloro-3-ethylphenylamino, 3-chlorobenzyloxy, 4-chlorobenzyloxy,

- 4-chlorobenzylsulfonyl, 4-chlorophenylamino, 4-chlorophenylsulfonyl,
 5-chloropyrid-3-yloxy, 2-cyanopyrid-3-yloxy, 2,3-difluorobenzylloxy,
 2,4-difluorobenzylloxy, 3,4-difluorobenzylloxy, 2,5-difluorobenzylloxy,
 3,5-difluorophenoxy, 3,5-difluorobenzylloxy, 4-difluoromethoxybenzylloxy,
 5 2,3-difluorophenoxy, 2,4-difluorophenoxy, 2,5-difluorophenoxy,
 3,5-dimethylphenoxy, 3,4-dimethylphenoxy, 3,4-dimethylbenzylloxy,
 3,5-dimethylbenzylloxy, 4-ethoxyphenoxy, 4-ethylbenzylloxy, 3-ethylphenoxy,
 4-ethylaminophenoxy, 3-ethyl-5-methylphenoxy, 4-fluorobenzylloxy,
 2-fluoro-3-trifluoromethylbenzylloxy, 3-fluoro-5-trifluoromethylbenzylloxy,
 10 4-fluoro-2-trifluoromethylbenzylloxy, 4-fluoro-3-trifluoromethylbenzylloxy,
 2-fluorophenoxy, 4-fluorophenoxy, 2-fluoro-3-trifluoromethylphenoxy,
 2-fluorobenzylloxy, 4-fluorophenylamino, 2-fluoro-4-trifluoromethylphenoxy,
 4-isopropylbenzylloxy, 3-isopropylphenoxy, 4-isopropylphenoxy,
 4-isopropyl-3-methylphenoxy, 4-isopropylbenzylloxy, 3-isopropylphenoxy,
 15 4-isopropylphenoxy, 4-isopropyl-3-methylphenoxy, phenylamino,
 1-phenylethoxy, 2-phenylethoxy, 2-phenylethyl, 2-phenylethylamino,
 phenylsulfonyl, 3-trifluoromethoxybenzylloxy, 4-trifluoromethoxybenzylloxy,
 3-trifluoromethoxyphenoxy, 4-trifluoromethoxyphenoxy,
 3-trifluoromethylbenzylloxy, 4-trifluoromethylbenzylloxy,
 20 2,4-bis-trifluoromethylbenzylloxy, 3-trifluoromethylbenzyl,
 3,5-bis-trifluoromethylbenzylloxy, 4-trifluoromethylphenoxy,
 3-trifluoromethylphenoxy, 3-trifluoromethylthiobenzylloxy,
 4-trifluoromethylthiobenzylloxy, 2,3,4-trifluorophenoxy, 2,3,5-trifluorophenoxy,
 3-pentafluoroethylphenoxy, 3-(1,1,2,2-tetrafluoroethoxy)phenoxy, and
 25 3-trifluoromethylthiophenoxy;

Y^0 is selected from the group consisting of:

- 1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,
 2-Q^b-5-Q^s-6-R¹⁷-4-R¹⁸-3-R¹⁹ pyridine,
 3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine, 2-Q^b-5-Q^s-3-R¹⁶-6-R¹⁸ pyrazine,
 30 3-Q^b-6-Q^s-2-R¹⁸-5-R¹⁸-4-R¹⁹ pyridazine,
 2-Q^b-5-Q^s-4-R¹⁷-6-R¹⁸ pyrimidine, 5-Q^b-2-Q^s-4-R¹⁶-6-R¹⁹ pyrimidine,

- 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ furan, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ furan,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ pyrrole, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ pyrrole,
 4-Q^b-2-Q^s-5-R¹⁹ imidazole, 2-Q^b-4-Q^s-5-R¹⁷ imidazole,
 5 3-Q^b-5-Q^s-4-R¹⁶ isoxazole, 5-Q^b-3-Q^s-4-R¹⁶ isoxazole,
 2-Q^b-5-Q^s-4-R¹⁶ pyrazole, 4-Q^b-2-Q^s-5-R¹⁹ thiazole, and
 2-Q^b-5-Q^s-4-R¹⁷ thiazole;

- R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from the group
 consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino,
 10 guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino,
 aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino,
 N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio,
 methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl,
 pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl,
 15 trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo,
 hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;

R¹⁶ or R¹⁹ is optionally selected from the group consisting of NR²⁰R²¹,
 C(NR²⁵)NR²³R²⁴, and N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), with the proviso that R¹⁶,
 R¹⁹, and Q^b are not simultaneously hydrido;

- 20 Q^b is selected from the group consisting of NR²⁰R²¹, hydrido,
 C(NR²⁵)NR²³R²⁴, and N(R²⁶)C(NR²⁵)N(R²³)(R²⁴), with the proviso that no
 more than one of R²⁰ and R²¹ is hydroxy at the same time and with the further
 proviso that no more than one of R²³ and R²⁴ is hydroxy at the same time;

- R²⁰, R²¹, R²³, R²⁴, R²⁵, and R²⁶ are independently selected from the
 25 group consisting of hydrido, methyl, ethyl, propyl, butyl, isopropyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

19. Compound of Claim 18 or a pharmaceutically acceptable salt thereof, wherein;

5 B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butyl, (R)-2-butyl, (S)-2-butyl, *tert*-butyl, isobutyl, 1-pentyl, 3-pentyl, 2-methylbutyl, 2,2,2-trifluoroethyl, 6-amidocarbonylhexyl, 4-methyl-2-pentyl, 3-hydroxypropyl, 1-methoxy-2-propyl, 2-methoxyethyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 10 2-dimethylaminopropyl, 2-cyanoethyl, 6-hydroxyhexyl, 2-hydroxyethyl, 2-amidinoethyl, 2-guanidinoethyl, 3-guanidinopropyl, 4-guanidinobutyl, 3-hydroxypropyl, 4-hydroxybutyl, 6-cyanoethyl, 2-dimethylaminoethyl, 3-methylbutyl, 2-methylbutyl, (S)-2-methylbutyl, 3-aminopropyl, 2-hexyl, and 4-aminobutyl;

15 A is selected from the group consisting of a bond, CH₂, NHC(O),
CH₂CH₂, CH₂CH₂CH₂, and CH₃CHCH₂;

$$M \text{ is } N \text{ or } R^1\text{-}C;$$

R¹ is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, hydroxymethyl, methoxyamino, methylthio, trifluoromethoxy, fluoro, and chloro;

$$R^2 \text{ is } Z^0\text{-Q};$$

Z^0 is selected from the group consisting of a bond, CH_2 , O, S, NH, $N(CH_3)$, OCH_2 , and SCH_2 ;

25 Q is selected from the group consisting of
3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,
3-amino-5-benzylphenyl, 3-amino-5-(2-phenylethyl)phenyl,
3-amino-5-benzylaminophenyl, 3-amino-5-(2-phenylethylamino)phenyl,
3-amino-5-benzyloxyphenyl, 3-amino-5-(2-phenylethoxy)phenyl,
30 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,

- 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
 3-amino-5-(N-benzylamidosulfonyl)phenyl,
 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
 5 3-amino-5-(N-ethylamidocarbonyl)phenyl,
 3-amino-5-(N-isopropylamidocarbonyl)phenyl,
 3-amino-5-(N-propylamidocarbonyl)phenyl,
 3-amino-5-(N-isobutylamidocarbonyl)phenyl,
 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
 10 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 5-amino-2-fluorophenyl,
 3-amino-5-hydroxymethylphenyl, 5-amino-3-methoxycarbonylphenyl,
 3-amidinophenyl, 3-amino-2-methylphenyl, 5-amino-2-methylthiophenyl,
 15 3-aminophenyl, 3-amino-5-(4-trifluoromethylbenzylamino)phenyl,
 3-amino-5-(4-trifluoromethylbenzyloxy)phenyl, 3-carboxyphenyl,
 3-carboxy-5-hydroxyphenyl, 3-amino-5-carboxyphenyl, 3-chlorophenyl,
 2-chlorophenyl, 3-cyanophenyl, 3,5-diaminophenyl, 3-dimethylaminophenyl,
 2-fluorophenyl, 3-fluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl,
 20 3-methanesulfonylaminophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
 3-methoxyaminophenyl, 3-methoxycarbonylphenyl, 2-methylaminophenyl,
 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,
 phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl,
 2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl,
 25 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;

Y^0 is selected from the group consisting of:

- 1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,
 2-Q^b-5-Q^s-6-R¹⁷-4-R¹⁸-3-R¹⁹ pyridine,
 3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine,
 30 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene, and 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene;

R^{16} and R^{19} are independently selected from the group consisting of hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy, hydroxymethyl, fluoro, chloro, and cyano;

R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} ,

5 R^{19} , and Q^b are not simultaneously hydrido;


R^{17} and R^{18} are independently selected from the group consisting of hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido;

R^{23} , R^{24} , and R^{25} are independently hydrido or methyl;

10 Q^s is CH_2 .

20. Compound of Claim 17 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

15 B is selected from the group consisting of hydrido, C2-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

20 R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl,

alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

A is a bond or $(CH(R^{15}))_{pa}(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $N(R^7)$;

5 R^7 is hydrido or alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

10 R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0-Q ;

Z^0 is a bond;

15 Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

20 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkoxy, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, alkoxyamino, hydroxy, amino, alkylamino, alkylsulfonamido, amidosulfonyl, hydroxyalkyl, aminoalkyl, halo, haloalkyl, carboalkoxy, carboxy, carboxamido, carboxyalkyl, and cyano;

Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently hydrido or alkyl;

Q^s is CH_2 .

21. Compound of Claim 20 or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butenyl, 2-butyne, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 1-pentyl, 2-pentenyl, 3-pentenyl, 2-pentyne, 3-pentyne, 2-pentyl, 3-pentyl, 2-methylbutyl, 2-methyl-2-butenyl, 3-methylbutyl, 3-methyl-2-butenyl, 1-hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 2-hexyl, 1-methyl-2-pentenyl, 1-methyl-3-pentenyl, 1-methyl-2-pentyne, 1-methyl-3-pentyne, 3-hexyl, 1-ethyl-2-butenyl, 1-heptyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 2-heptyne, 3-heptyne, 4-heptyne, 5-heptyne, 2-heptyl, 1-methyl-2-hexenyl, 1-methyl-3-hexenyl, 1-methyl-4-hexenyl, 1-methyl-2-hexynyl, 1-methyl-3-hexynyl, 1-methyl-4-hexynyl, 3-heptyl, 1-ethyl-2-pentenyl, 1-ethyl-3-pentenyl, 1-ethyl-2-pentyne, 1-ethyl-3-pentyne, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 4-trifluoromethyl-5,5,5-trifluoropentyl, 4-trifluoromethylpentyl, 5,5,6,6,6-pentafluorohexyl, and 3,3,3-trifluoropropyl, wherein each member of group B is optionally substituted at any carbon up to and including 5 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;
- R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, carboxy, cyano, and Q^b ;

A is selected from the group consisting of a bond, NH, N(CH₃), CH₂, CH₃CH, and CH₂CH₂;

- A is optionally selected from the group consisting of CH₂N(CH₃), CH₂N(CH₂CH₃), CH₂CH₂N(CH₃), and CH₂CH₂N(CH₂CH₃) with the proviso that B is hydrido;

M is N or R¹-C;

R¹ is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, methylthio, trifluoromethoxy, fluoro, and chloro;

5 R² is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-pyrrolyl, 2-imidazolyl, 2-thiazolyl, 3-isoxazolyl, 2-pyridyl, and 3-pyridyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to the uracil ring is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two atoms from the carbon at the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;

15 R⁹, R¹¹, and R¹³ are independently selected from the group consisting of hydrido, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, methylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, carboxy, and cyano;

20 R¹⁰ and R¹² are independently selected from the group consisting of hydrido, amidino, amidocarbonyl, N-methylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl, N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl, 25 N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl, N-benzylamidosulfonyl, N-(2-chlorobenzyl)amidosulfonyl, N-ethylamidocarbonyl, N-isopropylamidocarbonyl, N-propylamidocarbonyl, N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl, N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl,

- N-cyclohexylamidocarbonyl, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxy, carboxymethyl, amino, acetamido, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, trifluoroacetamido, aminomethyl, N-methylamino, 5 dimethylamino, methoxyamino, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, methanesulfonamido, methoxycarbonyl, fluoro, chloro, bromo, and cyano;

Y^0 is selected from the group consisting of:

- 1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,
 10 2-Q^b-5-Q^s-6-R¹⁷-4-R¹⁸-3-R¹⁹ pyridine, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene,
 3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine, 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ furan, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ furan,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ pyrrole, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ pyrrole,
 4-Q^b-2-Q^s-5-R¹⁹ thiazole, and 2-Q^b-5-Q^s-4-R¹⁷ thiazole;

- 15 R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from the group consisting of hydrido, methyl, ethyl, amidino, guanidino, methoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, methylthio, ethylthio, trifluoromethylthio, methylsulfinyl, methylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 20 trifluoromethoxy, fluoro, chloro, hydroxymethyl, carboxy, and cyano;

Q^b is selected from the group consisting of NR²⁰R²¹,

C(NR²⁵)NR²³R²⁴, and N(R²⁶)C(NR²⁵)N(R²³)(R²⁴);

R²⁰, R²¹, R²³, R²⁴, R²⁵, and R²⁶ are independently selected from the group consisting of hydrido, methyl, and ethyl;

- 25 Q^s is CH₂.

22. Compound of Claim 21 or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butyl, (R)-2-butyl, (S)-2-butyl, *tert*-butyl, isobutyl, 1-pentyl, 3-pentyl, 2-methylbutyl, 2,2,2-trifluoroethyl, 6-amidocarbonylhexyl, 4-methyl-2-pentyl, 3-hydroxypropyl,
- 5 1-methoxy-2-propyl, 2-methoxyethyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2-dimethylaminopropyl, 2-cyanoethyl, 6-hydroxyhexyl, 2-hydroxyethyl, 2-amidinoethyl, 2-guanidinoethyl, 3-guanidinopropyl, 4-guanidinobutyl, 3-hydroxypropyl, 4-hydroxybutyl, 6-cyanoethyl, 2-dimethylaminoethyl, 3-methylbutyl, 2-methylbutyl, (S)-2-methylbutyl, 3-aminopropyl, 2-hexyl, and
- 10 4-aminobutyl;

A is selected from the group consisting of a bond, CH₂, CH₃CH, and CH₂CH₂;

M is N or R¹-C;

- R¹ is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and
- 15 fluoro;;

- R² is selected from the group consisting of
- 3-amidocarbonyl-5-aminophenyl, 3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,
- 20 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
- 25 3-amino-5-(N-benzylamidosulfonyl)phenyl, 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, 3-amino-5-(N-ethylamidocarbonyl)phenyl, 3-amino-5-(N-isopropylamidocarbonyl)phenyl, 3-amino-5-(N-propylamidocarbonyl)phenyl,
- 30 3-amino-5-(N-isobutylamidocarbonyl)phenyl, 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl, 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,

B is selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butyl, (R)-2-butyl, (S)-2-butyl, *tert*-butyl, isobutyl, 1-pentyl, 3-pentyl, 2-methylbutyl, 2,2,2-trifluoroethyl, 6-amidocarbonylhexyl, 4-methyl-2-pentyl, 3-hydroxypropyl, 1-methoxy-2-propyl, 2-methoxyethyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2-dimethylaminopropyl, 2-cyanoethyl, 6-hydroxyhexyl, 2-hydroxyethyl, 2-amidinoethyl, 2-guanidinoethyl, 3-guanidinopropyl, 4-guanidinobutyl, 3-hydroxypropyl, 4-hydroxybutyl, 6-cyanoethyl, 2-dimethylaminoethyl, 3-methylbutyl, 2-methylbutyl, (S)-2-methylbutyl, 3-aminopropyl, 2-hexyl, and 4-aminobutyl;

15 M is N or R^1 -C;

R^2 is selected from the group consisting of


20 3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,

25 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
3-amino-5-(N-benzylamidosulfonyl)phenyl,
3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
3-amino-5-(N-ethylamidocarbonyl)phenyl,
3-amino-5-(N-isopropylamidocarbonyl)phenyl,

30 3-amino-5-(N-propylamidocarbonyl)phenyl,
3-amino-5-(N-isobutylamidocarbonyl)phenyl,
3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,

- 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 3-aminophenyl,
 3-carboxy-5-aminophenyl, 3-chlorophenyl, 3,5-diaminophenyl,
 3-dimethylaminophenyl, 3-hydroxyphenyl, 3-methanesulfonylaminophenyl,
 5 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, phenyl,
 3-trifluoroacetamidophenyl, 3-bromo-2-thienyl, 2-thienyl, and 3-thienyl;
 Y^0 is selected from the group consisting of 5-amidino-2-thienylmethyl,
 4-amidinobenzyl, 2-fluoro-4-amidinobenzyl, and 3-fluoro-4-amidinobenzyl.

- 10 24. Compound of Claim 17 where said compound is selected from the group of
 the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

- R^2 is 3-aminophenyl, B is 2,2,2-trifluoroethyl, A is single bond, Y^0 is 4-
 15 amidinobenzyl, and M is CH;
 R^2 is 3-aminophenyl, B is (S)-2-butyl, A is single bond, Y^0 is 4-
 amidinobenzyl, and M is CH;
 R^2 is 5-amino-2-fluorophenyl, B is isopropyl, A is single bond, Y^0 is 4-
 amidinobenzyl, and M is CH;
 20 R^2 is 2-methyl-3-aminophenyl, B is isopropyl, A is single bond, Y^0 is 4-
 amidinobenzyl, and M is CH;
 R^2 is 3-aminophenyl, B is ethyl, A is single bond, Y^0 is 4-amidinobenzyl,
 and M is CH;
 R^2 is 3-aminophenyl, B is ethyl, A is single bond, Y^0 is 4-amidino-2-
 25 fluorobenzyl, and M is CH;

R² is 3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-propynyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-aminophenyl, B is hydrido, A is CH_2 , Y^0 is 4-amidinobenzyl, and
M is CH;

R² is 3-aminophenyl, B is ethyl, A is CH₂, Y⁰ is 4-amidinobenzyl, and M is CH:

20 R² is 3-aminophenyl, B is 2-methypropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-propyl, A is CH_3CH , Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is propyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

25 R² is 3-aminophenyl, B is 6-amidocarbonylhexyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is tert-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 3-hydroxypropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-methoxyethyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-aminophenyl, B is 2-propyl, A is single bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-propyl, A is single bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-aminophenyl, B is (S)-2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 2-methyl-3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is ethyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is isopropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-butyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-aminophenyl, B is 2-propynyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is hydrido, A is CH₂, Y⁰ is 4-amidinobenzyl, and
- 20 M is N:

R² is 3-aminophenyl, B is 2-methypropyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is propyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 6-amidocarbonylhexyl. A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is tert-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-aminophenyl, B is tert-butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 3-hydroxypropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-aminophenyl, B is 2-methylpropyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is N;

R^2 is 3-aminophenyl, B is butyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 1-methoxy-2-propyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-aminophenyl, B is 2-methoxyethyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 2-propyl, A is single bond, Y^0 is 5-amidino-2-thienylmethyl, and M is N;

20 R^2 is 3-aminophenyl, B is 2-propyl, A is single bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is N;

R^2 is 3-carboxyphenyl, B is 2-propyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-aminophenyl, B is 2-propyl, A is single bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

25 R^2 is 3-amino-5-carboxyphenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carbomethoxyphenyl, B is isopropyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-carboxamidophenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is
 20 isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 2-propyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is ethyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-carboxyphenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R² is 3-amino-5-carboxyphenyl, B is ethyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

20 R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 2,2,2-trifluoroethyl,
A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-carbomethoxyphenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-benzyl-N-methylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

25 R² is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is
20 isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

25 R^2 is 3-carboxyphenyl, B is 2-propyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CCl ;

R² is 3-aminophenyl, B is 2-propyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is N;

R² is 3,5-diaminophenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is N;

R² is 3,5-diaminophenyl, B is ethyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

15 R² is 3-amino-5-carboxyphenyl, B is (S)-2-butyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-carboxyphenyl, B is ethyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is 2,2,2-trifluoroethyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;


R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is isopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzylbenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is ethyl, A is a bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is N.

5

25. Compound of Claim 2 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

B is a C3-C7 cycloalkyl or a C4-C6 saturated heterocyclyl, wherein

- 10 each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or
- 15 nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring
- 20 carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen

four atoms from the point of attachment and adjacent to the R¹¹ and R³³ positions is optionally substituted with R³⁴;

R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkylsulfonamido, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboxy, carboxamido, and cyano;

R¹⁰ and R¹² are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino, alkoxyamino, alkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylsulfonamido, amidosulfonyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl, heteroarylsulfonyl, hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy, carboxyalkyl, carboxamido, halo, haloalkyl, and cyano;

20 R³³ and R³⁴ are independently selected from the group consisting of
hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino,
alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl,
haloalkoxy, hydroxyalkyl, hydroxyhaloalkyl, carboalkoxy, carboxy,
carboxamido, and cyano;

25 R³³ is optionally Q^b;

A is a bond or $(\text{CH}(\text{R}^{15}))_{\text{pa}}-(\text{W}^7)_{\text{rr}}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $(\text{R}^7)\text{NC}(\text{O})$ or $\text{N}(\text{R}^7)$;

R⁷ is selected from the group consisting of hydrido, hydroxy and alkyl;

$$M \text{ is } N \text{ or } R^1\text{-C};$$
$$R^2 \text{ is } Z^0\text{-}Q;$$

R⁴¹ and R⁴² are independently hydrido or alkyl;

20 Y⁰ is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^S, a carbon two or three atoms from the point of attachment of Q^S to said phenyl or said heteroaryl is substituted by Q^b, a carbon adjacent to the point of attachment of Q^S is optionally substituted by R¹⁷, another carbon adjacent to the point of

attachment of Q^s is optionally substituted by R¹⁸, a carbon adjacent to Q^b is optionally substituted by R¹⁶, and another carbon adjacent to Q^b is optionally substituted by R¹⁹;

R^{16}, R^{17}, R^{18} , and R^{19} are independently selected from the group

5 consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R¹⁶ or R¹⁹ is optionally NR²⁰R²¹ or and C(NR²⁵)NR²³R²⁴, with the

10 proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is hydroxy at the same time and with the further proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

15 $R^{20}, R^{21}, R^{23}, R^{24}$, and R^{25} are independently selected from the group consisting of hydrido, alkyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 , and CH_2CH_2 .

20 26. Compound of Claim 25 or a pharmaceutically acceptable salt thereof,
wherein;

B is selected from the group consisting of cyclopropyl, cyclobutyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, thiaetan-3-yl, cyclopentyl, cyclohexyl, norbornyl, 7-oxabicyclo[2.2.1]heptan-2-yl, bicyclo[3.1.0]hexan-6-yl, cycloheptyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl,

optionally substituted with R³³, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R⁹ or R¹³, a ring carbon or nitrogen adjacent to the R⁹ position and two atoms from the point of attachment is optionally substituted with R¹⁰, and a ring carbon or nitrogen adjacent to the R¹³ position and two atoms from the point of

R^9, R^{11} , and R^{13} are independently selected from the group consisting

15 trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl,
2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro,
chloro, bromo, methanesulfonamido, amidosulfonyl, N-methylamidodisulfonyl,
N,N-dimethylamidodisulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl,
2,2,2-trifluoro-1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl,
20 N,N-dimethylamidocarbonyl, and cyano;

hydrido, amidino, guanidino, carboxy, carboxymethyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methanesulfonamido, amidosulfonyl, N-methylamidodisulfonyl, N,N-dimethylamidodisulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl,

301

302

4-trifluoromethylthiobenzyloxy, 2,3,4-trifluorophenoxy, 2,3,5-trifluorophenoxy, 3-pentafluoroethylphenoxy, 3-(1,1,2,2-tetrafluoroethoxy)phenoxy, and 3-trifluoromethylthiophenoxy;

R^{33} is selected from the group consisting of hydrido, amidino,

- 5 guanidino, carboxy, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, methoxyamino, ethoxyamino, acetamido, trifluoroacetamido, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, 10 chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2,2,2-trifluoro-1-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, amidocarbonyl, N-methylamidocarbonyl, N,N-dimethylamidocarbonyl, cyano, and Q^b ;

- 15 A is selected from the group consisting of a bond, NH, N(CH₃), N(OH), CH₂, CH₃CH, CF₃CH, NHC(O), N(CH₃)C(O), C(O)NH, C(O)N(CH₃), CH₂CH₂, CH₂CH₂CH₂, CH₃CHCH₂, and CF₃CHCH₂;

M is N or R^1 -C;

- 20 R^1 is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, 1-aminoethyl, methylamino, dimethylamino, cyano, methyl, ethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyamino, methylthio, ethylthio, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, and bromo;

- 25 R^2 is Z^0 -Q;


Z^0 is selected from the group consisting of a bond, CH₂, CH₂CH₂, O, S, NH, N(CH₃), OCH₂, SCH₂, N(H)CH₂, and N(CH₃)CH₂;

- 30 Q is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl,

4-pyridyl, 2-pyrazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 1,3,5-triazin-2-yl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point

- 5 of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

- 10 Y^0 is selected from the group consisting of:



R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

consisting of hydrido, methyl, ethyl, isopropyl, propyl, carboxy, amidino, guanidino, methoxy, ethoxy, isopropoxy, propoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, N-ethylamino, methylthio, ethylthio, isopropylthio, trifluoromethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, ethylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, fluoro, chloro, bromo, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, and cyano;

10 R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} .

R^{19} , and Q^b are not simultaneously hydrido;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido, with the proviso that no more than one of R^{23} and R^{24} is hydroxy at the same time;

R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of

15 hydrido, methyl, ethyl, and hydroxy;

Q^s is selected from the group consisting of a bond, CH_2 and CH_2CH_2 .

27. Compound of Claim 26 or a pharmaceutically acceptable salt thereof, wherein;

20 B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, 1-pyrrolidinyl, 1-piperidinyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, 7-oxabicyclo[2.2.1]heptan-2-yl, bicyclo[3.1.0]hexan-6-yl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 1-piperazinyl, 2-piperazinyl, 25 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-dioxanyl, 4H-2-pyranyl, 4H-3-pyranyl, 4H-4-pyranyl, 4H-pyran-4-one-2-yl, 4H-pyran-4-one-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl;

CH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{CH}_2$;

R¹ is selected from the group consisting of hydrido, hydroxy, amino, amidino, hydroxyamino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, hydroxymethyl, methoxyamino, methylthio, trifluoromethoxy, fluoro, and chloro;

Z^0 is selected from the group consisting of a bond, CH_2 , O, S, NH,

Q is selected from the group consisting of
 amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl,
 5-amino-5-benzylphenyl, 3-amino-5-(2-phenylethyl)phenyl,
 5-amino-5-benzylaminophenyl, 3-amino-5-(2-phenylethylamino)phenyl,
 5-amino-5-benzylloxyphenyl, 3-amino-5-(2-phenylethoxy)phenyl,
 5-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
 5-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
 5-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
 5-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
 5-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
 5-amino-5-(N-benzylamidosulfonyl)phenyl,
 5-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
 5-amino-5-(N-ethylamidocarbonyl)phenyl,
 5-amino-5-(N-isopropylamidocarbonyl)phenyl,
 5-amino-5-(N-propylamidocarbonyl)phenyl,
 5-amino-5-(N-isobutylamidocarbonyl)phenyl,
 5-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
 5-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
 5-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 5-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 5-amino-2-fluorophenyl,
 5-amino-5-hydroxymethylphenyl, 5-amino-3-methoxycarbonylphenyl,
 5-amino-2-methylphenyl, 5-amino-2-methylthiophenyl,

- 3-aminophenyl, 3-amino-5-(4-trifluoromethylbenzylamino)phenyl,
 3-amino-5-(4-trifluoromethylbenzyloxy)phenyl, 3-carboxyphenyl,
 3-carboxy-5-hydroxyphenyl, 3-amino-5-carboxyphenyl, 3-chlorophenyl,
 2-chlorophenyl, 3-cyanophenyl, 3,5-diaminophenyl, 3-dimethylaminophenyl,
 5 2-fluorophenyl, 3-fluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl,
 3-methanesulfonylaminophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
 3-methoxyaminophenyl, 3-methoxycarbonylphenyl, 2-methylaminophenyl,
 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,
 phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl,
 10 2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl,
 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;

Y^0 is selected from the group consisting of:

- 1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,
 2-Q^b-5-Q^s-6-R¹⁷-4-R¹⁸-3-R¹⁹ pyridine,
 15 3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene, and 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene;

R^{16} and R^{19} are independently selected from the group consisting of
 hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy,
 hydroxymethyl, fluoro, chloro, and cyano;

- 20 R^{16} or R^{19} is optionally $C(NR^{25})NR^{23}R^{24}$ with the proviso that R^{16} ,
 R^{19} , and Q^b are not simultaneously hydrido;


R^{17} and R^{18} are independently selected from the group consisting of
 hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or hydrido;

- 25 R^{23} , R^{24} , and R^{25} are independently hydrido or methyl;

Q^s is CH_2 .

28. Compound of Claim 25 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

B is a C3-C7 cycloalkyl or a C4-C6 saturated heterocyclyl, wherein

- 5 each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or
- 10 nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{10} position is optionally substituted with R^{11} , a ring
- 15 carbon or nitrogen three atoms from the point of attachment and adjacent to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or nitrogen four atoms from the point of attachment and adjacent to the R^{11} and R^{33} positions is optionally substituted with R^{34} ;

R^9 , R^{11} , and R^{13} are independently selected from the group consisting

- 20 of hydrido, hydroxy, amino, amidino, guanidino, alkylamino, alkylthio, alkoxy, alkylsulfinyl, alkylsulfonyl, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboxy, carboxamido, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkyl, alkoxy, alkoxyamino, hydroxy, amino, alkylamino, alkylsulfonamido, amidosulfonyl, hydroxyalkyl, aminoalkyl, halo, haloalkyl, carboalkoxy, carboxy, carboxamido, carboxyalkyl, and cyano;

R^{33} and R^{34} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, amidosulfonyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, carboalkoxy, carboxy, carboxamido, and cyano;

R^{33} is optionally Q^b ;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an integer selected from 0 through 3, and W^7 is $N(R^7)$;

R^7 is hydrido or alkyl;

R^{15} is selected from the group consisting of hydrido, halo, alkyl, and haloalkyl;

M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, hydroxy, hydroxyamino, amidino, amino, cyano, hydroxyalkyl, alkoxy, alkyl, alkylamino, aminoalkyl, alkylthio, alkoxyamino, haloalkyl, haloalkoxy, and halo;

R^2 is Z^0-Q ;

Z^0 is a bond;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the

carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

- Y^0 is phenyl or a heteroaryl of 5 or 6 ring members, wherein one carbon of said phenyl or said heteroaryl is substituted by Q^s , a carbon two or three atoms from the point of attachment of Q^s to said phenyl or said heteroaryl is substituted by Q^b , a carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{17} , another carbon adjacent to the point of attachment of Q^s is optionally substituted by R^{18} , a carbon adjacent to Q^b is optionally substituted by R^{16} , and another carbon adjacent to Q^b is optionally substituted by R^{19} ;

- R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

- R^{16} or R^{19} is optionally $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

- Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, and $C(NR^{25})NR^{23}R^{24}$;

- R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently hydrido or alkyl;
- Q^s is CH_2 .

29. Compound of Claim 28 or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, bicyclo[3.1.0]hexan-6-yl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 1-piperazinyl, 2-piperazinyl,
- 5 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-dioxanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl, wherein each ring carbon is optionally substituted with R^{33} , ring carbons and a nitrogen
- 10 adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment are optionally substituted with R^{10} , and a ring carbon or nitrogen atom adjacent to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} ;
- 15 R^9 , R^{11} , and R^{13} are independently selected from the group consisting of hydrido, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, N,N-dimethylamino, methylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamid sulfonyl, N,N-dimethylamid sulfonyl, hydroxymethyl,
- 20 1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, carboxy, and cyano; R^{10} and R^{12} are independently selected from the group consisting of hydrido, amidino, amidocarbonyl, N-methylamidocarbonyl, N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl, N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl,
- 25 N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl, N-benzylamid sulfonyl, N-(2-chlorobenzyl)amid sulfonyl, N-ethylamidocarbonyl, N-isopropylamidocarbonyl, N-propylamidocarbonyl, N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl, N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl,

- N-cyclohexylamidocarbonyl, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxy, carboxymethyl, amino, acetamido, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, trifluoroacetamido, aminomethyl, N-methylamino, 5 dimethylamino, methoxyamino, amidosulfonyl, N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, methanesulfonamido, methoxycarbonyl, fluoro, chloro, bromo, and cyano;
- R^{33} is selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, carboxy, amino, 10 N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, cyano, and Q^b ;
- A is selected from the group consisting of a bond, NH, $N(CH_3)$, CH_2 , 15 CH_3CH , CH_2CH_2 , and $CH_2CH_2CH_2$;
- M is N or R^1-C ;
- R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, methylthio, trifluoromethoxy, fluoro, and chloro;
- 20 R^2 is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-pyrrolyl, 2-imidazolyl, 2-thiazolyl, 3-isoxazolyl, 2-pyridyl, and 3-pyridyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to the uracil ring is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally
- 25 substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the carbon at the point of attachment is optionally

substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

Y^0 is selected from the group consisting of:

- 1-Q^b-4-Q^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,
 5 2-Q^b-5-Q^s-6-R¹⁷-4-R¹⁸-3-R¹⁹ pyridine, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene,
 3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine, 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ furan, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ furan,
 3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ pyrrole, 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ pyrrole,
 4-Q^b-2-Q^s-5-R¹⁹ thiazole, and 2-Q^b-5-Q^s-4-R¹⁷ thiazole;

- 10 R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrido, methyl, ethyl, amidino, guanidino, methoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino, dimethylamino, methylthio, ethylthio, trifluoromethylthio, methylsulfinyl, methylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, fluoro, chloro, hydroxymethyl, carboxy, and cyano;

Q^b is $NR^{20}R^{21}$ or $C(NR^{25})NR^{23}R^{24}$;

- 15 R^{20} , R^{21} , R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of hydrido, methyl, and ethyl;

Q^s is CH_2 .

20

30. Compound of Claim 29 or a pharmaceutically acceptable salt thereof, wherein;

- 25 B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, 1-pyrrolidinyl and 1-piperidinyl;

A is selected from the group consisting of a bond, CH_2 , CH_2CH_2 and $\text{CH}_2\text{CH}_2\text{CH}_2$;

M is N or $\text{R}^1\text{-C}$:

R^1 is selected from the group consisting of hydrido, hydroxy,
 5 hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and fluoro;

R^2 is selected from the group consisting of
 3-amidocarbonyl-5-aminophenyl, 3-amidocarbonyl-5-aminophenyl,
 3-amino-5-(N-benzylamidocarbonyl)phenyl,
 10 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
 15 3-amino-5-(N-benzylamidosulfonyl)phenyl,
 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
 3-amino-5-(N-ethylamidocarbonyl)phenyl,
 3-amino-5-(N-isopropylamidocarbonyl)phenyl,
 3-amino-5-(N-propylamidocarbonyl)phenyl,
 20 3-amino-5-(N-isobutylamidocarbonyl)phenyl,
 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 5-amino-2-fluorophenyl,
 25 3-amino-5-hydroxymethylphenyl, 5-amino-3-methoxycarbonylphenyl,
 3-amidinophenyl, 3-amino-2-methylphenyl, 5-amino-2-methylthiophenyl,
 3-aminophenyl, 3-carboxyphenyl, 3-carboxy-5-aminophenyl,
 3-carboxy-5-hydroxyphenyl, 3-carboxymethyl-5-aminophenyl,
 3-carboxymethyl-5-hydroxyphenyl, 3-carboxymethylphenyl, 3-chlorophenyl,
 30 2-chlorophenyl, 3-cyanophenyl, 3,5-diaminophenyl, 3-dimethylaminophenyl,
 2-fluorophenyl, 3-fluorophenyl, 2,5-difluorophenyl, 2-hydroxyphenyl,
 3-hydroxyphenyl, 3-methanesulfonylaminophenyl, 2-methoxyphenyl,
 3-methoxyphenyl, 3-methoxyaminophenyl, 3-methoxycarbonylphenyl,

2-methylaminophenyl, 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl, 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;

5 Y^0 is selected from the group consisting of:

1-O^b-4-O^s-2-R¹⁶-3-R¹⁷-5-R¹⁸-6-R¹⁹ benzene,

$$2\text{-Q}^b\text{-5-Q}^s\text{-6-R}^{17}\text{-4-R}^{18}\text{-3-R}^{19}\text{ pyridine,}$$

3-Q^b-6-Q^s-2-R¹⁶-5-R¹⁸-4-R¹⁹ pyridine,

3-Q^b-5-Q^s-4-R¹⁶-2-R¹⁹ thiophene, and 2-Q^b-5-Q^s-3-R¹⁶-4-R¹⁷ thiophene;

10 R¹⁶ and R¹⁹ are independently selected from the group consisting of
hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy,
hydroxymethyl, fluoro, chloro, and cyano;

R¹⁷ and R¹⁸ are independently selected from the group consisting of hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;

15 Q^b is $C(NR^{25})NR^{23}R^{24}$;

R^{23} , R^{24} , and R^{25} are independently hydrido or methyl;

Q^s is CH_2 .

31. Compound of Claim 30 or a pharmaceutically acceptable salt thereof,
20 wherein;

B is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, and 1-piperidinyl;

A is selected from the group consisting of a bond, CH₂, CH₂CH₂ and

25 $\text{CH}_2\text{CH}_2\text{CH}_2$;

$$M \text{ is } N \text{ or } R^1\text{-}C;$$


R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and fluoro;

R^2 is selected from the group consisting of

- 5 3-amidocarbonyl-5-aminophenyl, 3-amino-5-(N-benzylamidocarbonyl)phenyl, 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl, 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
- 10 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl, 3-amino-5-(N-benzylamidosulfonyl)phenyl, 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, 3-amino-5-(N-ethylamidocarbonyl)phenyl, 3-amino-5-(N-isopropylamidocarbonyl)phenyl,
- 15 3-amino-5-(N-propylamidocarbonyl)phenyl, 3-amino-5-(N-isobutylamidocarbonyl)phenyl, 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl, 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
- 20 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl, 3-aminophenyl, 3-carboxy-5-aminophenyl, 3-chlorophenyl, 3,5-diaminophenyl, 3-dimethylaminophenyl, 3-hydroxyphenyl, 3-methanesulfonylaminophenyl, 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, phenyl, 3-trifluoroacetamidophenyl, 3-bromo-2-thienyl, 2-thienyl, and 3-thienyl;
- 25 Y^0 is selected from the group consisting of 5-amidino-2-thienylmethyl, 4-amidinobenzyl, 2-fluoro-4-amidinobenzyl, and 3-fluoro-4-amidinobenzyl.

30

32. Compound of Claim 25 where said compound is selected from the group of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

- 5 R^2 is 3-aminophenyl, B is cyclopropyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

- 10 R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclopropyl, A is single bond, Y^0 is 4-amidino-2-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

- 15 R^2 is 3-aminophenyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidino-3-fluorobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclopentyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

- 20 R^2 is 5-amino-2-thienyl, B is cyclobutyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is cyclopropyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-aminophenyl, B is 2-(2R)-bicyclo[2.2.1]-heptyl, A is single bond, Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is cyclohexyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CH;

R² is 3-aminophenyl, B is 1,1-dioxothiolan-3-yl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

15 R² is 3-aminophenyl, B is 1-pyrrolidinyl, A is CH₂CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-thienyl, B is cyclobutyl, A is single bond, Y⁰ is 4-

R² is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CF₃;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 3-aminophenyl, B is cyclopentyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF₃;

R^2 is 3-aminophenyl, B is cyclopropyl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

15 R² is 3-aminophenyl, B is cyclopentyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CF;

R² is 3-aminophenyl, B is cyclohexyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

20 R^2 is 3-aminophenyl, B is oxalan-2-yl, A is CH_2 , Y^0 is 4-amidinobenzyl, and M is CF_3 ;

R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is CF;

R² is 3-aminophenyl, B is 1-piperidinyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is CF;

25 R² is 3-aminophenyl, B is 1,1-dioxothiolan-3-yl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 2-hydroxyphenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is phenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF;

R² is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CF₃;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

15 R² is 3-aminophenyl, B is cyclopropyl, A is single bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidino-3-
20 fluorobenzyl, and M is N;

R² is 5-amino-2-thienyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 2-(2R)-bicyclo[2.2.1]-heptyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is cyclohexyl, A is CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R^2 is phenyl, B is 1-pyrrolidinyl, A is CH_2CH_2 , Y^0 is 4-amidinobenzyl, and M is N;

R² is 3-aminophenyl, B is 1,1-dioxothiolan-3-yl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-aminophenyl, B is 1-pyrrolidinyl, A is CH₂CH₂CH₂, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-thienyl, B is cyclobutyl, A is single bond, Y⁰ is 4-

R² is 2,6-dichlorophenyl, B is cyclobutyl, A is single bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-amino-5-carboxyphenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-carbomethoxyphenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 2,6-dichlorophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

15 R² is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3,5-diaminophenyl, B is cyclopentyl, A is a bond, Y⁰ is 4-
 20 amidinobenzyl, and M is CH;

R² is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-carboxy-5-aminophenyl, B is cyclopentyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

15 R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-benzylamidocarbonyl)phenyl, B is cyclopentyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

20 R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-aminobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclopropyl, A is a bond, Y⁰ is 4-amidino-2-fluorobenzyl, and M is CH;

15 R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is N;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidino-3-fluorobenzyl, and M is CH;

R² is 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)-phenyl, B is
 20 cyclopentyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-carboxamidophenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R² is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

25 R² is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y⁰ is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

5 R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

10 R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

15 R^2 is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

20 R^2 is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

25 R^2 is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is CH;

R^2 is 3-amino-5-carboxamidophenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-amino-5-(N-(2-phenyl-2-propyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2,4-dichlorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-(N-(4-bromobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-trifluoromethylbenzyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

20 R^2 is 3-amino-5-(N-isobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

25 R^2 is 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-cycloheptylamidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(3-pyridylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

5 R^2 is 3-amino-5-(N-(2-(4-methoxyphenyl)ethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;


R^2 is 3-amino-5-(N-(3-phenylpropyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

10 R^2 is 3-amino-5-(N-(2,2-diphenylethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

R^2 is 3-amino-5-(N-(2-naphthylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N;

15 R^2 is 3-amino-5-(N-(1,2,3,4-tetrahydronaphth-2-ylmethyl)amidocarbonyl)phenyl, B is cyclobutyl, A is a bond, Y^0 is 4-amidinobenzyl, and M is N.

33. The compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

20 B is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon

adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

- 5 R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, acetamido, haloacetamido, amidino, guanidino, alkylendioxy, haloalkylthio, alkanoyloxy, alkoxy, hydroxy, amino, alkoxyamino, haloalkanoyl, nitro, alkylamino, alkylthio, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, alkylsulfonamido, amidosulfonyl, 10 alkyl, alkenyl, halo, haloalkyl, haloalkenyl, haloalkoxy, hydroxyalkyl, alkylamino, carboalkoxy, carboxy, carboxamido, cyano, and Q^b ;

- B is optionally selected from the group consisting of hydrido, trialkylsilyl, C2-C8 alkyl, C3-C8 alkylenyl, C3-C8 alkenyl, C3-C8 alkynyl, and C2-C8 haloalkyl, wherein each member of group B is optionally substituted at 15 any carbon up to and including 6 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

- B is optionally a C3-C12 cycloalkyl or a C4-C9 saturated heterocyclyl, wherein each ring carbon is optionally substituted with R^{33} , a ring carbon other than the ring carbon at the point of attachment of B to A is optionally 20 substituted with oxo provided that no more than one ring carbon is substituted by oxo at the same time, ring carbons and a nitrogen adjacent to the carbon atom at the point of attachment are optionally substituted with R^9 or R^{13} , a ring carbon or nitrogen adjacent to the R^9 position and two atoms from the point of attachment is optionally substituted with R^{10} , a ring carbon or nitrogen adjacent 25 to the R^{13} position and two atoms from the point of attachment is optionally substituted with R^{12} , a ring carbon or nitrogen three atoms from the point of

attachment and adjacent to the R^{10} position is optionally substituted with R^{11} ,
 a ring carbon or nitrogen three atoms from the point of attachment and adjacent
 to the R^{12} position is optionally substituted with R^{33} , and a ring carbon or
 nitrogen four atoms from the point of attachment and adjacent to the R^{11} and
 5 R^{33} positions is optionally substituted with R^{34} ;

R^9 , R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from the group

consisting of hydrido, acetamido, haloacetamido, alkoxyamino, alkanoyl,
 haloalkanoyl, amidino, guanidino, alkylendioxy, haloalkylthio, alkoxy,
 cycloalkoxy, cycloalkylalkoxy, aralkoxy, aryloxy, heteroaryloxy,
 10 heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, hydroxy, amino,
 alkylamino, N-alkyl-N-arylamino, arylamino, aralkylamino, heteroarylamino,
 heteroaralkylamino, heterocyclylamino, heterocyclylalkylamino, alkylthio,
 alkylsulfinyl, arylsulfinyl, aralkylsulfinyl, cycloalkylsulfinyl, heteroarylsulfinyl,
 alkylsulfamido, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, cycloalkylsulfonyl,
 15 heteroarylsulfonyl, amidosulfonyl, alkyl, aryl, aralkyl, cycloalkyl,
 cycloalkylalkyl, heteroaryl, heterocyclyl, halo, haloalkyl, haloalkoxy,
 hydroxyalkyl, hydroxyhaloalkyl, aminoalkyl, carboalkoxy, carboxy,
 carboxyalkyl, carboxamido, and cyano;

A is a bond or $(CH(R^{15}))_{pa}-(W^7)_{rr}$ wherein rr is 0 or 1, pa is an

20 integer selected from 0 through 3, and W^7 is selected from the group
 consisting of O, S, C(O), $(R^7)NC(O)$, $(R^7)NC(S)$, and $N(R^7)$;

R^7 is selected from the group consisting of hydrido, hydroxy and alkyl;

R^{15} is selected from the group consisting of hydrido, hydroxy, halo,
 alkyl, and haloalkyl;

25 M is N or R^1-C ;

R^1 is selected from the group consisting of hydrido, alkyl, cyano, halo,
 haloalkyl, haloalkoxy, amino, aminoalkyl, alkylamino, amidino, hydroxy,
 hydroxyamino, alkoxy, hydroxyalkyl, alkoxyamino, thiol, and alkylthio;

R^2 is Z^0 -Q;

Z^0 is selected from the group consisting of a bond, $(CR^{41}R^{42})_q$

wherein q is 1 or 2, and $(CH(R^{41}))_g-W^0-(CH(R^{42}))_p$ wherein g and p are integers independently selected from 0 through 3 and W^0 is selected from the group consisting of O, S, C(O), S(O), $N(R^{41})$, and $ON(R^{41})$;

Z^0 is optionally $(CH(R^{41}))_e-W^{22}-(CH(R^{42}))_h$ wherein e and h are independently 0 or 1 and W^{22} is selected from the group consisting of

$CR^{41}=CR^{42}$, 1,2-cyclopropyl, 1,2-cyclobutyl, 1,2-cyclohexyl, 1,3-cyclohexyl,

1,2-cyclopentyl, 1,3-cyclopentyl, 2,3-morpholinyl, 2,4-morpholinyl,

2,6-morpholinyl, 3,4-morpholinyl, 3,5-morpholinyl, 1,2-piperazinyl,

1,3-piperazinyl, 2,3-piperazinyl, 2,6-piperazinyl, 1,2-piperidinyl, 1,3-piperidinyl,

2,3-piperidinyl, 2,4-piperidinyl, 2,6-piperidinyl, 3,4-piperidinyl, 1,2-pyrrolidinyl,

1,3-pyrrolidinyl, 2,3-pyrrolidinyl, 2,4-pyrrolidinyl, 2,5-pyrrolidinyl,

3,4-pyrrolidinyl, 2,3-tetrahydrofuranyl, 2,4-tetrahydrofuranyl,

2,5-tetrahydrofuranyl, and 3,4-tetrahydrofuranyl, wherein Z^0 is directly bonded

to the uracil ring and W^{22} is optionally substituted with one or more

substituents selected from the group consisting of R^9 , R^{10} , R^{11} , R^{12} , and R^{13} ;

R^{41} and R^{42} are independently selected from the group consisting of hydrido, hydroxy, and amino;

Q is phenyl or a heteroaryl of 5 or 6 ring members, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to Z^0 is optionally substituted by R^9 , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{13} , a carbon adjacent to R^9 and two atoms from the carbon at the point of attachment is

optionally substituted by R^{10} , a carbon adjacent to R^{13} and two atoms from the

carbon at the point of attachment is optionally substituted by R^{12} , and any carbon adjacent to both R^{10} and R^{12} is optionally substituted by R^{11} ;

Q is optionally hydrido with the proviso that Z^0 is other than a bond;

K is CHR^{4a} wherein R^{4a} is selected from the group consisting of

5 hydrido, hydroxyalkyl, alkyl, alkoxyalkyl, alkylthioalkyl, and haloalkyl;

E^0 is selected from the group consisting of a bond, $C(O)N(H)$, $(H)NC(O)$, $(R^7)NS(O)_2$, and $S(O)_2N(R^7)$;

Y^{AT} is Q^b-Q^s ;

Q^s is $(CR^{37}R^{38})_b$ wherein b is an integer selected from 1 through 4,

10 R^{37} is selected from the group consisting of hydrido, alkyl, and haloalkyl, and

R^{38} is selected from the group consisting of hydrido, alkyl, haloalkyl, aroyl, and heteroaroyl with the proviso that there is at least one aroyl or heteroaroyl substituent, with the further proviso that no more than one aroyl or heteroaroyl is bonded to $(CR^{37}R^{38})_b$ at the same time, with the still further proviso that

15 said aroyl and said heteroaroyl are optionally substituted with one or more substituents selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} , with another further proviso that said aroyl and said heteroaroyl are bonded to the $CR^{37}R^{38}$ that is directly bonded to E^0 , with still another further proviso

that no more than one alkyl or one haloalkyl is bonded to a $CR^{37}R^{38}$ at the

20 same time, and with the additional proviso that said alkyl and haloalkyl are bonded to a carbon other than the one bonding said aroyl or said heteroaroyl;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

consisting of hydrido, amidino, guanidino, carboxy, haloalkylthio, alkoxy, hydroxy, amino, alkoxyamino, alkylamino, alkylthio, alkylsulfinyl,


25 alkylsulfonyl, alkanoyl, haloalkanoyl, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, and cyano;

R^{16} or R^{19} is optionally selected from the group consisting of $NR^{20}R^{21}$, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that R^{16} , R^{19} , and Q^b are not simultaneously hydrido;

Q^b is selected from the group consisting of $NR^{20}R^{21}$, hydrido, $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$, and $C(NR^{25})NR^{23}R^{24}$, with the proviso that no more than one of R^{20} and R^{21} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time and with the further proviso that no more than one of R^{23} and R^{24} is selected from the group consisting of hydroxy, amino, alkylamino, and dialkylamino at the same time;

R^{20} , R^{21} , R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group consisting of hydrido, alkyl, hydroxy, amino, alkylamino and dialkylamino.

34. Compound of Claim 33 of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of phenyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 3-isoxazolyl, and 5-isoxazolyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to A is optionally substituted by R^{32} , the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R^{36} , a carbon

adjacent to R^{32} and two atoms from the carbon at the point of attachment is optionally substituted by R^{33} , a carbon adjacent to R^{36} and two atoms from the carbon at the point of attachment is optionally substituted by R^{35} , and any carbon adjacent to both R^{33} and R^{35} is optionally substituted by R^{34} ;

- 5 R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} are independently selected from the group consisting of hydrido, amidino, guanidino, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino, dimethylamino, methoxyamino, methylthio, ethylthio, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl, N-methylamidosulfonyl, hydroxymethyl, amidocarbonyl, carboxy, cyano, and Q^b ;

- B is optionally selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butenyl, 2-butylnyl, sec-butyl, *tert*-butyl, isobutyl, 2-methylpropenyl, 1-pentyl, 2-pentenyl, 3-pentenyl, 2-pentynyl, 3-pentynyl, 2-pentyl, 3-pentyl, 2-methylbutyl, 2-methyl-2-butenyl, 3-methylbutyl, 3-methyl-2-butenyl, 1-hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 2-hexyl, 1-methyl-2-pentenyl, 1-methyl-3-pentenyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 3-hexyl, 1-ethyl-2-butenyl, 1-heptyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 5-heptynyl, 2-heptyl, 1-methyl-2-hexenyl, 1-methyl-3-hexenyl, 1-methyl-4-hexenyl, 1-methyl-2-hexynyl, 1-methyl-3-hexynyl, 1-methyl-4-hexynyl, 3-heptyl, 1-ethyl-2-pentenyl, 1-ethyl-3-pentenyl, 1-ethyl-2-pentynyl, 1-ethyl-3-pentynyl, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 4-trifluoromethyl-5,5,5-trifluoropentyl, 4-trifluoromethylpentyl, 5,5,6,6,6-pentafluorohexyl, and 3,3,3-trifluoropropyl, wherein each member of group B is optionally substituted at any carbon up to and including 5 atoms from the point of attachment of B to A with one or more of the group consisting of R^{32} , R^{33} , R^{34} , R^{35} , and R^{36} ;

- B is optionally selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl,

3-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, and 3-tetrahydrothienyl, wherein each ring carbon is optionally substituted with R³³, ring carbons and a nitrogen adjacent to the carbon atom at the point of

attachment are optionally substituted with R⁹ or R¹³, a ring carbon or nitrogen adjacent to the R⁹ position and two atoms from the point of attachment is

optionally substituted with R¹⁰, and a ring carbon or nitrogen adjacent to the R¹³ position and two atoms from the point of attachment is optionally substituted with R¹²;

R^9, R^{11} , and R^{13} are independently selected from the group consisting

of hydrido, methyl, ethyl, methoxy, ethoxy, hydroxy, amino, N-methylamino,
15 N,N-dimethylamino, methylthio, trifluoromethyl, pentafluoroethyl,
2,2,2-trifluoroethyl, fluoro, chloro, bromo, amidosulfonyl,
N-methylamidosulfonyl, N,N-dimethylamidosulfonyl, hydroxymethyl,
1-hydroxyethyl, amidocarbonyl, N-methylamidocarbonyl, carboxy, and cyano;

R^{10} and R^{12} are independently selected from the group consisting of

20 hydrido, amidino, amidocarbonyl, N-methylamidocarbonyl,
N-benzylamidocarbonyl, N-(2-chlorobenzyl)amidocarbonyl,
N-(3-fluorobenzyl)amidocarbonyl, N-(2-trifluoromethylbenzyl)amidocarbonyl,
N-(1-phenylethyl)amidocarbonyl, N-(1-methyl-1-phenylethyl)amidocarbonyl,
N-benzylamidosulfonyl, N-(2-chlorobenzyl)amidosulfonyl,

25 N-ethylamidocarbonyl, N-isopropylamidocarbonyl, N-propylamidocarbonyl,
N-isobutylamidocarbonyl, N-(2-butyl)amidocarbonyl,
N-cyclobutylamidocarbonyl, N-cyclopentylamidocarbonyl,
N-cyclohexylamidocarbonyl, guanidino, methyl, ethyl, methoxy, ethoxy,
hydroxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxy,
30 carboxymethyl, amino, acetamido, trifluoromethyl, pentafluoroethyl,

2,2,2-trifluoroethyl, trifluoroacetamido, aminomethyl, N-methylamino, dimethylamino, methoxyamino, amidosulfonyl, N-methylamidulosulfonyl, N,N-dimethylamidulosulfonyl, methanesulfonamido, methoxycarbonyl, fluoro, chloro, bromo, and cyano;

- 5 A is selected from the group consisting of a bond, NH, N(CH₃), CH₂, CH₃CH, CH₂CH₂, and CH₂CH₂CH₂;

M is N or R¹-C;

- R¹ is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, methylamino, cyano, methyl, trifluoromethyl, methoxy, methylthio, trifluoromethoxy, fluoro, and chloro;

- R² is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-pyrrolyl, 2-imidazolyl, 2-thiazolyl, 3-isoxazolyl, 2-pyridyl, and 3-pyridyl, wherein a carbon adjacent to the carbon at the point of attachment of said phenyl or heteroaryl ring to the uracil ring is optionally substituted by R⁹, the other carbon adjacent to the carbon at the point of attachment is optionally substituted by R¹³, a carbon adjacent to R⁹ and two atoms from the carbon at the point of attachment is optionally substituted by R¹⁰, a carbon adjacent to R¹³ and two atoms from the carbon at the point of attachment is optionally substituted by R¹², and any carbon adjacent to both R¹⁰ and R¹² is optionally substituted by R¹¹;







Y^{AT} is Q^b-Q^s;

Q^s is selected from the group consisting of:

C[R³⁷(benzoyl)(CR³⁷R³⁸)_b],

C[R³⁷(2-pyridylcarbonyl)(CR³⁷R³⁸)_b],

25 C[R³⁷(3-pyridylcarbonyl)(CR³⁷R³⁸)_b],



from 1 through 3, R^{37} and R^{38} are independently selected from the group

consisting of hydrido, alkyl, and haloalkyl, with the proviso that said benzoyl and the heteroaroyls are optionally substituted with one or more substituents

10 selected from the group consisting of R^{16} , R^{17} , R^{18} , and R^{19} with the proviso

that R^{17} and R^{18} are optionally substituted at a carbon selected from other than

the meta and para carbons relative to the carbonyl of the benzoyl or heteroaroyl, with the further proviso that said benzoyl or said heteroaroyl are bonded to the carbon directly bonded to amide nitrogen of the 1-(amidocarbonylmethylene)

15 group, and with the still further proviso that is no more than one alkyl or one haloalkyl is bonded to a $CR^{37}R^{38}$ at the same time;

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group

consisting of hydrido, methyl, ethyl, amidino, guanidino, methoxy, hydroxy, amino, aminomethyl, 1-aminoethyl, 2-aminoethyl, N-methylamino,

20 dimethylamino, methylthio, ethylthio, trifluoromethylthio, methylsulfinyl, methylsulfonyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, fluoro, chloro, hydroxymethyl, carboxy, and cyano;

Q^b is $C(NR^{25})NR^{23}R^{24}$ or $N(R^{26})C(NR^{25})N(R^{23})(R^{24})$;

R^{23} , R^{24} , R^{25} , and R^{26} are independently selected from the group

25 consisting of hydrido, methyl, and ethyl.

35. Compound of Claim 34 or a pharmaceutically acceptable salt thereof, wherein;

- B is selected from the group consisting of 2-aminophenyl, 3-aminophenyl, 3-amidinophenyl, 4-amidinophenyl, 3-carboxyphenyl, 3-carboxy-5-hydroxyphenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-methoxyaminophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, 3-trifluoromethylphenyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, 5-chloro-3-trifluoromethyl-2-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, and 3-trifluoromethyl-2-pyridyl;

- B is optionally selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butyl, (R)-2-butyl, (S)-2-butyl, *tert*-butyl, isobutyl, 1-pentyl, 3-pentyl, 2-methylbutyl, 2,2,2-trifluoroethyl, 6-amidocarbonylhexyl, 4-methyl-2-pentyl, 3-hydroxypropyl, 1-methoxy-2-propyl, 2-methoxyethyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2-dimethylaminopropyl, 2-cyanoethyl, 6-hydroxyhexyl, 2-hydroxyethyl, 2-amidinoethyl, 2-guanidinoethyl, 3-guanidinopropyl, 4-guanidinobutyl, 3-hydroxypropyl, 4-hydroxybutyl, 6-cyanoethyl, 2-dimethylaminoethyl, 3-methylbutyl, 2-methylbutyl, (S)-2-methylbutyl, 3-aminopropyl, 2-hexyl, and 4-aminobutyl;

- B is optionally selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxalan-2-yl, 2-(2R)-bicyclo[2.2.1]-heptyl, oxetan-3-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, 1-pyrrolidinyl and 1-piperidinyl;

A is selected from the group consisting of a bond, CH_2 , CH_3CH , CH_2CH_2 , and $\text{CH}_2\text{CH}_2\text{CH}_2$;

M is N or $\text{R}^1\text{-C}$;

- R^1 is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, fluoro, and chloro;

R^2 is selected from the group consisting of 3-amidocarbonyl-5-aminophenyl, 3-amidocarbonyl-5-aminophenyl,

- 3-amino-5-(N-benzylamidocarbonyl)phenyl,
 3-amino-5-(N-(2-chlorobenzyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(3-fluorobenzyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(2-trifluoromethylbenzyl)amidocarbonyl)phenyl,
 5 3-amino-5-(N-(1-phenylethyl)amidocarbonyl)phenyl,
 3-amino-5-(N-(1-methyl-1-phenylethyl)amidocarbonyl)phenyl,
 3-amino-5-(N-benzylamidosulfonyl)phenyl,
 3-amino-5-(N-(2-chlorobenzyl)amidosulfonyl)phenyl,
 3-amino-5-(N-ethylamidocarbonyl)phenyl,
 10 3-amino-5-(N-isopropylamidocarbonyl)phenyl,
 3-amino-5-(N-propylamidocarbonyl)phenyl,
 3-amino-5-(N-isobutylamidocarbonyl)phenyl,
 3-amino-5-(N-(2-butyl)amidocarbonyl)phenyl,
 3-amino-5-(N-cyclobutylamidocarbonyl)phenyl,
 15 3-amino-5-(N-cyclopentylamidocarbonyl)phenyl,
 3-amino-5-(N-cyclohexylamidocarbonyl)phenyl,
 5-amino-2-fluorophenyl, 3-amino-5-hydroxymethylphenyl,
 5-amino-3-methoxycarbonylphenyl, 3-amidinophenyl,
 3-amino-2-methylphenyl, 5-amino-2-methylthiophenyl, 3-aminophenyl,
 20 3-carboxyphenyl, 3-carboxy-5-aminophenyl, 3-carboxy-5-hydroxyphenyl,
 3-carboxymethyl-5-aminophenyl, 3-carboxymethyl-5-hydroxyphenyl,
 3-carboxymethylphenyl, 3-chlorophenyl, 2-chlorophenyl, 3-cyanophenyl,
 ,5-diaminophenyl, 3-dimethylaminophenyl, 2-fluorophenyl, 3-fluorophenyl,
 2,5-difluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl,
 25 3-methanesulfonylaminophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
 3-methoxyaminophenyl, 3-methoxycarbonylphenyl, 2-methylaminophenyl,
 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,
 phenyl, 3-trifluoroacetamidophenyl, 3-trifluoromethylphenyl,
 2-trifluoromethylphenyl, 5-amino-2-thienyl, 5-amino-3-thienyl,
 30 3-bromo-2-thienyl, 3-pyridyl, 4-pyridyl, 2-thienyl, and 3-thienyl;

Y^{AT} is Q^b-Q^s ;

Q^s is selected from the group consisting of:

$[CH(benzoyl)](CH_2)_b$, $[CH(2-pyridylcarbonyl)](CH_2)_b$,

[CH(3-pyridylcarbonyl)](CH₂)_b, [CH(4-pyridylcarbonyl)](CH₂)_b,

[CH(2-thienylcarbonyl)](CH₂)_b, [CH(3-thienylcarbonyl)](CH₂)_b,

[CH(2-thiazolylcarbonyl)](CH₂)_b, [CH(4-thiazolylcarbonyl)](CH₂)_b,

and [CH(5-thiazolylcarbonyl)](CH₂)_b, wherein b is an integer selected from 1

- 5 through 3, with the proviso that said benzoyl and said heteroaroyls are optionally substituted with one or more substituents selected from the group consisting of R¹⁶, R¹⁷, R¹⁸, and R¹⁹ with the proviso that R¹⁷ and R¹⁸ are optionally substituted at a carbon selected from other than the meta and para carbons relative to the carbonyl of the benzoyl or the heteroaroyl, and that said benzoyl or said heteroaroyl are bonded to the carbon directly bonded to amide nitrogen of the 1-(amidocarbonylmethylene) group;

R¹⁶ and R¹⁹ are independently selected from the group consisting of hydrido, amidino, amino, aminomethyl, methoxy, methylamino, hydroxy, hydroxymethyl, fluoro, chloro, and cyano;

- 15 R¹⁷ and R¹⁸ are independently selected from the group consisting of hydrido, fluoro, chloro, hydroxy, hydroxymethyl, amino, carboxy, and cyano;

Q^b is N(R²⁶)C(NR²⁵)N(R²³)(R²⁴);

R²³, R²⁴, R²⁵, and R²⁶ are independently hydrido or methyl.

- 20 36. Compound of Claim 35 or a pharmaceutically acceptable salt thereof, wherein;

B is selected from the group consisting of 3-aminophenyl, 3-amidinophenyl, 4-amidinophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 4-methylphenyl, phenyl, 2-imidazolyl, 3-pyridyl, 4-pyridyl, and 3-trifluoromethyl-2-pyridyl;

B is optionally selected from the group consisting of hydrido, ethyl, 2-propenyl, 2-propynyl, propyl, isopropyl, butyl, 2-butyl, (R)-2-butyl, (S)-2-butyl, *tert*-butyl, isobutyl, 1-pentyl, 3-pentyl, 2-methylbutyl, 2,2,2-trifluoroethyl, 6-amidocarbonylhexyl, 4-methyl-2-pentyl,

5 2-dimethylaminoethyl, 3-methylbutyl, 2-methylbutyl, (S)-2-methylbutyl, 3-aminopropyl, 2-hexyl, and 4-aminobutyl;

10 A is selected from the group consisting of a bond, CH_2 , CH_2CH_2 and $\text{CH}_2\text{CH}_2\text{CH}_2$;

R¹ is selected from the group consisting of hydrido, hydroxy, hydroxymethyl, amino, aminomethyl, cyano, methyl, trifluoromethyl, and fluoro:


340

3-dimethylaminophenyl, 3-hydroxyphenyl, 3-methanesulfonylaminophenyl, 3-methylaminophenyl, 2-methylphenyl, 3-methylphenyl, phenyl, 3-trifluoroacetamidophenyl, 3-bromo-2-thienyl, 2-thienyl, and 3-thienyl;

Y^{AT} is selected from the group consisting of

- 5 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, 5-guanidino-1-oxo-1-(4-thiazolyl)-2-pentyl, 5-guanidino-1-oxo-1-(5-thiazolyl)-2-pentyl, 5-guanidino-1-oxo-1-(4-amino-2-thiazolyl)-2-pentyl, and 5-guanidino-1-oxo-1-phenyl-2-pentyl.

- 10 37. Compound of Claim 33 where said compound is selected from the group of the Formula:



or a pharmaceutically acceptable salt thereof, wherein;

- 15 R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

- 20 R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

- 25 R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

- R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF₃;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CF;

15 R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl ;

R^2 is benzyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl ;

R² is benzyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

25 R^2 is 3-aminophenyl, B is phenyl, A is CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is phenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R² is phenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R² is 3-carboxy-5-aminophenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

15 R² is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R² is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R² is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-
 20 guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CH;

R² is 3,5-diaminophenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl₄;

R² is 3-carboxy-5-aminophenyl, B is phenyl, A is CH₂CH₂, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl₄;

25 R² is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R² is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is CCl;

5 R^2 is 3,5-diaminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3-carboxy-5-aminophenyl, B is phenyl, A is CH_2CH_2 , Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

10 R^2 is 3,5-diaminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3-carboxy-5-aminophenyl, B is isopropyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

R^2 is 3,5-diaminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N;

15 R^2 is 3-carboxy-5-aminophenyl, B is cyclobutyl, A is a bond, Y^{AT} is 5-guanidino-1-oxo-1-(2-thiazolyl)-2-pentyl, and M is N.

20 38. A composition for inhibiting thrombotic conditions in blood comprising a compound of any one of Claims 8, 16, 24, 32, and 37 and a pharmaceutically acceptable carrier.

25 39. A composition for inhibiting thrombotic conditions in blood comprising a compound of any one of Claims 1 through 7, Claims 9 through 15, Claims 17 through 23, Claims 25 through 31, and Claims 33 through 36 and a pharmaceutically acceptable carrier.

30 40. A method for inhibiting thrombotic conditions in blood comprising adding to blood a therapeutically effective amount of a composition of any one of Claims 38 and 39.

41. A method for inhibiting formation of blood platelet aggregates in blood comprising adding to blood a therapeutically effective amount of a composition of any one of Claims 38 and 39.
- 5 42. A method for inhibiting thrombus formation in blood comprising adding to blood a therapeutically effective amount of a composition of any one of Claims 38 and 39.
43. A method for treating or preventing venous thromboembolism and
10 pulmonary embolism in a mammal comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims 38 and 39.
44. A method for treating or preventing deep vein thrombosis in a mammal
15 comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims 38 and 39.
45. A method for treating or preventing cardiogenic thromboembolism in a mammal comprising administering to the mammal a therapeutically effective
20 amount of a composition of any one of Claims 38 and 39.
46. A method for treating or preventing thromboembolic stroke in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims 38 and 39.
25
47. A method for treating or preventing thrombosis associated with cancer and cancer chemotherapy in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims 38 and 39.
30
48. A method for treating or preventing unstable angina in humans and other mammals comprising administering to the mammal a therapeutically effective amount of a composition of any one of Claims 38 and 39.

**Substituted Polycyclic Aryl and Heteroaryl Uracils Useful for Selective
Inhibition of the Coagulation Cascade**

Abstract

The invention relates to substituted polycyclic aryl and heteroaryl uracil compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

000217051 112000